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3. INTRODUCTION 
 
 
3.1. Cancer, general considerations 
 
A tumour may be defined as an abnormally growing mass of cells resulting from uncontrolled 
division, which serves no physiological function [1]. Benign tumours grow by local expansion 
and are confined to their tissue of origin. Such tumours are usually not life threatening and 
their surgical removal is in general curative. On the other hand, malignant tumour cells are 
characterised by their capacity to invade the extracellular matrix and to destroy adjacent 
tissues [2]. Eventually, cancer cells may enter the circulation or the lymphatic system and 
colonise other organs (metastasis). Such advanced cancer is a fatal disease, as it is not cured 
by surgical removal of the primary lesion. Accordingly, metastatic dissemination and the 
subsequent infiltration and destruction of vital secondary organs is the major cause of death in 
most cancer forms [3]. Malignant lesions found at the site of their origin are referred to as 
primary tumours, whereas those found in an organ distinct from where they originated are 
referred to as secondary tumours (Figure 1). 
 
 
 
Figure 1: Growth characteristics of primary cancers and metastases. Large mass of a primary lung tumour, a bronchogenic 
carcinoma, seen adjacent to the bronchus where the cancer probably originated (A). Coronal brain section showing a primary brain 
tumour, glioblastoma multiforme (GBM) with heterogeneous tumour mass, central necrosis (cell death) and spread to the contralateral 
hemisphere. Glioblastomas grow both by local expansion and by diffuse cell invasion. However, they are confined to the central nervous 
system and do not metastasise to other organs (B). The mushroom-shaped tumour is adenocarcinoma of the breast metastasised to the 
bronchus (C). A liver peppered with metastatic deposits of small-cell lung carcinoma. The tumour nodules vary in size, indicating that 
some of the deposits have resided in the liver longer than others. The metastases have compressed some of the intrahepatic bile ducts, 
turning the liver green (D). Multiple foci of carcinoma metastases to the kidneys. Several of the metastases show central indentations of 
necrotic areas (E). A meningioma, a primary brain tumour. Meningiomas grow by local expansion, however they do not exhibit single-
cell infiltration such as GBMs. This tumour has compressed the cerebrum (F). Images: R. Harley, Medical University of South Carolina 
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Today, more than 100 different cancer types have been acknowledged, with distinct phenotypic 
traits and growth characteristics. However, common to the diverse cancer types is their genesis. 
Early pre-malignant lesions arise after having acquired critical alterations within the genome of a 
cancer initiating progenitor cell, by a process known as malignant transformation [2]. It is 
assumed that a progenitor cell may either be a fully differentiated cell or an undifferentiated stem 
cell that has the potential to evolve into different tissue-specific cell types [4]. After 
transformation, newly acquired genetic traits of the cancer progenitor cell may enable it to 
proliferate in an autonomous fashion, no longer restrained by the physiological context of the 
tissue microenvironment.  
      Genes that contribute to the development of cancer are referred to as cancer predisposition 
genes.  Based on their functions, such genes may be divided into three groups: tumour suppressor 
genes, stability genes and oncogenes [5]. Tumour suppressor genes encode key regulators of cell-
cycle progression and survival. Their loss leads to the shortfall of normal mitogenic control or to 
the disruption of apoptotic pathways, that normally would arrest or eliminate such damaged cells 
[5]. Oncogenes are erroneously activated genes that encode proteins with essential roles in 
mitogenic signal transduction pathways, such as growth factors, cell surface receptors, 
intracellular messengers and transcription factors [6]. The activation of these pathways provides 
the “drive” for malignant proliferation. Stability genes encode proteins that maintain genomic 
integrity. They may be involved in nucleotide repair pathways or in more profound mechanisms 
such as those responsible for correct mitotic recombination or chromosomal segregation [5]. 
Defects in these genes contribute to genomic instability, allowing for further accumulation of 
mutations. The number of genetic alterations which have been found in cancer cells is immense 
[5,7]. Still, the vast array of cancer cell genotypes are manifested in a few essential changes in 
cellular physiology, which are collectively responsible for malignant growth [8]. They are: self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed 
cell death (apoptosis), limitless replicative potential, sustained angogenesis, and tissue invasion 
and metastasis (Figure 2). Each of these acquired capabilities represents a successful conquering 
by the early progenitor cell of an anti-cancer defence mechanism essential for normal tissue 
homeostasis.  
     It is becoming clear that cancer progression is not sustained by the tumour cells alone, but is  
also assisted by the host microenvironment [9]. Host fibroblasts are associated with tumour cells at 
all stages of cancer progression, and their structural and functional contributions to this process are 
beginning to emerge.  
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Growth factors, chemokines and extracellular matrix produced by fibroblasts facilitates the 
recruitment of endothelial cells and pericytes [10]. As cancer progresses, tumour-associated host 
cells may obtain phenotypes that are different from those normally seen in the tissue. For example, 
the molecular signature of tumour endothelial cells is distinct from that found in endothelial cells 
in normal tissue [11], providing evidence for a cross talk between the tumour and the host 
orchestrated by biological factors in the tumour-host microenvironment.  
 
 
 
 
Figure 2. The acquired capabilities of cancer. The facilities presented above may arise from genetical alterations in a 
number of genes. When acquired, they are thought to enable transformed cells to develop into full-blown malignant lesions.  
Figure modified from Hanahan and Weinberg [8]. 
 
 
3.2. Astrocytomas, classification and malignant progression 
 
Astrocytes, the most numerous glial cells in the brain, provide physical support to the 
neuronal network and have multiple functions in maintaining tissue homeostasis as well as in 
tissue repair [12]. Tumours that arise after malignant transformation and proliferation of 
astrocytes are termed astrocytomas. The World Health Organisation’s classification of central 
nervous system tumours [13] categorises astrocytomas based on their grade of malignancy, 
determined by the presence of key histological features (table I). As a group, astrocytomas 
include tumours with a wide range of histological forms from benign to highly malignant. In 
the classification scheme, they are divided into grade I (juvenile pilocytic astrocytoma), grade  
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II (low-grade astrocytoma), grade III (anaplastic astrocytoma) and grade IV (glioblastoma 
multiforme; GBM) tumours. Grade II-IV tumours diffusely infiltrate into the surrounding 
brain tissue, hence they are also referred to as diffuse astrocytomas. In contrast, grade I 
astrocytomas display more circumscribed growth and have a different age distribution, 
intracranial location and biology; thus they comprise a group of tumours distinct from diffuse 
astrocytomas. Grade I astrocytomas retain their well-differentiated histological features as 
opposed to diffuse astrocytomas, which inevitably de-differentiate and progress to more 
malignant tumour phenotypes [13]. Diffusely infiltrating astrocytomas account for over 60 % 
of all primary brain tumours, with a world-wide incidence of about 5-7 new cases per 100.000 
population per year [13].  
   The grade IV astrocytoma, glioblastoma multiforme, is the most de-differentiated primary 
tumour of the central nervous system. Two distinct types of GBMs are recognised, based on 
their clinical history. Secondary glioblastomas evolve from grade II and grade III 
astrocytomas in the course of several months or years (mean, 4-5 years). This glioblastoma 
form typically affects young adults (35-40 years) [14]. Primary glioblastomas; on the other 
hand, usually present with a clinical history of less than 6 months and they are more frequent 
in elderly people (mean, 55 years)[14]. Primary GBMs constitute around 95 % of all 
glioblastoma cases [15]. Although these glioblastoma forms are associated with different 
clinical presentations and genetic alterations, they can not be distinguished by routine 
histological evaluation [13]. The following sections will concentrate on diffuse astrocytomas, 
with special emphasis on glioblastoma multiforme. 
 
WHO grade WHO designation Histological criteria 
I. Pilocytic astrocytoma None of the below criteria 
II. Astrocytoma Nuclear atypia 
III. Anaplastic astrocytoma Nuclear atypia and mitotic activity 
IV. Glioblastoma multiforme Nuclear atypia, mitoses, endothelial proliferation 
and/or necrosis 
 
Table 1. The World Health Organisation’s classification and grading system of astrocytomas. 
 
3.3. Diffuse astrocytomas, aetiology and genetic susceptibility  
 
Of the various environmental risk factors known to cause cancers, radiotherapy exposure has  
been clearly associated with the formation of diffuse astrocytomas [13]. Children that have  
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been treated by prophylactic cranial irradiation for acute lymphocytic leukaemia (ALL) have 
an increased risk of developing diffuse astrocytomas of all malignancy grades [16-19]. In a 
retrospective cohort of 9720 children receiving therapeutic irradiation for ALL, a 22-fold 
excess risk of subsequent tumour development in the CNS was documented, and the 
estimated cumulative proportion of affected children was 2.5%[20]. The gliomas appeared 7 
to 9 years after radiation treatment [18]. Similarly, a 16-fold excess risk for the emergence of 
gliomas has been observed after irradiation of pituitary adenomas [21]. Neuroepithelial 
tumours have been observed to occur after cranial irradiation for several other tumour types as 
well [22-24]. 
    Of the known hereditary defects known to be associated with oncogenesis, TP53 germline 
mutations (Li-Fraumeni syndrome)[25], the Brain tumour polyposis syndrome (Turcot 
syndrome)[26] and NF1 mutations (neurofibromatosis type I syndrome) [27] have all been 
implicated in the development of diffuse astrocytomas. 
    
3.4. Diffuse astrocytomas, oncogenesis  
 
The classical view presented in section 3.2., considers mature glia to be the founder cells of 
glioblastomas. However, the pathways of glioma oncogenesis have been extensively debated. 
It has been argued that neural stem cells (NSCs; self-renewing cells capable of differentiating 
into both neurons and glia) or glial progenitors (self-renewing precursors capable of 
differentiating into astrocytes or oligodendrocytes) may well be the targets of malignant 
transformation [28,29]. The notion that such primitive cells may give rise to gliomas offers 
some advantages compared to the classical hypothesis. First, it may be argued that the concept 
of de-differentiation of mature glia is a theoretical model that has not been adequately proven 
in experimental systems. Furthermore, this model does not explain the origin of mixed 
gliomas that contain both oligodendroglial- and astroglial components [29]. It is likely that 
NSCs and glial progenitors are more prone to proliferate than mature cells since they are 
already at a de-differentiated state. Therefore, these cell types would transform and develop 
more readily to multicellular lesions given a few key mutational events. Support for this 
thought has been gained from transgenic animal models, where the activation of two 
independent signalling pathways was sufficient to transform neural stem cells, but not mature 
astrocytes to give rise to glioblastoma-like lesions in mice [30].  
In addition to diffuse infiltration, grade IV tumours are also associated with accelerated 
tumour cell proliferation and rapid local expansion. This is facilitated by the recruitment of  
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tumour blood vessels (angiogenesis), which supplies the rapidly dividing neoplastic cells with 
oxygen and nutrients. Since the brain is confined to the rigid case of the skull, the expansive 
growth of a neoplasm quickly meets physical barriers, resulting in elevated intracranial 
pressure and, in some cases, the compression of vital brain structures. In addition, the 
expansion of a tumour within- or adjacent to the cerebral ventricles may block the clearance 
of cerebrospinal fluid.  
 
3.5. Diffuse astrocytomas, genetic alterations 
As mentioned above, primary and secondary GBMs present with distinct clinical profiles. It 
has become clear that they are also associated with mutations affecting different genes [13]. 
Figure 3 reviews the most frequent aberrations that are associated with the two pathways of 
glioblastoma development. These genetic alterations will be briefly discussed below.  
 
3.5.1. TP53 
The TP53 gene, found on chromosome 17p, encodes p53, a 53-kDa transcription factor.  
p53 has a principal role in the cell in preventing the accumulation of mutations through the 
regulation of critical checkpoints in response to distinct exogenous stresses [31,32]. p53 is 
rapidly degraded in normal cells, however, it is stabilised in response to DNA damage, 
hypoxia, growth factors and activated oncogenes [31]. Important downstream effects of p53-
mediated transcription include growth arrest, induction of apoptosis, senescence, 
differentiation and anti-angiogenesis [31,33]. The central hydrophobic core of the p53 
molecule, encoded by exons 5 to 8, contains four highly conserved regions that are 
responsible for proper three-dimensional folding and DNA binding [34]. Inactivating 
mutations are most often found at 7 hotspots within these exons, which lead to loss-of 
function of the affected protein [35]. According to the International Agency for Research on  
Cancer database (IARC, http://www-p53.iarc.fr/Statistics.html), the distribution of somatic 
TP53 mutations are found to vary between 5% and 45 % in human cancers, with around 27 % 
prevalence in various brain tumours. The introduction of wild-type TP53 into deficent 
glioblastoma cell lines leads to growth arrest and morphological changes [36,37], suggesting 
that the loss of p53 is functionally involved in GBM oncogenesis. 
     Allelic losses of chromosome 17p and TP53 mutations are present with similar frequency 
in low-grade astrocytomas, anaplastic astrocytomas and in glioblastomas [15,38]; thus TP53 
mutations are considered to be early events in astrocytoma progression.  
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Figure 3. Two pathways to glioblastoma development with associated genetic mutations. The numbers in 
parentheses indicate the percentage of mutations found in each tumour group taken from a recent population-based study 
[15]. Asterisks indicate the mutations that differ significantly in frequency between primary and secondary glioblastomas. 
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Since the transition from low-grade astrocytomas to anaplastic astrocytomas and to secondary 
GBM occurs in the course of several years, p53-related genomic instability is probably not the 
direct promoter of malignant progression. However, p53-deficiency may play a permissive 
role, by conferring selective growth advantage to TP53-mutated tumour cells. Supporting this 
notion, targeted germ-line inactivation of both TP53 alleles did not give rise to gliomas in 
mice, even though all cells of the CNS proved to be p53-deficient [39]. Interestingly however, 
the majority of these animals spontaneously developed other cancer types, such as malignant 
lymphomas and sarcomas. Still, high-grade gliomas do develop when TP53 knockouts are 
supplied with additional mutations in the tumour suppressor gene NF1 (neurofibromatosis 
type I) [40].  
 
3.5.2. RB, CDK4, CDK6, INK4a 
The transition from low-grade astrocytoma to anaplastic astrocytoma has been associated with 
allelic losses on chromosome 9p and 13q and, less frequently, by 12q amplification. These  
chromosomal changes are mutually exclusive events [41,42], and it is now clear that they are 
all associated with the RB pathway.  
     The 107 kDa retinoblastoma protein (pRB) is a major regulator of cell-cycle progression 
[43]. About one-third of the high-grade astrocytomas have alterations at the RB locus [44], 
which maps to chromosome 13q14. Under normal, non-permissive conditions, the pRB 
protein is in a hypophosphorylated state bound to transcription factor E2F. This prevents E2F-
mediated activation of several genes that are important for mitosis, consequently inhibiting 
cell cycle progression beyond the G1/S restriction point. Phosphorylation of pRB by cyclin-
dependent kinases CDK4 and CDK6, in conjunction with cyclin D, and later by CDK2 
releases E2F and leads to the transactivation of E2F-responsive genes, which take the cell into 
the S-phase [45]. Uncontrolled activity of the RB pathway may result from mutational 
inactivation of RB, amplification or over-expression of the cyclin-dependent kinases, or 
mutational defects or down-regulation of the cyclin-dependent kinase inhibitors.  
     p16 and p15, encoded by the genes INK4a and INK4b, respectively, are inhibitors of the 
cyclin-dependent kinases CDK4 and CDK6 [46]. Loss of chromosome 9q, leading to p16 
inactivation occurs in about 50 % of high grade-astrocytomas [47] and is found in about two-
third of the analysed glioma cell lines [48].  
     All these genetic events serve to activate the RB pathway, taking the cell beyond the G1/S 
restriction point. Histologically, this molecular transition is seen as a dramatic increase of 
mitotic figures, marking the progression from grade II astrocytoma to grade III anaplastic 
astrocytoma.  
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 3.5.3. PTEN 
While loss of heterozygosity on the long arm of chromosome 10 affects the majority of 
anaplastic astrocytomas and almost all glioblastomas [49-52], this abnormality is absent in 
low-grade diffuse astrocytomas [49] [51]. At least three tumour suppressor genes, shown to be 
dysfunctional or deleted in high-grade astrocytomas, are located here. 
PTEN (phosphatase and tensin homology gene) maps to the 10q23 region. It has been 
found to be mutated in a wide range of sporadic advanced cancer types, such as melanomas 
and carcinomas of the prostate, breast, kidney and lung [53-55], as well as in haematological 
malignancies [56]. PTEN mutations have been found in 23-44% of the primary GBMs 
analysed in different series [15,57-59], however they are rare in secondary GBMs and are 
absent in astrocytomas [15,60]. The loss of PTEN function in tumour cells and in PTEN-
deficient mouse cells leads to increased cellular levels of phosphatidylinositol (3,4,5) 
trisphosphate, activating AKT/PKB (Protein kinase B) [61-63]. Activated AKT/PKB 
promotes cell survival through several pathways, as for example by BAD phosphorylation, 
which suppresses apoptosis [64]. It has been shown that activated Ras can co-operate with 
AKT/PKB to give rise to gliomas in mice [30]. The introduction of wild-type PTEN into 
glioma cells that contain endogenous mutant alleles leads to growth suppression in vitro and 
in vivo, but it has no effect in cells which express wild-type PTEN [65,66]. Growth 
suppression after PTEN supplementation is caused by G1 cell-cycle block and by increased 
sensitivity to detachment-induced apoptosis [53,61,67].  
Thus, PTEN is a principal tumour suppressor, whose absence seems to promote 
progression to the latest stage of this disease, histologically manifested as an increase in 
mitotic figures. However, it is clear from the rates of LOH 10q and that of PTEN mutations in 
GBMs that additional alterations at proximal loci contribute to the observed frequencies. 
Other tumour suppressor genes in this region include MXI1 (Max-interacting protein 1) and 
DMBT1 (deleted in malignant brain tumours) both of which have been shown to be deleted in 
the majority of glioblastomas [68,69]. 
 
3.5.4. EGF-EGFR 
A major genetic aberration associated with high-grade diffuse astrocytomas is EGFR 
amplification, prevalent in about 40 % of the GBMs and in a few anaplastic astrocytomas [70-
72]. According to a recent population-based study, EGFR amplifications are far more 
common in primary (36%) than in secondary (8%) glioblastomas [15].  
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 EGFR is a 170 kDa transmembrane receptor, which conveys mitogenic signals from EGF and 
TGF-α (transforming growth factor-α). EGFR signalling has been implicated in the early 
embryonic development of glial cells as well as in the proliferation and survival of neural 
stem cells [73]. There is evidence that GBMs express EGF and TGF-α together with EGFR, 
establishing an autocrine stimulatory loop [74,75]. Approximately 31 % of the GBMs 
analysed in a recent series expressed a truncated receptor (EGFRvIII), which lacks the 
extracellular ligand-binding domain [76]. These mutant receptors are constitutively 
autophosphorylated; however, unlike wild-type EGFR, they are not down-regulated. Taken 
together, these traits lead to continuous mitogenic activation of the affected cells. 
 
3.6. Diffuse astrocytomas, vascular induction 
 
Low-grade diffuse astrocytomas do not initiate angiogenesis but migrate extensively 
throughout the brain parenchyma and co-opt with the physiological vasculature to meet their 
need for oxygen and nutrients [77]. The picture is dramatically altered during progression to 
glioblastoma, a lesion that exhibits prominent microvascular proliferations and regions of 
elevated vessel density [77,78]. The appearance of the angiogenic phenotype is clearly 
associated with poor prognosis [14]. 
     Genetic alterations associated with the transition to GBM imply the erroneous activation of 
growth factor receptors, leading to strong mitogenic induction. As a consequence, the oxygen 
demand of rapidly dividing tumour cells may no longer be supported by the physiological 
vasculature, and hypoxic regions (regions with oxygen pressure below 30 mm Hg) develop 
[79]. Within these regions, tumour cells reach the lower limits of oxygen tension necessary 
for their survival. As a consequence, they undergo necrosis. Other tumour cells that are 
adjacent to the necrotic areas start to express the key transcription factor Hif-1α (hypoxia-
inducible factor-1α), which together with Hif-1 β transactivate hypoxia-responsive target 
genes. Some of these are VEGF (vascular endothelial growth factor), nitric oxide synthase 
[80-82] and erythropoietin [83]. VEGF is likely the most potent endothelial cell-specific 
growth factor that is activated in this setting [84,85]. When angiogenesis is initiated, the 
proliferation and migration of endothelial cells forms a tumour vascular network, a process 
assisted by the angiopoietins [86]. In the following section, these two growth factors and their 
roles in GBM angiogenesis are discussed. 
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 3.6.1. VEGF/VEGFR 
Vascular endothelial growth factor, initially termed vascular permeability factor, is an 
endothelial cell-specific mitogen [87]. The VEGF family of proteins includes VEGF (i.e. 
VEGF-A), VEGF-B, C, D and E and placenta-growth factor, which all interact with one of the 
three tyrosine kinase receptors VEGFR-1 (Flt-1), VEGFR-2 (Flk-1/KDR) and VEGFR-3 (Flt-
4). During normal embryonic development, VEGF receptors are expressed by invading 
endothelial cells [88,89], whereas VEGF mRNA is found expressed by cells in the 
periventricular matrix zone [90], indicating that this family of growth factors participates in 
early angiogenesis. In GBM in situ, there is a marked up-regulation of VEGF expression in 
hypoxic areas close to necrotic regions [91,92] [93]. The concentrations of VEGF in the cyst 
fluid of GBMs have been shown to be 200 to 300-fold higher than those found in the serum of 
the patients [94], suggesting the importance of this growth factor in GBM angiogenesis.  
    Elevated VEGF levels have been shown to correlate with increased tumour vascularity and 
inversely with survival [94,95]. Knockdown of VEGF expression by antisense technology or 
with anti-VEGF antibodies transformed intracranial glioblastomas to less-vascularised low-
grade glioma-like lesions in rodent tumour models [96,97], demonstrating the functional 
dependence of glioma vascularisation on VEGF. The VEGF receptors VEGFR-1 and 
VEGFR-2 are up-regulated on endothelial cells found in high-grade gliomas, but are not 
expressed on endothelial cells of the adult brain [85]. The interaction of VEGF with its 
receptors initiates a signalling cascade that promotes endothelial cell proliferation [98]. In 
addition, VEGF induces vascular permeability, allowing plasma proteins to extravasate, 
which creates a provisional matrix for endothelial cell invasion and subsequent blood vessel 
formation [99]. VEGF-induced plasma fluid extravasation also results in peritumoral 
vasogenic edema (an increase in the water content in the tissue, which leads to excessive 
enlargement of the extracellular space) [100]. In newly formed blood vessels, the survival of 
endothelial cells is also dependent on VEGF [101]. Hypoxia is a potent stimulator of VEGF 
expression, mediated by the Hif-1α/ Hif1-β heterodimer through a hypoxia responsive 
element (HRE) within the VEGF gene [102]. Interference with the Hif pathway prevents 
tumour growth in vivo, demonstrating the functional importance of the Hif pathway in 
neoplasia [80]. In addition to inducing transcriptional activation of VEGF, hypoxia also 
increases the stability of the VEGF-A mRNA [103].  
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Dominant oncogenes that are active in glioblastoma cells may contribute to elevated 
VEGF levels [104]. For example, activation of the PI3K/AKT pathway by mutant ras 
oncogenes induces VEGF expression [105-107]. EGFR over-expression is also demonstrated 
to up-regulate VEGF through the PI3K/AKT pathway, however it is not clear if it occurs by a 
Hif-dependent or Hif-independent mechanism [108,109]. In addition to VEGF, VEGF-B 
mRNA has also been found to be up-regulated in astrocytomas irrespective of histological 
grade, suggesting that this isoform may also contribute to tumour angiogenesis [110]. 
 
3.6.2. Angiopoietins/Tie-2 
The angiopoietins Ang-1 and Ang-2 and their receptors Tie-1 and Tie-2 are involved in 
embryonic vasculogenesis and are co-expressed by most of the blood vessels and capillaries 
during early development [111,112]. Ang-1 recruits and sustains peri-endothelial support cells 
and is necessary for the maturation of newly formed blood vessels. Ang-2 seems to counteract 
these functions, by acting as an antagonist on the Tie-2 receptor [113,114]. Knockout models 
of Ang-1 display defective modelling of the primitive vascular plexus and lack of perivascular 
cells, an effect similar to that seen in Tie-2 knockouts [115]. On the other hand, Ang-2 over-
expression can lead to endothelial cell apoptosis and to the regression of newly formed blood 
vessels in the absence of VEGF [113]. It is now clear that both angiopoietins bind to the Tie-2 
receptor, Ang-1 as an agonist and Ang-2 as an antagonist.  
    The ligand for Tie-1 receptor is not known. In contrast to Tie-2 deficiency, which results in 
an unfinished capillary tree, the absence of Tie-1 results in a poor capillary integrity 
[114,116]. This demonstrates that the Tie receptors are responsible for distinct mechanisms 
during the process of blood vessel formation and maturation.  
   In transgenic mice, VEGF over-expression yields leaky blood vessels, whereas Ang-1 over-
expression gives rise to tight blood vessels [117]. Thus; VEGF and Ang-1 may co-operate 
during embryonic blood vessel formation, VEGF by providing mitogenic stimuli for the 
endothelial cells, and Ang-1 by stabilising and enlarging the newly formed vessels [118]. Up-
regulation of Ang-1 and concomitant down-regulation of VEGF has been implicated in the 
development of the blood-brain barrier [119]. Conversely; in the incidence of brain ischemia 
following stroke, disruption of the blood-brain barrier is associated with increased mRNA 
levels of VEGF and decreased levels Ang-1 mRNA [120].  
     Evidence suggests that the angiopoietins and Tie-1 are also involved in glioblastoma 
vascularisation [86,121,122]. Whereas Ang-1 mRNA is localised to tumour cells, Ang-2 
mRNA is seen has been detected endothelial cells of hyperplastic and non-hyperplastic 
tumour vessels [121].  
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 Ang-2 was found expressed in partially sclerotic vessels and in vascular channels surrounded 
by tumour cells in the brain tissue adjacent to the tumour. In human brain tumours, 
significantly elevated levels of Tie-1 mRNA is seen expressed both in the tumour 
endothelium and in the endothelium of the bordering brain tissue [123].  
 
3.7. In vivo glioma models 
 
There are two main reasons for modelling brain tumours in animals. The first is to identify the 
genetic events that contribute to oncogenesis within the central nervous system; thereby 
identifying possible targets for tumour therapy, as well as providing insight into brain tumour 
biology. The second reason is to obtain representative models to evaluate potential therapeutic 
strategies [124]. Three different in vivo models are discussed below, two are based on the 
grafting of foreign tumour material into animals, and one involves creating experimental 
tumours within the animal host by genetic manipulation. Foreign brain tumour material may 
be grafted intracranially or subcutaneously. The former is thought to be a more representative 
model, however the latter is widely employed for therapeutic purposes for its ease of 
evaluation by direct measurement with a calliper. 
 
3.7.1. Cell line-based models 
A number of glioma and glioblastoma cell lines generated from both rodent and human 
sources exist. The rodent cell lines are usually derived from tumours that have been induced 
in experimental animals by exposure to carcinogenic chemicals, for example to DNA 
alkylating agents such as ethyl-nitrosourea [125] [126,127]. Human glioma cell lines are 
derived from patient biopsy material by transferring the resected tumours to tissue culture 
flasks, which may subsequently be cultured for more than hundred passages [128]. 
Transplantation of the various cancer cell lines either to syngeneic- (rodent cell lines) or to 
immuno-compromised (human cell lines) animals leads to the development of tumours with 
typical growth characteristics.  
The advantage of cell line-based tumour models is good reproducibility with respect to 
tumour take, growth characteristics and survival. In addition, immortalised cell lines are 
readily expanded in vitro, yielding almost unlimited amounts of tumour material for 
experimental use. A major disadvantage of cell-line based models when evaluating 
therapeutic modalities is the genetic- and phenotypic deviation of the obtained lesions from 
the patient situation.  
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 The reasons for this deviation relate mostly to the genetic and epigenetic changes that occur 
during adaptation to the artificial situation of monolayer tissue cultures. During this process, 
tumour cell clones that are not able to adapt are lost. Therefore, the resulting cell lines tend to 
be genetically more homogenous than the parent tumours. Moreover, an additional genetic 
drift may occur during subsequent passaging in culture, which further increases the 
divergence from the original tumour. For example, an aberrant expression of ECM 
components was observed when GBM patient biopsies were transferred to culture and 
passaged as monolayers, suggesting that a certain (mesenchymal) differentiation may occur in 
vitro [129].  
In general, transplantation of tumour cell lines to animal hosts do not recapitulate the 
diffuse infiltrative growth pattern of malignant brain tumours in situ [130]. These tumours 
grow as well-circumscribed lesions localised around the injection site [131,132]. However, 
since cell line-derived tumours often exhibit extensive angiogenesis, they are suited for 
studying anti-angiogenic therapies.  
 
3.7.2. Biopsy xenografts 
GBM models may also be generated by culturing the patient biopsy in the form of 
multicellular aggregates (spheroids) without previous passaging in monolayers [133]. Such 
”organotypic” spheroids contain preserved vessels, connective tissue, and macrophages, 
displaying the cellular constituents of GBMs in situ [133]. In addition, the spheroids preserve 
other characteristics of the patient tumours, such as the same DNA ploidy and a similar 
percentage of proliferating cells [133,134]. Importantly, tumour cells maintained in this way 
display diffuse infiltrative growth similar to the parent neoplasm, when the spheroids are co-
cultured with fetal brain tissue or implanted into the nude rat brain [131,132,135,136]. 
Standardised transplantation of equal amounts of biopsy spheroids derived from the same 
patient yields high reproducibility with respect to tumour take, growth rates and survival 
[131]. As this model better preserves the invasive characteristics of the original tumour, 
histological variations occur between tumours established from different patients. They are 
characterised by differences in cellularity, growth pattern and invasiveness [131]. When 
serially transplanted in nude rats, the xenografts display necrotic areas as well as endothelial 
proliferation, typical for GBM in situ [131]. Taken together, this model system seems to be 
more representative for human glioblastoma, making it a favourable choice for studying 
tumour biology and for evaluating therapeutic strategies.  
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This system has been employed both in intracranial and subcutaneous locations for the 
evaluation of gene therapeutic approaches ([137-140] and papers III-IV). 
 
  
Figure 4. Growth patterns of intracranial GBM xenografts. 
A comparison of the growth characteristics of xenografts established from patient biopsy spheroids (A,C) or the D-54Mg cell line 
(B,D). The macroscopic image to the left shows a brain section immunostained for human-specific vimentin, labelling tumour cells 
dark brown. Invasive spread of glioma cells to the contralateral hemisphere (indicated by arrow) is evident (A). Higher power 
magnification of the tumour-brain border-zone reveals diffuse single-cell infiltration into the host brain tissue (C). Cell-line 
xenografts grew as spherical lesions localised to the vicinity of the injection site. They show demarcated growth within the same 
hemisphere and do not spread to the contralateral side (B). Magnification of peripheral tumour regions reveals a sharp border 
toward the host brain tissue. Images reproduced by permission [132]. 
 
 
3.7.3. Transgenic models 
Transgenic animals are generated by implementing defined genetic- or epigenetic changes in 
otherwise normal animal hosts [141,142]. These models have the advantage that the genetic 
alterations are precisely defined and are homologous throughout the organism. Therefore, 
they may be employed to dissect the minimum genetic alterations that are necessary for 
malignant transformation, or to define the interplay between the pathways involved in 
oncogenesis [124]. Rodent models with either gain-of-function (transgenic animals) or loss-
of-function (targeted deletion) mutations have been developed. Tumour-bearing transgenic 
mice may be generated by directing the expression of an oncogene from a tissue-specific 
promoter [130,143]. In addition, tissue-specific enhancers may be added to elevate gene 
expression [144].  
Targeted deletions were originally achieved by germ-line deletions, leading to gene knockout 
in every cell of the host animal. However, methods for conditional gene deletion have now 
been developed, where a tumour suppressor may be turned off in a tissue-or time specific  
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manner, making it possible to study specific deletions that would be fatal if they were 
constitutively lost in all tissues [142]. Another approach still is to generate tumours by 
somatic transfer of oncogenes with the use of viral vectors [30,145,146]. To recapitulate 
GBM development, Holland and co-workers infected mice with viral vectors which directed 
the expression of K-ras and AKT/PKB in infected cells either through the nestin- or the GFAP 
promoter (specific for neural-progenitors and astrocytes, respectively) [30]. This way, the 
expression of the oncogenes could be restricted to the desired cell types. While these models 
were originally developed to study oncogenesis and tumour biology, one might anticipate the 
use of such models to test therapeutic approaches directed against distinct genes or pathways.  
 
3.8. Clinical treatment strategies 
 
The current standard treatment for patients with high-grade gliomas consists of surgical 
resection followed by radiotherapy and chemotherapy [147,148]. In spite of improvements in 
these modalities, the median survival of patients diagnosed with diffuse astrocytic tumours 
remains disappointingly low, 2-3 years for anaplastic astrocytoma and 5-11 months for GBM 
[149]. Survival is primarily affected by the age of the patient as well as the histological grade 
of the tumour and its anatomic location [150,151]. 
 
3.8.1. Surgery 
Surgery is performed to remove as much tumour tissue as possible [152]. Tumour resection 
improves the immediate neurological function of the patient by relieving the elevated 
intracranial pressure and by decompressing adjacent brain tissue [153]. Surgery allows for the 
insertion of single direction catheters, which drain excess accumulated fluid from the cerebral 
ventricles to other body cavities, such as the right ventricle of the heart or the abdominal 
cavity. This approach is especially useful for relieving chronic elevated intracranial pressure 
in cases where tumour growth blocks the normal clearing of cerebrospinal fluid.   
     The contribution of surgery to increasing patient survival has been a matter of debate. 
Retrospective studies indicate that radical surgery may result in significant survival benefit 
when compared to partial resection or simple biopsy procedures [150,153]. In a large study 
comprising 645 glioblastoma cases, patients undergoing total resection had a median survival 
of 11.3 months, versus 6.6 months for biopsy only [154]. Similarly, re-operation of recurrent 
gliomas may offer a reasonable extension of survival with good quality of life [153]. For both 
first-time operation and re-operation, there is a clear correlation between the pre-operative 
neurological status and the post-operative quality of life and duration of survival [153,155].  
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 However, these trials have been subject to selection bias, since the extent of attempted 
resection is greatly influenced by the condition of the patient (age and performance status) 
and the size and site of the tumour.  
     Notably, no prospective randomised trials have compared surgery and radiotherapy-
/chemotherapy with radiotherapy/chemotherapy alone for high-grade gliomas. Such a trial is 
probably not possible for ethical reasons, as current literature suggests that radical surgery 
should be attempted in all cases where the tumour is accessible and lies in non-eloquent areas 
[150,156]. 
      
3.8.2. Radiation treatment 
Radiation treatment is routinely performed in the treatment of malignant gliomas as a 
supplement to surgery, as well as in cases where tumour resection is not feasible. All radiation 
treatment modalities are designed to achieve local tumour control. Post-operative radiotherapy 
of anaplastic astrocytomas and glioblastomas significantly improved survival when analysed 
in randomised controlled trials [157,158].  
   Ionising radiation delivered during radiotherapy may affect the target cells in a direct 
manner by random interactions between the photons and the biological molecules. The effects 
may also be indirect, mediated by reactive photon products, such as oxygen radicals. Ionising 
radiation mainly affects DNA, yielding both single- and double-stranded breaks, with double 
stranded breaks considered as the lethal effect. Radiation damage is most pronounced in the 
G2 and the metaphase of the cell cycle [159]. Therefore, radiotherapy is most effective in 
cycling cells, such as those found in a growing neoplasm. Since the reactive intermediates that 
are produced have extremely short half-lives, they are only able to produce damage when they 
are generated within tens of ångstrøms from the DNA. However, the lifetime of the radicals, 
and therefore, their range and efficacy are enhanced in the presence of oxygen or other 
radiosensitisers. Unfortunately, glioblastomas tend to be more poorly oxygenated than the 
surrounding brain tissue, therefore maximal doses must be limited to avoid normal tissue 
damage [160].  
   
Radiotherapy 
 For conventional radiotherapy of malignant gliomas, patients usually receive a total dose of 
60 Gy divided into 30 fractions of 2 Gy per day, directed against the tumour [160]. Initial 
studies indicated that increasing the total radiation dose from 45 to 60 Gy led to a significant 
improvement of survival time [161,162].  
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 Decreasing the size of each fraction may reduce damage caused by radiation to normal 
tissues. On the other hand, tumour cell death is more dependent on the total radiation dose. 
Therefore the total dose is often divided into a larger number of less intensive fractions 
(hyperfractionation therapy) [160].  
 
Stereotactic radiosurgery 
In stereotactic radiosurgery, high doses of precise electron beams are delivered using a linear 
accelerator or a “gamma knife”. The gamma knife was originally designed for functional 
neurosurgery of inaccessible cerebral lesions, in particular small arteriovenous malformations 
and benign tumours such as acoustic neuroma and craniopharyngioma [163]. The beams from 
two hundred and one 60Co sources placed within the gamma knife are directed towards a 
common focal point, creating spherical irradiation fields of 4-35 mm [164]. Tumours larger 
than 35 mm may be treated by employing multiple radiation fields. The advantage of this 
method is the possibility to deliver highly focused radiation to the tumour mass with a sharp 
fall of radiation dose toward the neighbouring brain tissue. Today, computer-guided dose 
calculation and volume planning is employed to deliver the radiation to the precise tumour 
shape. Promising results have been obtained using the Gamma knife for the treatment of low-
grade gliomas, resulting in local tumour control and improvement of clinical status [165,166]. 
An analysis of the available clinical trials for high-grade gliomas suggests that any 
improvement reported is probably attributable to patient selection bias and does not support 
the continued application of strereotactic radiosurgery [167]. Other more recent studies have 
arrived at the same conclusion [168,169]. 
 
Brachytherapy 
In cases where the tumour is localised and radiologically detectable, interstitial radiation 
therapy (or brachytherapy) may be used. This method employs radioactive pellets implanted 
into the tumour to kill the cancer cells, thereby minimising the exposure of normal brain 
tissue to radioactivity. Early clinical studies performed in the 1990s suggested improved 
survival of glioblastoma patients treated with brachytherapy combined with external radiation 
when compared to radiotherapy only [170,171]. Unfortunately, several of these studies were 
shown to be biased in patient selection and subsequent prospective randomised trials failed to 
reveal any survival benefit compared to standard treatment protocols [172,173].  
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 Boron Neutron Capture Therapy 
Boron Neutron Capture Therapy (BNCT) uses thermal or epithermal neutron beams to 
activate a boron drug concentrated within the tumour cells. Boron may be delivered to the 
tumours using appropriate pharmacological agents. When 10B is exposed to radiation, it 
becomes unstable and disintegrates, releasing harmful radiation, which kills the cells. The 
penetration distance of the fission products 4He2+ and 7Li3+ is 9 and 5 µm, respectively; 
therefore it is mainly the cells that have incorporated the boron-containing substance that are 
destroyed [174]. The experimental application of BNCT has revealed significant survival 
benefit in rodent glioma models [175,176]. Recent clinical studies show that BNCT is 
relatively well tolerated by the patients [177-179] and early clinical data have suggested that 
BNCT treatment may yield occasional long time survivors [180]. However, analyses of the 
survival data for some of these patients (analysed following the stratification criteria 
according Curran et al. [181]) has not revealed significant survival benefit [182]. The 
following issues should be addressed to improve BNCT-treatment of brain tumours: the 
application of more selective and more effective compounds that would deliver sufficient 
amounts of boron to the tumour tissue, improvements in methods to evaluate boron content in 
the tumour, and the co-localisation of BNCT delivery facilities with medical centres to 
facilitate better treatment conditions for the patients [183]. Importantly, the potential of this 
treatment form would need to be re-evaluated in randomised prospective trials.   
 
3.8.3. Chemotherapy 
The use of chemotherapy is now well established for the treatment of several types of brain 
tumours. Chemotherapy of brain tumours is not curative, and is offered as adjuvant or neo-
adjuvant treatment in addition to surgery and/or radiotherapy. The goal is to control tumour 
growth and to maintain good performance and quality of life for the patients [147].  
   Low-grade gliomas (astrocytomas and oligodendrogliomas) as well as CNS tumours of 
other origin (medulloblastomas, primitive neuroectodermal tumours, germ cell tumours and 
primary CNS lymphomas) have responded well to chemotherapy, resulting in significant 
survival benefit for the patients [151]. On the other hand, glioblastomas tend to become 
resistant and show only temporary responses [151]. For a chemotherapeutic treatment to be 
effective, the drug has to be distributed throughout the tumour at cytotoxic- or cytostatic 
concentrations for a sufficient time-period. Response to the drug depends on several factors, 
such as the mechanism of action, the kinetics of tumour cell growth, the chemosensitivity of 
the tumour cells and the mode of delivery [184].  
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     Alkylating agents were introduced to cancer therapy nearly 60 years ago and are still in 
clinical use [158,185,186]. Of these drugs, alkylating nitrosourea compounds (BCNU, 
CCNU) are widely employed for glioma chemotherapy, either alone or in combination with 
other drugs [148,184]. Alkylating agents decompose to reactive chloroethyl-carbonium ions 
that deliver alkyl groups to DNA, and to organic isocyanates that inhibit nucleic acid 
replication and transcription [187]. Nitrosoureas are highly lipophilic; they have a relatively 
low molecular weight, and do not ionise readily at physiological pH. These properties cause 
efficient penetration of the blood-brain barrier when administered intravenously, resulting in 
good distribution within the CNS.  
     Another class of drugs is the vinca-alkaloids such as vincristine and vinblastine. These 
compounds inhibit the polymerisation of microtubuli, which mainly affects the mitotic 
spindle, blocking the cells in metaphase [188,189]. In addition, microtubuli arrest also affects 
tumour cell migration, invasion and intracellular transport mechanisms, which may yield 
secondary anti-neoplastic effects [184]. For adjuvant chemotherapy, the first line of treatment 
consists of BCNU or a three-drug regimen consisting of procarbazine, CCNU and vincristine, 
(PCV) [185]. The treatment of recurrent gliomas by chemotherapy may show limited effects, 
since the tumour cells often develop resistance toward nitrosoureas. This may be 
circumvented by the use of non-nitrosourea based agents. Temozolomide is an 
imidazotetrazine-derived prodrug that is converted into a DNA methylating agent in vivo. It is 
absorbed well upon oral administration with nearly 100 % bio-availability [190]. 
Temozolomide crosses the blood-brain barrier, resulting in widespread distribution 
throughout the CNS [191]. For recurrent GBMs, temozolomide has proven to be effective at 
first relapse with an acceptable safety profile [191-193]. 
     A meta-analysis review which has processed the data from 16 clinical trials has detected an 
8% increase in the 2-year survival for anaplastic astrocyoma patients and a 4 % increase in the 
2-year survival in GBM patients when adjuvant chemotherapy was given in addition to 
radiotherapy [194]. More recently, the Glioma Meta-analysis Trialist Group (GMT) has 
performed a statistical review of individual patient data from 12 randomised trials, including a  
total of 3004 patients that have been treated with nitrososurea-based adjuvant chemotherapy 
for high-grade glioma [195]. Chemotherapy was found to provide a modest, but highly 
significant increase in the median survival time (of 2 months duration) compared to treatment 
with radiotherapy alone. A recent randomised phase III trial which enrolled 573 patients with 
GBM compared concomitant and adjuvant use of temozolomide versus radiotherapy alone 
[196].  
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The results were encouraging, with a 2.5 months increase in median survival for the combined 
chemo-and radiotherapy group compared to radiotherapy alone (14.6 vs. 12.1 months, 
respectively). The data were statistically significant and also clinically meaningful, with a 2-
year survival rate of 26% versus 10% for radiotherapy alone. Thus, both nitorosoureas and 
temozolomide show similar clinical benefit for patients with high-grade glioma. However, the 
superior safety profile of temozolomide indicates that it may be the drug of choice for 
recurrent tumours [148].   
     Even though certain patients show marked and prolonged responses to chemotherapy, the 
overall contribution to survival is modest and needs to be re-evaluated in the light of a 
possible worsening of quality of life for some agents.  
 
3.9. Experimental therapy 
 
Based on the limited effects using conventional clinical therapies, there is a search for new 
and effective therapeutic modalities for malignant brain tumours. Some of the more novel 
molecular approaches are presented below. 
 
3.9.1. Immunotherapy 
Clinical studies conducted throughout the 1970s and 1980s have demonstrated that patients 
harbouring malignant gliomas present with impaired cell-mediated immunity [197]. The 
observed systemic immunosuppression appears primarily to result from cytokine 
dysregulation, mediated by soluble factors secreted by the glioma cells [197]. Transforming 
growth factor -β, and other related growth factors inhibit IL-2 production and the proliferation 
of T-cells [198-200]. Supporting this contention, the extent of immunosuppression shows 
significant correlation with tumour size [201], and surgical debulking has been associated 
with the partial restoration of systemic T-cell function [202]. In addition, gliomas may also 
have suppressed immunogenicity at the tumour site as a consequence of either down-
regulation of major histocompatibility molecules [203] or Fas ligand over-expression, which 
induces apoptosis in infiltrating lymphocytes upon direct contact through Fas/APO-1 
[204,205].  
There is substantial evidence that boosting the compromised tumour-specific immune 
responses can improve survival time lengths in rodent glioma models [206-209]. However, 
the benefit of immunotherapy for the treatment of human brain tumours remains to be settled.  
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In the following paragraphs, passive serologic immunotherapy, cytokine therapy, adoptive T-
cell transfer and vaccination strategies for in vivo T-cell activation will be discussed. 
 
Passive serologic immunotherapy 
 
In theory, monoclonal antibodies (mAbs) generated against tumour-specific molecules may be 
utilised to target and destroy neoplastic cells. Such therapeutic antibodies may be directed 
towards cell-surface receptors, thereby blocking signalling pathways that are necessary for 
neoplastic cell survival; or against extracellular matrix components that are known to be 
widely expressed by malignant gliomas [210]. For this application, the ECM molecules serve 
as “anchors” to guide the antibodies to the cells, which need to be armed with cytotoxic 
conjugates (such as a radioactive isotope or an immunotoxin) to exert their effects. 
      Passive serologic immunotherapy faces several challenges in order to be considered for 
the treatment of malignant gliomas. First, it is difficult to identify highly glioma-specific 
surface markers that are not expressed by normal brain cells. Although there are several 
antigens whose expression is up-regulated in malignant gliomas (such as the receptors for 
EGF [70], PDGF [211] and TGF-β [212]), none of these antigens are exclusive to tumour 
cells. Therefore, the application of antibodies directed against these molecules may induce 
normal tissue toxicity. Furthermore, the antigen of choice has to exhibit both stable- (lack of 
internalisation or down-regulation upon antibody binding) and robust expression throughout 
the glioma tissue to have any therapeutic effect [213]. The kinetics of transport within the 
tumour (affected by tumour vascularity, vascular permeability, extracellular fluid dynamics 
and interstitial pressure) of the antibody considered also needs to be favourable [210].  
   Early clinical evaluation of passive serologic immunotherapy for malignant gliomas has 
provided inconclusive results. Favourable outcomes have been reported from a phase II trial, 
which involved a 131I-labelled mAb against tenascin (an ECM molecule which aids tumour 
cell invasion) in 33 patients with malignant gliomas applied by direct injection into the 
surgical resection cavity [214]. After antibody administration, the patients received 
conventional external beam radiotherapy followed by a year of chemotherapy. The median 
survival for all malignant glioma patients undergoing the combined treatment was 86.7 
weeks; whereas for GBM patients it was 79.4 weeks. After accounting for established 
prognostic factors such as age and Karnofsky performance status, the authors concluded that 
the median survival times achieved by serologic immunotherapy exceeded that of historical 
controls.  
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     Prolonged patient survival has also been observed in a phase II trial where 180 patients 
with malignant gliomas were treated with a 125I-labeled monoclonal antibody directed against 
the EGF receptor [215].  
 
Cytokine therapy 
Cytokines are soluble effector molecules that are responsible for initiating, supporting or 
blunting specific immune pathways. The therapeutic over-expression of appropriate cytokines 
may potentiate immune surveillance and induce cellular anti-tumour immunity [216]. For 
glioma immunotherapy, the focus has been on cytokines that are involved in the promotion of 
tumoricidal T-cell activity, such as IL-2 [217,218], IL-4 [219,220], IL-12 [207,216,221] and 
the interferons (IFN-α, β and γ) [222,223]. Initial investigations have involved recombinant 
cytokine therapy, where high systemic doses of cytokines have been applied to stimulate 
strong anti-tumour responses. Although this approach has proved to be highly effective in 
rodent tumour models [224,225], it has not been met with success in the clinical setting. 
Major limitations have been the considerable tissue toxicity and the low half-life of the 
delivered molecules [226], preventing sustained therapeutic effect. Attempts to address these 
issues have resulted in new approaches using viral vectors [207,219] or producer cells 
[217,220,227] for site-directed delivery of the cytokines to the tumours. Both approaches have 
been highly successful in pre-clinical experiments [207,217,219,220,228].  
     Recently, the use of neural stem cells (NSCs) to deliver such therapeutic cytokines has 
been investigated [229]. Neural stem cells have been shown to track glioma cells and display 
tumour-tropism even after implantation in the contralateral brain hemisphere [227,230]. NSCs 
expressing IL-12 or TRAIL were highly efficient at inducing T-cell infiltration and tumour 
cell apoptosis, respectively, resulting in strong tumoricidal effects in rodent glioma models 
[227,228].  
 
Adoptive T-cell transfer 
Initial experiments of adoptive cellular therapy have been conducted using autologous, non-
activated immune cells delivered through intratumoral- [231,232] or intrathecal [233,234] 
administration. Subsequently, the identification of IL-2 as a potent T-cell mitogen led to the 
application of lymphokine-activated killer (LAK) cells for glioma therapy. The clinical 
evaluation of LAK cells transplanted into the resection cavity has yielded confounding results 
[235,236]. In one study, neurological side effects associated with immunotherapy were seen 
in all of the treated patients [237].  
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     Subsequent studies have focused on the adoptive transfer of specifically activated T-cell 
populations. The results have been inconclusive. In one clinical study including 12 patients 
with grade II-IV astrocytomas, anti-T-cell receptor (CD3) antibodies, bacterial superantigens 
and IL-2 were employed to stimulate T-cell activation before the cells were administered 
intravenously to the recipients [238]. Partial tumour regression was seen in four patients and 
only mild treatment discomforts could be related to therapy. No long-term adverse effects 
were observed.  
 
Active immunotherapy (vaccination strategies for in vivo T-cell activation) 
Substantial evidence has now accumulated to prove that the successful activation of cytotoxic, 
glioma-specific T-cells is of major importance to generate effective anti-tumour immune 
responses [239,240]. In general terms, the adoptive cell transfer of in vitro-expanded and 
activated T-cells does not generate true anti-tumour T-cell immunity, given the lack of 
specificity and the inability to generate protective memory [241]. Thus, identifying and 
successfully presenting immunologically relevant tumour antigens to T-cells in vivo is the 
main challenge for enhancing tumour-specific T-cell responses. Still, as discussed above, the 
difficulty of identifying glioma-specific, immunologically relevant tumour antigens remains a 
major hurdle.  
     Initial vaccination experiments have utilised either irradiated whole tumour cells or 
dendritic cells (DCs) pulsed with non-specific tumour-derived peptides or lysates in order to 
present a broad range of unknown, tumour-derived antigens to the T-cells in vivo. The 
subcutaneous implantation of irradiated, autologous tumour cells together with IL-2 secreting 
fibroblasts resulted in marked tumour necrosis and enhanced T-cell mediated anti-tumour 
immunity in a phase I study for glioblastoma [242]. Although there have been some 
encouraging results with such modalities, the main limitation of this approach is the poor 
antigen-presenting capability of the glioma cells. Thus, more recent strategies have focused 
on employing professional APCs, such as dendritic cells, rather than trying to augment the 
antigen-presenting capabilities of the glioma cells. In theory, the application of DCs should 
prove to be superior for T-cell priming, since DCs abundantly express many of the co-
stimulatory molecules that are essential for the appropriate activation of naive T-cells. Recent 
evidence suggests that direct physical interaction between the DCs and the tumour cells may 
be essential to induce therapeutically effective immune responses [243] and that DCs are 
capable of processing apoptotic tumour cells to induce cytotoxic T-lymphocyte activity 
[244,245].  
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Thus, the most recent experimental approaches involve the intratumoral administration of 
DCs in the context of radiotherapy to induce tumour cell death. Therapeutic modalities based 
on this principle have been found to be effective in rodent models, resulting in robust T-cell 
infiltration, inhibition of glioma growth and prolonged survival [246,247]. 
 
3.9.2. Therapy targeted to the tumour vasculature 
In 1971, Judah Folkman and colleagues proposed that solid tumour growth could be 
prevented by interfering with tumour vascular sprouting (angiogenesis)[248]. The angiogenic 
switch, which controls the onset or the shutdown of new vessel formation, is regulated by the 
balance between angiogenic growth factors (inducers) and inhibitors present in the tumour 
microenvironment [249]. Accordingly, local over-expression of angiogenesis inhibitors may 
be exploited for solid tumour therapy [250]. The main advantage of anti-angiogenic therapy is 
that it is directed toward the genetically more stable endothelial cells. In theory, this would 
circumvent the problem of acquired drug resistance that may develop in cases where 
treatment is aimed at the genetically volatile neoplastic cells [251]. To date, multiple 
angiogenesis inhibitors have been identified, and several of these have entered clinical trials 
[252]. Since high-grade gliomas are among the most vascularised lesions known, they are 
considered to be particularly attractive targets for anti-angiogenic therapy. The therapeutic 
over-expression of angiogenesis inhibitors, as well as the inhibition of key angiogenic factors 
have been attempted in pre-clinical experiments for malignant gliomas [253]. Most often, 
endogenous- or synthetic inhibitors of angiogenesis have been employed to control tumour 
growth. Some of these inhibitors are listed in table IV (appendix). The application of 
angiogenesis inhibitors has been attempted in the framework of different delivery systems. 
Early studies typically utilised the purified inhibitor in its protein form, often given as 
intravenous- or intratumoral injections. Disadvantages of this type of anti-angiogenic therapy 
are the necessity of applying repeated injections due to the short half-life of the inhibitors, as 
treatment needs to be continuous to maintain tumour dormancy. Obtaining sufficient amounts 
of clinical grade purified inhibitor is associated with high costs. For these reasons, subsequent 
research has concentrated on gene therapy by viral vectors or protein delivery by genetically 
engineered producer cells. Importantly, the anti-angiogenic strategies discussed above 
typically target immature vessels that participate in angiogenesis, which are sensitive to 
agents that block proliferation or induce regression of the tumour endothelium.  
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However, the relative number of proliferating endothelial cells in human malignant lesions is 
low, considerably smaller than those found in rodent tumour models [254], a notion that 
might explain the relatively poor efficacy of angiogenesis inhibitors in clinical trials. 
Recently, research efforts have focused on identifying molecular markers expressed by the 
entire tumour-associated endothelium to improve drug delivery to endothelial cells that are 
not participating in angiogenesis at a given time. Serial analysis of gene expression profiling 
and phage display technology have provided us with molecular signatures of the tumour 
vasculature [11,255,256]. Investigators have presented proof-of-principle for the efficient of 
re-targeting of a wide range of therapeutic molecules as well as viral vectors to endothelium-
specific peptides [257,258]. Further unravelling of the cellular mechanisms involved in the 
specific inhibition of tumour vasculature will probably provide us with novel, specific 
markers associated with the tumour endothelium, which may be used in vascular targeting.  
 
Endostatin 
Endostatin is an endogenous angiogenesis inhibitor [259]. It is a 20-kD proteolytic fragment 
of collagen XVIII, an ECM component mainly found in blood vessel walls and in the 
basement membranes of the liver, kidney and the lung [260]. Endostatin may be cleaved from 
collagen XVIII by a range of proteolytic enzymes [261]. Since both capillary sprouting and 
tumour cell migration are associated with enzymatic degradation of the extracellular matrix, 
endostatin release is thought to be a direct consequence of these processes. Indeed, the serum 
levels of endostatin have been shown to be significantly elevated among patients with a 
variety of cancer types [262].  
      Research has revealed a variety of mechanisms by which endostatin signalling down-
regulates endothelial cell survival, motility and invasion. Blockade of VEGF/VEGFR 
signalling [263,264], inhibition of metalloproteinases [265] and down-regulation of c-myc and 
cyclin-D [266,267] are all thought to be downstream effects of endostatin signalling. It has 
recently been shown that endostatin down-regulates the expression of several Hif-1 pathway 
activators leading to strong transcriptional inactivation of Hif-1α, thereby inhibiting its 
responsive pro-angiogenic gene targets [268]. Endostatin was shown to down-regulate Id1 
and Id3, which play critical roles in angiogenesis, possibly by suppressing the expression 
levels of MMP-2 and αvβ3 integrin [269]. Importantly, Id1 transcriptionally represses 
thrombospondin-1, a potent angiogenesis inhibitor [270]. Other studies have shown that 
collagen XVIII expression is directly induced by p53, through its binding to the COL18A1 
promoter [33].  
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This evidence suggests that endostatin is part of the body’s natural anti-angiogenic response 
cascade. 
     In the initial study by O’Reilly and co-workers, the administration of recombinant murine 
endostatin protein resulted in tumour growth arrest and the regression of several subcutaneous 
cancer types [259]. Although regression of pre-established tumours has not been reproduced, 
several studies have confirmed that endostatin is a potent inhibitor of a variety of 
experimental tumour types, such as melanomas, mammary- and lung carcinomas, 
hepatocellular carcinomas and gliomas [271-274]. The initial publication, which described 
complete tumour remission upon endostatin treatment, employed E.coli-produced 
recombinant protein [259].  Subsequent studies, where yeast-derived endostatin was used 
have also reported tumour growth inhibition [275,276]. Recent work has focused on 
endostatin gene delivery, such as the application of naked plasmid [277,278], liposome-
complexed plasmid [279], adenovirus [263,272,273,280-287], retrovirus [266,274,288-297], 
adeno-associated virus [298-300] and lentivirus [301,302].  
      Endostatin protein delivery has also been attempted by in vivo transplantation of 
mammalian producer cells genetically engineered to secrete this inhibitor [303,304]. 
 
3.9.3. Suicide gene therapy 
Suicide genes are exogenous transgenes which code for metabolic enzymes that convert non-
toxic prodrugs into cytotoxic end-products [305]. Accordingly, the systemic administration of 
a prodrug only harms cells that express sufficient levels of the exogenous suicide gene. The 
application of suicide genes for glioblastoma therapy has been attempted in the framework of 
several vector systems, as reviewed recently by Pulkkanen and Herttuala [306]. Of the several 
suicide enzymes that may be exploited for these purposes [305], the herpes simplex virus 
thymidine kinase gene (HSV-tk) has been the most widely applied. Thymidine kinase 
converts the non-toxic nucleoside analogue gancyclovir (GCV) into its mono-phosphorylated 
form. Further modification by cellular enzymes yields toxic GCV-triphosphate, which inserts 
into DNA during synthesis, blocking replication and killing the target cell. A desirable feature 
of suicide gene therapy is the so-called bystander effect.  The toxic product can escape from 
infected hosts to adjacent cells via gap junctions, leading to lateral spread of the cytotoxic 
effect. Thus, adjacent tumour cells not initially infected by the vector may also be efficiently 
killed. 
      Since most tumours are genetically heterogeneous, complementing- or knocking out a 
single gene product may not target the whole lesion efficiently.  
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The main advantage of suicide gene therapy is its broad target range, affecting every dividing 
cell that expresses the enzyme. However, the promiscuity of this approach renders specific 
targeting to the tumour cells important in order to protect normal tissue [307]. This may be 
accomplished by using gene delivery vectors that have enhanced tumour-specificity by virtue 
of their binding to cancer cell-related receptors. Another way to achieve specificity is to 
exploit tumour-specific promoters to direct transgene expression; such as those that promote 
hypoxia-, angiogenesis- or invasion-related genes. 
 
3.10. Vehicles for the delivery of anti-neoplastic agents within the CNS 
 
3.10.1. Microencapsulated producer cells 
The application of genetically engineered producer cells to deliver cytokines or angiogenesis 
inhibitors has been investigated for the treatment of experimental brain tumours [308] [309]. 
The main advantage of this approach is the possibility to achieve sustained delivery of 
biologically active substances without the use of potentially hazardous gene therapy vectors. 
In general, the application of cell-based therapies employing non-autologous cells results in 
graft rejection. Encapsulation of the producer cells into microcapsules composed of immuno-
isolating substances, such as alginate, offers a way to circumvent this problem [310]. Alginate 
forms a porous network with pore diameters of 5-200 nm, which allows the transmembrane 
exchange of soluble factors, meanwhile protecting the encapsulated cells from host immune 
cells. At least within the confines of the central nervous system, the immunological response 
is mainly cellular, which supports the application of this treatment modality for brain tumours 
as well as for other neurological disorders.  
Several studies have characterised how the producer cells adapt to the microcapsules and 
examined the potential application of this delivery system within the CNS. Upon 
encapsulation into alginate, the producer cells established viable multicellular aggregates 
[311]. Importantly, 70 % of the cells within the capsules remained viable 4 months post-
encapsulation, and only mild inflammatory reactions were observed when alginate beads were 
implanted into the rat brain [312].  
The delivery of human growth hormone (hGH) to mammalian brain tissue by alginate-
encapsulated murine myoblast producer cells has also been evaluated in an experimental 
study [313]. After intraventricular implantation in the mouse brain, hGH secretion from the 
bioreactors was detectable for 16 weeks, with peak levels observed after 8 weeks post-
implantation.  
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 Immunohistochemical studies revealed that the secreted hGH protein was distributed 
throughout a radius of 1.5-2 mm from the implantation site.  
Similar experiments employing alginate-encapsulated hybridoma cells showed that 
antibody release increased up to day 12 in vitro, whereafter stable secretion was achieved at 
high levels [311]. Upon implantation into the rat brain, the secreted immunoglobulins were 
detected at least 1 mm from the implantation site, with a gradual decrease in concentration 
from the beads toward more peripheral areas [311]. These studies suggest that of alginate-
encapsulated producer cells may be a safe and a reliable way to deliver therapeutic molecules 
to the CNS. Further experiments were conducted to evaluate the anti-vascular effects of this 
delivery system using 293-EBNA producer cells that secreted endostatin. In two studies, the 
encapsulated cells were implanted together with BT4C- or C6 glioma cells into rodent hosts at 
an intracranial or a subcutaneous location. The delivery of endostatin by this application 
exerted a potent anti-angiogenic effect, resulting in a significant inhibition of tumour growth 
[303,314]. 
     In a clinical study aimed at correcting amyotrophic lateral sclerosis (ALS; a degenerative 
neurological disorder), microencapsulated producer cells secreting ciliary neurotrophic factor 
(CNTF) were surgically placed into the intrathecal lumbar space of patients [315]. By this 
approach, elevated levels of CNTF were obtained in the patients' cerebrospinal fluid (CSF) for 
at least 17 weeks post-transplantation. Importantly, the limiting side effects observed after 
systemic delivery of CNTF were not seen after local delivery. For malignant gliomas, no 
clinical trials have been performed employing microencapsulated producer cells. The efficacy 
and the potential toxicity of this approach needs to be evaluated in large animal models before 
clinical trials could commence [316]. 
 
 
        
 
     Figure 5. Light microscopic image of alginate bioreactors. Ultrapure alginate microcapsules containing viable 293 cells are non-
      immunogenic and can be engineered to release anti-angiogenic factors or other molecules that are thought to interfere with tumor growth 
     within the CNS. The production of enzymes, growth factors applied to complement a range of CNS pathologies may also be envisioned 
       using this system. Scalebar: 100µm. Image reproduced by permission. 
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3.10.2. Viral vectors 
Retroviral (RV) vectors  
Retroviruses are lipid-enveloped viruses, which contain a double-stranded RNA genome of 8-
11 kB. Upon entry into the host, viral reverse transcriptase converts RNA to double-stranded 
DNA, which then integrates into the genome at random loci. Retroviral vectors based on 
Moloney murine leukaemia viruses (MMLV) can only insert transgenes into dividing cells. 
Therefore, when administered by site-directed delivery to the adult brain, these vectors would 
only infect neoplastic cells and endothelial cells participating in angiogenesis, conferring 
them an element of tumour-selectivity [317].  
RV vector systems were among the first to be applied for brain tumour therapy [318,319], 
and they have been investigated in more than half of the clinical trials employing viral vectors 
for gliomas [320]. The most common strategy has been to use replication-incompetent 
MMLV vectors carrying the HSV-tk gene [321]. A major drawback of RV vectors for clinical 
use is the fact that human serum antibodies inactivate the viral particles that are released by 
mouse-derived packaging cells [322]. In addition, RVs are difficult to purify to high titres. 
Therefore, the most common application has been to transplant the vector producer cells 
(VPCs) into the resection cavity to ensure a continuos supply of active vector at the site where 
tumour recurrence is expected.  
RV vectors have shown favourable safety profiles and some efficacy in early phase I and 
phase II trials for malignant gliomas has been reported [323-325]. However, a more recent 
randomised, prospective phase III trial which enrolled 248 patients with previously untreated 
GBMs failed to demonstrate significant survival benefit after RV-mediated suicide gene 
therapy [326]. The failure of the phase III protocol has mainly been attributed to the poor 
transduction rates, resulting in insufficient transgene delivery [326]. Since the producer cells 
were of a non-migratory fibroblast phenotype, they stayed in the vicinity of the injection site, 
limiting vector spread to more distant glioma microsatellites. The lack of penetration to more 
distal areas of the tumour mass by the viral particles has probably contributed to the poor 
transduction efficacy. Indeed, from experimental glioma models there is evidence that 
successful treatment of smaller tumours by RV vectors is feasible, but larger tumours seem to 
be refractory, underlining the contention that inadequate tissue penetration limits anti-tumour 
efficacy [319,323]. It is generally accepted that in the context of HSV-tk suicide gene therapy 
approach, a stable transduction of at least 10 % of the tumour mass is needed [327-330]. In 
contrast, the figures for gene transfer efficiency from clinical studies with RV vectors have 
been disappointingly low, in the range of 0.002-0.03 % [331,332].  
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Adenoviral (Ad) vectors 
Adenoviruses contain a double-stranded linear DNA genome of 36 kB, which encode more 
than 50 proteins, generated through extensive splicing of the primary transcripts [333]. In 
humans, adenoviruses typically cause benign respiratory tract infections. Ads can infect a 
wide range of cell types with high efficacy without the risk of insertional mutagenesis, 
making them attractive tools for gene therapy.  
     Ads have evolved to exploit the cellular machinery for the production of viral progeny, as 
well as to evade the cell´s major regulatory pathways that would restrict their replication. 
During adenoviral infection, the Ad E1A protein binds the retinoblastoma tumour suppressor 
protein (pRB). The subsequent uncoupling of E2F from pRB initiates S-phase and to leads to 
the transcription of viral genes that are essential to replication [334]. The large E1B protein 
binds p53, thereby inhibiting p53-mediated anti-viral apoptotic response. These events ensure 
an active cell cycle, allowing the Ad to multiply its genome efficiently without facing host-
cell apoptosis. Selectively replicating oncolytic vectors have been generated by deleting such 
essential early genes or by placing them under the control of tumour selective promoters. By 
deleting E1A or E1B from recombinant Ads, these vectors are restricted in normal cells that 
harbour functional pRB or p53, whereas they replicate in cancer cells where these proteins are 
defective or absent. Both E1A-deficient (Δ24) and E1B-deficient (ONYX-015) Ads have been 
constructed. Of these, the Δ24 vectors have shown superior therapeutic efficacy in 
experimental glioma models [335,336].  
     Since the native Ad receptor, CAR, was shown to be poorly expressed by some cancer 
types, limiting transduction efficacy in tumour tissues [337], a further modification was made 
by incorporating an integrin binding peptide into the Δ24 fiber knob. This novel vector, 
designated Δ24RGD, showed enhanced oncolytic effect, leading to tumour regression in 60% 
of the treated animals in an intracranial mouse glioma model [338]. Other manipulations of 
recombinant Ad vectors have included placing the E1A gene under control of the HIF-
promoter [339] to create vectors that replicate in hypoxic tumour cells known to be 
particularly resistant to radio- and chemotherapy. The administration of this vector together 
with BCNU treatment to target normoxic cells has resulted in enhanced anti-tumour efficacy 
in two independent glioma models with 50% of the tumours showing complete long-term 
regression [340].  
      To date, 8 clinical trials focusing on adenoviral gene therapy of brain tumours have been 
published [306]. A recent phase I trial employing Ad-mediated delivery of TP53 to recurrent 
GBMs confirmed tolerated doses up to 3x1012 viral particles with only minor vector-related 
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symptoms such as headache, fatigue or fever [341]. TP53 transfer to the patient tissue was 
validated, and subsequent p21 activation and the occurrence of apoptoses were confirmed in 
the vicinity of the catheter in the resected tumour samples. Of note, the maximal spread of 
exogenous p53 expression was only 8 mm (mean: 4.9 mm) from the catheter, suggesting that 
these vectors may have an inherent inability to penetrate and transduce tissues for the 
distances required in the clinical setting. An assessment of survival revealed that one patient 
was alive for 3 years without recurrence, with 4 more patients surviving for more than 6 
months [341]. Two phase II trials have been conducted in Finland, where 3.0 x1010 plaque-
forming units of Ad-HSV/tk was injected directly into the resection cavity of patients with 
primary- or recurrent malignant gliomas [342,343]. In the first study, comprising 21 patients 
divided into three groups, the application of Ad-HSV/tk resulted in a significantly increased 
survival of 15 months as compared to 7.4 months with RV- HSV/tk and 8.3 months (Ad-lacZ, 
control). A new phase II trial was conducted to corroborate these findings, where 36 patients 
were divided into two groups, receiving either Ad-HSV/tk or standard clinical treatment. This 
study confirmed the significant gain in survival obtained in the previous trial, with 70.9 weeks 
for the Ad-HSV/tk group vs. 39.0 weeks only in the standard care group. The treatment was 
well-tolerated.  
Clinical trials have confirmed the safety of adenoviral vectors for local therapy in the 
human CNS, with mild treatment discomforts such as headache, low-grade fever and 
confusion reported in some of the studies [306]. Further randomised trials are necessary to 
evaluate the potential contribution to the various adenovirus-based gene therapy vectors to 
overall survival. Importantly, the evaluation of replicating Ads in phase II clinical trials awaits 
execution. 
 
Herpes simplex virus (HSV) vectors 
HSV is a common human pathogen that establishes life-long asymptomatic infections of the 
nervous system with occasional reactivation in epidermal cells, leading to cell lysis [344]. 
HSV type 1 (HSV-1) has a linear double stranded DNA genome of 152 kB, encoding more 
than 80 genes [345].  
Much of the genome is redundant, allowing for the insertion of 50 kB foreign DNA without 
significantly affecting viral packaging [346]. The HSV envelope glycoproteins bind to 
ubiquitous cell-surface proteoglycans for entry, thus they have a naturally broad tissue host 
range. These traits make HSV vectors attractive gene delivery vehicles.  
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Intracerebral injection of wild-type HSV in rodent models resulted in lethal encephalitis 
[347]. Thus, in order to apply these vectors for therapeutic purposes within the CNS, it was 
important to abolish their neurotoxicity. Conditionally replicating HSV-based vectors have 
been generated where non-essential viral genes are deleted. The defective functions of the 
vectors can be compensated for by the up-regulation of complementary cellular enzymes in 
actively dividing host cells. Engineered mutants for the γ34.5 gene (e.g. HSV vector 1716) 
have reduced neurovirulence and do replicate; although at a lower rate, in dividing cells 
[348,349]. Double mutant vectors such as G207 [350] or MGH1 [351] which have an 
additional inactivation of the ribonucleotide reductase gene, have further reduced toxicity. An 
extra safety feature of these vectors is their sensitivity to gancyclovir and to temperatures 
above 39º C, which restricts proliferation in cases of possible encephalitis or fever [350].   
In a phase I dose-escalation study for recurrent malignant glioma, the maximal given 
dose of 3x109 PFU of G207 was tolerated well, without signs of acute toxicity, viral shedding 
or delayed reactivation of latent virus [352]. The vector was delivered by direct inoculation 
into the enhancing tumour region at five different sites. Eight of the 20 patients showed 
treatment response, noted as a decrease in tumour volume on MRI scans taken 1 month post-
inoculation. Phase Ib/II trials are currently underway to establish the maximal tolerated dose 
as well as to assess the ability of G207 to replicate within the tumours.  
Clinical studies have validated the safety of HSV1716 administered up to 105 PFU [353], 
as well as the ability of this vector to replicate in patient GBM tissue [354]. In a more recent 
trial enrolling 12 patients with high-grade gliomas, HSV1716 was injected at 8-10 sites in the 
cavity created after surgical resection, before the patients proceeded to radiotherapy or 
chemotherapy [355]. Three long time survivors were noted in this study, being alive 15, 18 
and 22 months post-injection. Medical imaging has demonstrated tumour regression in one of 
the patients, despite no further clinical intervention.  
In conclusion, HSV-based replicating oncolytic vectors show promise for the treatment of 
malignant gliomas. Their efficacy is currently being further evaluated in clinical ongoing 
trials. 
 
Adeno-associated virus (AAV) 
AAVs are small, non-enveloped viruses containing a single-stranded DNA genome of about 
4.7 kB [356]. They were originally isolated as contaminants of human adenoviral stocks 
[357]. AAVs are naturally replication-defective, requiring helper functions from adenoviruses 
or HSV for productive replication and infection [358].  
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50-80 % of the adult population world-wide is seropositive for AAV serotype 2, with 
conversion occurring around 10 years of age [359-361]. AAVs usually spread with adenoviral 
infections [359]. In comparison to other viruses, AAVs are not associated with any form of 
disease in humans. In fact, some studies have even described anti-neoplastic features of AAVs 
and of other parvoviruses [359,362,363].  
     Wild-type AAVs contain two genes, coding for replicase (rep) and capsid structural 
proteins (cap). The Rep protein mediates site-specific integration of the AAV genome into the 
AAVS1 site of chromosome 19 [364,365]. Thus, AAV is unique in a sense that it integrates 
into a specific location of the chromosome, evading potential site-specific mutagenesis seen 
with other viral vectors.  
To date, 8 AAV serotypes of human and simian origin have been isolated (AAV1-
8)[366]. The serotypes maintain identical genomic organisation, but differ somewhat in their 
coding sequences. A major consequence is that they utilise different receptors for cell 
attachment and entry, thus each serotype has characteristic transduction patterns in different 
tissues [366]. The cell surface receptors responsible for binding and uptake of some of the 
AAV serotype vectors have been elucidated. Thus, AAV2 binds αvβ5 integrin, fibroblast 
growth factor receptor-1 and heparan sulfate proteoglycan [367-369]; whereas AAV4 binds 
α2-3 O-linked sialic acid [370] and AAV5 binds N-linked α2-3 sialic acid and platelet-
derived growth factor receptor [370-372]. Importantly, as they are bound by different cell-
surface-receptors, the serotype vector of choice for each tissue may vary.  
     Superior safety profiles, high particle stability and broad host ranges render AAVs one of 
the most promising gene therapy vectors. A major drawback of AAV vectors however, is the 
small transgene capacity; 5 kB is considered to be the upper limit to be packed by a single 
virion [373]. Currently, 33 clinical trials are underway using AAV vectors (source: 
http://www.wiley.co.uk/genmed/clinical/). Many of these target neurological disorders such 
as Late Infantile Neuronal Ceroid Lipofuscinosis, Alzheimer’s Disease, Temporal Lobe 
Epilepsy, Parkinson Disease and Canavan Disease.  
     Initial studies have obtained proof of principle for AAV2-mediated HSV/tk-treatment of 
GBM xenografts [374,375]. In the study by Mizuno et al., U-251-SP gliomas transplanted 
into nude mice completely regressed after three AAV/tk injections followed by gancyclovir 
treatment. Six of seven mice became long time survivors at the end of the experiment (120 
days), whereas all control animals died at 45 days post-implantation. However, a more recent 
report has shown limited efficacy of AAV2/tk on intracranial tumour growth, even when 
transduction efficiencies up to 39 % were initially observed [376]. The absence of therapeutic 
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benefit has mainly been attributed to the gradual loss of the tk transgene, which has been  
observed both in vitro and in vivo.   
Recently, gene delivery by AAV serotypes other than AAV2 has been evaluated in more 
representative in vitro- and in vivo model systems based on human GBM biopsy material 
(paper III). In these studies, a proof of principle for the utility AAV serotypes 1 and -6 for 
gene transfer to glioblastoma tissue was shown. Importantly, AAV showed better penetration 
abilities in both model systems than Ad type 5 [139]. Among the different serotypes of AAVs 
examined, infection by AAV2 led to the most efficient transduction of glioma cell lines (paper 
III and paper IV). However, these studies and those of others [377-379] show that the 
intracerebral delivery of AAV1 results in more widespread transduction in the CNS than does 
AAV2 or AAV5. 
In order to be considered for the treatment of human malignant gliomas, AAV vectors 
need to be further developed. Important modifications that have to be made relate to 
modification of the vectors to render them tumour-selective and to persist for prolonged 
periods in dividing tumour tissue, as well as the expansion of transgene packaging capability. 
 
 
Figure 6. AAV. The figure to the left shows an AAV particle (arrowhead) in an adenoviral stock. The size difference between the 
two viruses may explain why AAV vectors better penetrate solid tissue and show a more widespread distribution in vivo than 
larger vectors such as Ads or HSV. Genomic- and transcriptional organisation of AAV (right). The ITRs encompass the rep and 
cap genes, which code for the replicase and capsid proteins, respectively. Four rep proteins and three capsid component 
proteins are generated after alternative splicing of the primary mRNA transcripts. Two of the replicase mRNAs are transcribed 
from the p5 promoter and two from the p19 promoter. All capsid-encoding transcipts are transcribed from the p40 promoter. The 
size of the AAV2 genome is about 4.7 kb. 
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4. AIMS OF THE CURRENT STUDY 
  
 
 
Based on the introductory paragraphs describing the potentials as well as limitations of the viral 
gene transfer and angiogenesis inhibiton strategies, the following aims were outlined: 
 
I. 
To assess the effects of endostatin treatment on vascular physiology, tumour perfusion and tumour growth 
as well as to evaluate the potential utility of cell encapsulation therapy for malignant gliomas. Dorsal skin-
fold chambers and cranial windows were prepared containing a glioma spheroid together with alginate-
bioreactors secreting human endostatin. The morphology, density, functionality and the diameters of the 
developing blood vessels were studied by fluorescent intravital microscopy in the endostatin-treated 
animals and compared to control animals which received alginate beads without producer cells. 
 
II. 
To compare the anti-vascular effects and anti-tumour efficacy of human and murine endostatin in an 
intracranial rat glioma model. In this study, BT4C gliosarcoma cells were initially transduced by retroviral 
vectors encoding the human- or murine endostatin cDNA, selected to obtain a homogenous population and 
implanted intracerebrally into BDIX rats. Tumour volumes, blood-plasma volumes and vessel permeabilities 
were studied by functional magnetic resonance imaging. Vascular area fractions and microvessel densities 
were quantified after endothelium-specific immunostaining of the tumour sections. In addition, survival time 
lengths for the two treatment groups and the controls were compared. 
 
III. 
To compare and quantify the transduction efficacies of adeno-associated virus serotype 1 (AAV1) and 
AAV2 in a panel of human glioma cell lines in vitro. To assess the spread of AAV1 and AAV6 vectors in 
multicellular tumour spheroids prepared from patient biopsy material. To characterise the pattern of gene 
delivery by recombinant AAV1 and AAV6 vectors to intracranial glioblastoma xenografts and to assess the 
ability of these vectors to tranduce the host rodent brain.  
 
IV. 
To evaluate the transduction efficacies of recombinant AAV2, AAV4 and AAV5 vectors in a panel of 
human glioma cell lines. Furthermore, to investigate the abilities of these vectors to transduce GBM biopsy 
spheroids in vitro as well as intracranial GBM xenografts in vivo.  
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5. DISCUSSION 
 
 
 
5.1. Experimental design 
 
5.1.1. Tumour models 
The main objective of papers I and II was to evaluate the effect of recombinant endostatin on 
angiogenesis and tumour growth in experimental gliomas. The conclusions of the studies are 
drawn from two different in vivo models and involve the use of basic molecular biology and 
cell culture techniques. In paper I, C6 glioma cells were implanted subcutaneously as well as 
intracranially, to allow for continuous observation of tumour-induced angiogenesis through 
dorsal skinfold-and cranial window preparations. Since the effect of endostatin has been 
observed to vary in tumours that grow at different anatomical locations, two different sites of 
tumour cell implantation were employed. 
In paper II, BT4C gliosarcoma cells were delivered to the corpus callosum region, to establish 
intracerebral lesions at the site where many human gliomas manifest. Both cell lines display 
predictable tumour take and reproducible growth rates [380,381]. The BT4C cell line is 
syngeneic in BD-IX rats [382,383], whereas the C6 glioma cell line was induced in a strain of 
outbred Wistar rats, and is therefore only tumorigenic in immuno-compromised hosts [381]. 
Since both cell lines give rise to highly vascular lesions in vivo [384,385], these models are 
well-suited to evaluate therapeutic approaches based on angiogensis inhibition.  
Disappointing results from clinical follow-ups of successful pre-clinical gene therapy trials 
are thought to be a consequence of inadequate transduction efficiency and the use of 
inappropriate pre-clinical model systems [130,326]. In many respects, cell-line based tumour 
grafts fail to represent the lesions encountered in the clinical setting [130]. However, there are 
model systems that preserve the biological heterogeneity of the cancer in situ. The GBM 
biopsy xenograft model [131], employed in papers III and IV is a favourable choice for 
evaluating gene transfer strategies for the treatment of glioblastomas. GBM spheroids that are 
generated directly from patient biopsies are not cultured as monolayers, and therefore retain 
the phenotypic features, as well as the same DNA ploidy and a similar percentage of 
proliferating cells as the original patient tumour [133]. The lesions that develop after 
intracerebral implantation of biopsy spheroids in nude rats display regions of necrosis as well 
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as microvascular proliferation (Figure 5, paper III); and importantly, diffuse single-cell 
infiltration into the host brain tissue is observed.  
 
5.1.2. Viral vectors 
MMLV vectors 
In paper II, recombinant vectors based on Moloney murine leukaemia virus were employed to 
deliver the endostatin gene to BT4C glioma cells. The limitations of using murine retroviruses 
for in vivo gene transfer are the low particle numbers (titres) of the generated vector stocks 
and the observed inactivation of the viral particles in body fluids [322]. However, these 
limitations do not affect their application in tissue culture. For our purpose, retroviral 
transduction was chosen since it results in stable integration of the transgene sequences into 
the host genome. This ensures long-term expression of the transgene and continuos 
propagation of the expression cassette to daughter cells. Since implanted tumour cells undergo 
a vast number of cell divisions before they give rise to macroscopic lesions, chromosomal 
integration was important in order to maintain persistent and uniform endostatin levels in the 
tumours. After selecting for the neomycin resistance gene, nearly 100 % of the cell population 
was transgene positive, as observed for BT4C cells infected by EGFP-encoding retroviruses 
with identical vector backbones (paper II, figure 1C). Endostatin production in the BT4C 
ENDO cells was validated by western blot analysis of the conditioned media. Colonies were 
expanded from single-cell clones to ensure that the implanted cells had the retroviral cassette 
inserted into the same genomic location. This was essential in order to avoid possible 
variations in the levels of transgene expression between the tumour cells implanted into each 
animal. The different resistant clones secreted highly varying levels of endostatin. If not 
eliminated, such differences would be amplified after multiple cell divisions in vivo, giving 
rise to tumours-or tumour regions with varying endostatin expression. In this case, the 
therapeutic effect would not be uniform and would greatly enhance variation within the 
treatment groups. In addition, the cloning procedure facilitated the isolation of the tumour cell 
clone that secreted the highest amounts of endostatin, which was selected for the in vivo 
experiments. 
 
AAV vectors 
While a retroviral vector system was applied as an in vitro tool in paper II, in papers III and 
IV the objective was to gain a proof of principle for the utility of AAV vectors as gene 
delivery vehicles in vivo.  
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The failure of vector particles to infect sufficient number of cells in the target lesions is 
believed to be the main explanation for the disappointing results of gene therapeutic 
approaches in the clinical setting [321]. Three factors are thought to limit the spread of viral 
particles in the tumour tissue: the mobility of the viral particles in the tumour mass, the extent 
of host immune responses which may block virus dissemination, and the limited duration of 
lytic effect by replicating vectors [386]. Our current knowledge of vector biology suggests 
that AAVs may be the most suited gene delivery vehicles to address the problem of limited 
tissue penetration, since they are about one-fifth to one-tenth in diameter of other commonly 
employed viral vectors [387]. In addition, AAVs exhibit very low immunogenicity [388], and 
in the case of present neutralising complement in the patient, vectors of alternative serotypes 
may be used. The application of AAV vectors achieves persistent transgene expression in 
animal models of several diseases, such as haemophilia [389], retinal dysfunction [390,391] 
and several neurological disorders [392]. For example, vision was restored for the entire 
follow-up time of three years in a canine model of childhood blindness after subretinal 
administration of AAV vectors [391]. 
 
5.2. Experimental findings 
 
5.2.1. The therapeutic effect of endostatin 
Anti-tumour efficacy of endostatin 
To, date almost 800 papers have been published concerning the structure and function of 
endostatin. The vast majority of the experimental studies confirm endostatin’s inhibitory 
effect on tumour growth, in a variety of cancer types [271]. Endostatin has entered the clinical 
phase of development, and phase I trials suggest that endostatin administration is safe in 
humans [393-396]. To gain a proof-of-principle for the utility of this molecule for the 
treatment of brain tumours, we have applied endostatin in two different glioma models, a 
syngeneic BT4C-model and in the C6 model implanted in an orthotopic- or ectopic setting. 
We have observed clear anti-tumour effects with this inhibitor. However, the efficacy was 
discrepant, varying between the cell lines used as tumour models, the anatomical location of 
the lesions, the delivery system, as well as the species-specific form. 
     In paper I, recombinant human endostatin secreted by bioreactors implanted at the tumour 
site was shown to significantly inhibit C6 glioma growth in the subcutaneous setting. In 
contrast, in the cranial window model, the differences between the treatment group and the 
controls were not significant.  
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 The discrepancy may be attributed to the fact that in the dorsal tumours, endostatin`s effect 
was most pronounced at day 14 and onward at which time point the tumours overgrew the 
available space in the cranial windows. Thus, the animals with cranial windows were 
sacrificed before endostatin could exert its effects. Another study underlines that tumour cells 
transplanted to the orthotopic location are more aggressive, reaching critical size before 
sufficient levels of the inhibitor are achieved [275]. In addition, tumour-host interactions, such 
as angiogenesis are organ-specific, varying between ectopic- and orthotopic locations [397], 
further contributing to the discrepancy observed. 
     In paper II, local delivery of human endostatin did not result in significant tumour size 
reduction and only a trend toward longer survival was seen. This is in contrast to the 
observations in paper I as well as in previous publications [303], where human endostatin 
delivered by alginate bioreactors resulted in significant inhibition of  tumour growth. The 
differences in outcome may be attributed to the fact that the alginate bioreactors released 
higher amounts of endostatin than did the BT4C ENDO cells [303] (paper II and unpublished 
observations). Therefore, critical endostatin levels may not have been reached in the BT4C 
model in this setting. Still, some therapeutic effect by human endostatin was observed in the 
BT4C model in paper II, as large necrotic areas were present in the tumours treated with this 
endostatin form. Here, murine endostatin showed more potent anti-vascular and anti-tumour 
effects, which were comparable to that obtained with human endostatin in paper I and 
elsewhere [303]. In paper II, we show that at similar concentrations, murine endostatin has 
significant anti-tumour effect, whereas human endostatin treatment only shows a trend toward 
tumour inhibition. This might relate to the fact that the murine endostatin protein is more 
sequence-similar to its rat counterpart  (difference: 8 amino acids) than is human endostatin 
(difference: 25 amino acids). Thus, more favourable interactions with the rat receptor and thus 
more potent signalling by murine endostatin is expected in our model. 
 
Anti-vacular effects of endostatin 
The anti-vascular effects of endostatin have been reported to relate to reduced vascular 
densities in vivo, increased apotosis- and reduced endothelial cell proliferation in vitro 
[259,398-400]. In papers I and II, we studied endostatin-treated vasculature in experimental 
gliomas. This included analysis of vascular density, morphology and functionality. Whereas 
markedly dilated blood vessels were present in the control BT4C tumours (paper II), such 
vessels were not seen in the endostatin-treated lesions.  
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Immunostaining for blood vessels and subsequent assessment of microvessel density counts 
confirmed that endostatin-treated tumours were more scarcely vascualrised. It is worth noting, 
however, that reduced vessel densities alone do not necessarily predict a reduction in tumour 
perfusion, since this may be compensated for by an increase in vessel functionality (more 
vessels perfused) as well as an increase in vessel diameters. Therefore, we undertook studies 
involving fluorescent intravital microscopy (paper I) or functional MRI-analysis (paper II) to 
assess these parameters.  
     In paper I, tumour vascular density, microvessel diameters and vascular surface area 
fractions were significantly reduced after endostatin treatment. However, vessel permeability 
did not seem to be affected. In paper II, we show that murine endostatin significantly reduced 
plasma volume fractions, vascular area fractions and microvessel density counts. Both studies 
revealed that neoplastic blood vessels that have been treated by endostatin have smaller 
diameters and are more scarcely distributed throughout the tumour tissue than in non-treated 
controls. Importantly, tumour perfusion is impaired in the endostatin-treated tumours. As a 
consequence, necrotic areas develop as seen both on MR-images and on histological sections. 
Taken together, when sufficient levels of endostatin are reached in these experimental glioma 
models, vascular inhibition is achieved, offering the possibility of local tumour growth 
control. 
 
5.2.2. Transduction of tumour cell lines by AAV 
In papers III and IV, we sought to evaluate the abilities of recombinant AAV vectors of 
various serotypes to deliver reporter genes to human glioma cells and xenografts. We infected 
a panel of human glioma cell lines with AAV serotype vectors containing either the CMV 
promoter (AAV1 and AAV2, paper III) or the RSV promoter (AA2, AAV4 and AAV5, paper 
IV). In both studies, AAV2 proved to be the most efficient transducer of all the glioma cell 
lines. Transduction efficiency correlates with AAV serotype-specific uptake but also with 
intracellular processing mechanisms characteristic for the cell phenotype [401]. The 
molecular steps that characterise AAV infection have been intensively studied, and recently 
reviewed [402,403]. When added to target cells, AAV particles bind to primary attachment 
receptors and co-receptors before they are taken up by endocytosis in clathrin-coated pits 
[404,405]. Inside the cell, several successive steps involve AAV trafficking to the nucleus 
through the endosomal compartment [403]. Subsequently, viral uncoating and conversion of 
the single-stranded AAV genome to double-stranded replicative form takes place. In the 
absence of integration, AAV genomes reside as head-to-tail concatamers of over 12 kbp  
 [406], which are responsible for long-term transgene expression. 
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 The most significant factor affecting initial binding of the AAV particles is the distribution of 
serotype-specific cell surface receptors. Internalisation in clathrin-coated pits may be 
influenced by the abundance of serotype-specific co-receptors. Both primary attachment 
recpetors and co-receptors are required for AAV uptake, and the availability of these defines 
the host-range of a specific AAV serotype [403]. It has become increasingly clear that correct 
endosomal processing of AAV particles are important for transduction efficiency [403]. Entry 
of the AAV particles into the nucleus and subsequent conversion to transcriptionally active 
double-stranded form are both rate-limiting steps for transgene expression [403,407,408]. The 
rate of nuclear entry has been shown to diverge between permissive and non-permissive cell 
types [404,407,408]. 
      Thus; from our observations, we suggest that the AAV2 vectors are taken up with greater 
efficiency through the plasma membranes and are processed more efficiently than AAV1 or 
AAV4 and AAV5 (paper IV) in glioma cell lines. For both AAV1 and AAV2 (paper III), 
transgene expression was enhanced after a ten-fold increase in multiplicity of infection. This 
may indicate that the levels of AAV-specific cell surface receptors was not the limiting factor 
for transduction at the lower vector concentrations. However, the more modest enhancement 
for AAV2-mediated transgene expression may relate to the fact that the receptors responsible 
for uptake of these particles were saturated at the highest amount of particles added. Our data 
show that the D37 and U373 cell lines were the most permissive for AAV serotype 2, whereas 
GaMg was poorly transduced. Analysis of αvβ5 integrin expression (co-receptor molecule for 
AAV2) in these cell lines correlates well with our transduction data. Several studies confirm 
that U373 has a high expression of this integrin [409-411]. In paper III and previous studies 
[139], A172 was poorly transduced by AAV2, whereas in paper IV it was transduced at high 
efficiency. Previous studies of integrin expression in this cell line suggest variable expression 
levels of this integrin form [409,410,412], possibly resulting in variations in its 
permissiveness for AAV2 between the experiments.  
     The receptors and the co-receptors for AAV2, AAV4 and AAV5 have been identified 
[367-372], whereas for AAV1, the host receptor remains to be found. Quantitative analysis of 
the known AAV receptors and co-receptors in glioma cell lines may provide better insight 
into the relationship between transduction efficiency and the expression of AAV-specific cell 
surface molecules.  
    It should be emphasised that the transduction figures may only be compared within the 
frame of the individual study, based on the different experimental set-ups. This includes the 
differences in the promoter- and enhancer sequences in the vector backbones, the viral 
particle numbers added, the time period of culturing before analysis and the passage number 
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of the cell lines. The vectors were purified using slightly different protocols, which means that 
they may vary in their infectivity, even when the number of vector genomes is the same.  
     As mentioned above, the expression of serotype-specific receptors is important, however 
not exclusive when trying to predict transduction effciency of a given cell type with a certain 
AAV vector. The rate of uptake and intracellular processing of AAV vectors in glioma cell 
lines will need further elucidation to explain the results obtained in the present study. 
      
5.2.3. Tranduction of GBM xenografts by AAV 
The dissemination of a viral vector stock after direct delivery to solid tumour tissue depends 
on the mobility of the viral particles within the tumour mass as well as the extent of anti-viral 
immune responses [386]. The cell density in the tumour mass is usually much higher than in 
normal tissues, due to high proliferation rates and to the loss of contact inhibition, making it 
less permeable to viral particles [386]. In addition, host-derived fibrous tissue barriers may 
effectively limit vector dissemination [413]. 
The distribution of AAV vectors upon injection into solid tumours has not been studied in 
great detail. However, previous work from our group has indicated that intratumoral injection 
of AAV vectors results in a more widespread transgene expression than what is achieved after 
injecting a non-replicating adenoviral vector in the same setting [139]. While reporter gene 
expression after injection of an adenoviral vector stock was limited to the tumour periphery, 
AAV-mediated transgene expression was found in central tumour regions. We suggest that 
the observed facts relate to the difference in the size of the AAV particles vs. the Ad particles 
(20 nm vs.100 nm), enabling AAVs to penetrate solid tumour tissues more effectively. 
Furthermore, the distribution of the endogenous Ad receptor, CAR, is generally low in glioma 
biopsy tissue [414], whereas the known AAV receptors are widely expressed [414-417].  
     In studies III and IV, we injected recombinant AAV vectors into glioblastoma tumours 
growing in the rat brain to study vector spread and possible differences in the host ranges 
between the AAV serotypes. As for AAV2, we observed that AAV1 particles transduce 
central regions of the tumour tissue (paper III and paper IV). However, in this case transgene 
expression was more scattered in the central tumour regions compared to the periphery, where 
more robust reporter gene expression was seen (figure 5, paper III). The observed expression 
pattern may relate to the fact that the interstitial pressure in experimental tumours is elevated 
in central regions, with the pressure gradient falling toward the periphery [418]. Thus, viral 
particles as well as other macromolecules are expected to diffuse toward the periphery after 
intratumoral injection.  
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This effect relates to particles that do not have their attachment molecules widely distributed 
in the targeted tissue, thus precluding immediate binding and uptake at the site of injection 
[419]. Conversely, the widespread distribution of AAV2 receptors and co-receptors in the 
mammalian CNS may explain the restricted tissue transduction in the vicinity of the needle 
track observed for these vectors [420](paper IV). Other studies confirm that AAV1 transduces 
larger tissue volumes in the CNS than does AAV2 [378,379,421], indicating that AAV1 
particles are not bound and internalised at the vicinity of the injection site. To date, the cell-
surface molecules responsible for AAV1 binding have not been identified, precluding the 
assessment of their receptors in the CNS and in GBM xenografts.  
     In our setting, the time of vector injection was three weeks post tumour spheroid 
implantation. At this time point, vascularised tumours had not yet developed, as no lesions 
could be discerned on magnetic resonance images. After AAV injection, the xenografts grew 
for two to four months (depending on the aggressive nature of the patient biopsy) before 
tumour-related symptoms appeared. In our experimental set-up, we anticipated that the AAV-
infected tumour cells will pass on their transgene to daughter cells, and thus reporter gene 
expression should be achieved when the lesions have reached macroscopic sizes. In the 
majority of cases, however, transgene expression was disappointingly low, as only a few 
scattered cells were positive within most of the examined tumours. A brief discussion of the 
possible mechanisms for the low rates of gene transfer is provided below. 
 
Episomal persistence of AAV genomes 
In contrast to wild-type AAVs, recombinant AAV (rAAV) vectors do not display replicase 
(Rep)-mediated integration into the host cell chromosome [422], albeit non-site specific 
integration events have been encountered [423]. Prolonged expression of rAAV-delivered 
transgenes in quiescent tissues is mainly attributed to episomal persistence [406]. In dividing 
cells, chromosomally integrated vector genomes may be propagated to daughter cells, 
whereas episomal genomes are more likely to be lost. In a previous study, the rate of 
chromosomal integration by recombinant AAV vectors in dividing cells in vivo was studied 
after portal vein injection of AAV2 particles carrying the gene for human coagulation factor 
IX (F.IX) [424]. Upon hepatectomy and subsequent liver regeneration, the animals that 
carried the stably integrated transgene (delivered by a transposon) maintained factor IX 
expression at the same levels as before, whereas 85-95 % of the AAV-delivered transgene 
was lost. This number reflected the amount of cells containing episomal AAV genomes.  
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In this model, only a limited number of cell divisions occurred, leading the authors to argue 
that the 5-15 % of integrated vector genomes represents a maximum number. In growing 
tumours, however, numerous cell divisions occur before the lesions reach macroscopical 
sizes; thus, the transgene may be even further diluted. In a recent report [376], Hadaczek and 
colleagues studied the persistence of thymidine kinase expression from an AAV2-cassette in 
U87 glioma xenografts [376]. The authors observed loss of transgene expression both when 
the glioma cells were transduced and selected in vitro before transplantation as well as when 
the AAV vector was delivered in vivo to growing tumours. Gancyclovir administration 
yielded only a modest survival benefit in these animals, suggesting that loss of the tk gene 
resulted in the shortfall of suicide effect. In another study, where AAV2-GFP vectors 
containing the CMV or the EF-1 promoter were injected into experimental pancreatic 
carcinomas, only a few cells were transgene-positive [420]. The authors argue that vector 
dilution may cause the observed poor transduction efficacy. These studies point to the same 
conclusion: AAV genomes are lost during the multitude of cell division steps encountered in 
growing tumours. The correction of this trait by molecular strategies will be necessary if this 
vector system is to be considered for therapeutic application in humans. For example, 
developments in vector construction have made possible the inclusion of the rep gene into 
second-generation AAV-based gene therapy systems [425]. This would ensure site-specific 
integration of the AAV genome into the AAVS1 in chromosome 19 and continuous 
propagation to daughter cells, increasing transduction efficiency [426]. 
 
Gene silencing 
Gene silencing may have contributed to the loss of reporter gene-positive cells in the tumour 
grafts. In paper III, the vectors contained the cytomegalovirus immediate early promoter 
(pCMV), whereas in paper IV, the Rous sarcoma virus promoter (pRSV) was employed. Both 
sequences are able to direct constitutive gene expression in a number of cell types, with the 
CMV sequences displaying stronger transgene expression in vitro and in vivo [427,428]. 
However, the CMV promoter may be silenced by hypermethylation [429]. Silencing of the 
CMV promoter has previously been described in the context of AAV for gene delivery to 
human cancer cells in vitro as well as in vivo [430]. This problem can be circumvented by 
applying promoters that are not subjected to hypermethylation or to other silencing 
mechanisms, which substantially improves the persistence of transgene expression [431-433] 
[430].   
     Recent data suggests that the AAV vector genome in the cells is in the histone-associated 
chromatin form, which is capable of superior transcription [434]. However, histone 
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deacetylation efficiently silences transcription from AAV genomes [434]. Histone deacetylase 
inhibitors may improve tumour cell transduction by enhancing the acetylation of the histone-
associated chromatin of the rAAV genome [434]. 
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6. FUTURE PROSPECTS 
 
 
Today, modern biotechniques provide us with tools to get a functional insight into living 
systems. More than before, we are enabled to understand the molecular complexity of the 
regulatory mechanisms and signalling pathways that drive tumour progression. Many specific 
as well as compensatory mechanisms exist within cancer cells and in the host environment 
that favour malignant growth. Therefore, inhibition of one particular pathway can often 
trigger compensatory changes, which counteract the desired therapeutic effects [435]. 
However, in a cell-signalling network there are key molecules that integrate several signal 
transduction pathways. Such integration sites may be critical for cellular function. A main 
objective should be to identify vital components within the cancer cell signalling networks 
that can be abolished without destroying normal tissue function. After discovery, these 
components may be targeted on the protein- or the mRNA level (i.e. gene silencing 
strategies), in the framework of cell-based or viral delivery systems.  
     In gene therapy, the lack of effect observed in clinical studies has been attributed to a low 
transduction efficacy, as well as lack of delivery to distant tumour sites [321,326]. Novel 
vectors have been developed with the ability to replicate within transformed cells, yielding 
excellent tumour-specificity. Malignant cells are destroyed by oncolysis, while nearby 
untransformed cells are spared [436]. Still, such conditionally replicating vectors have been 
based on larger size viruses such as adenoviruses and retroviruses that have limited 
penetration capacities in solid tumour tissues. AAV vectors, on the other hand, have been 
shown to spread and transduce host tissues more extensively [139], however their persistence 
is poor in rapidly dividing cancer cells. Therefore, one would need to capitalise on the 
beneficial traits of several viral vectors to develop new generation gene delivery systems. 
Better delivery to the tumour may also be achieved by additional treatments to induce 
penetrability (ex.g. by proteases) or by altering the physical relationships, such as by 
convection-enhanced delivery. Hopefully, further refinements will provide clinicians with 
more potent vector systems that have the capacity to penetrate the tumour tissue while only 
replicating in neoplastic cells.  
Cell-based therapy with encapsulated producer cells makes possible the sustained release of 
therapeutic proteins for prolonged time periods, enabling us to maintain high local tissue 
concentrations of substances with a short biological half-life, such as endostatin.  
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Moreover, such producer cells can be genetically engineered to secrete other substances, such 
as differentiation factors, which could induce the alteration of primitive tumour cell 
phenotypes toward more benign, differentiated forms. Finally, based on extensive biological 
information obtained from patient biopsies, treatments may be individually tailored using 
genetically engineered cells that deliver active substances fitted to the biological profile of the 
tumour. The same pathways or molecules may be targeted using viral vectors, which may 
deliver the gene of interest. When these factors are brought into play with a concerted action, 
progress can be made. 
 
 
 
 
 
 
 
 
 55
7. REFERENCES 
 
 
 
 
 
 
1. Lodish, H. and Baltimore, D. (1995) Molecular cell biology. Scientific American Books, New York. 
2. Yokota, J. (2000) Tumor progression and metastasis. Carcinogenesis, 21, 497-503. 
3. Wittekind, C. and Neid, M. (2005) Cancer invasion and metastasis. Oncology, 69 Suppl 1, 14-6. 
4. Gage, F.H. (2000) Mammalian neural stem cells. Science, 287, 1433-8. 
5. Vogelstein, B. and Kinzler, K.W. (2004) Cancer genes and the pathways they control. Nat Med, 10, 789-99. 
6. Todd, R. and Wong, D.T. (1999) Oncogenes. Anticancer Res, 19, 4729-46. 
7. Mohr, S., Leikauf, G.D., Keith, G. and Rihn, B.H. (2002) Microarrays as cancer keys: an array of possibilities. J 
Clin Oncol, 20, 3165-75. 
8. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70. 
9. Tlsty, T.D. and Hein, P.W. (2001) Know thy neighbor: stromal cells can contribute oncogenic signals. Curr 
Opin Genet Dev, 11, 54-9. 
10. Kalluri, R. and Zeisberg, M. (2006) Fibroblasts in cancer. Nat Rev Cancer, 6, 392-401. 
11. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K.E., Montgomery, E., Lal, A., Riggins, G.J., 
Lengauer, C., Vogelstein, B. and Kinzler, K.W. (2000) Genes expressed in human tumor endothelium. Science, 
289, 1197-202. 
12. Ciccarelli, R., Ballerini, P., Sabatino, G., Rathbone, M.P., D'Onofrio, M., Caciagli, F. and Di Iorio, P. (2001) 
Involvement of astrocytes in purine-mediated reparative processes in the brain. Int J Dev Neurosci, 19, 395-
414. 
13. Kleihues, P., Cavenee, W.K. and International Agency for Research on Cancer (2000) Pathology and genetics 
of tumours of the nervous system. IARC Press, Lyon. 
14. Kleihues, P., Louis, D.N., Scheithauer, B.W., Rorke, L.B., Reifenberger, G., Burger, P.C. and Cavenee, W.K. 
(2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol, 61, 215-25; 
discussion 226-9. 
15. Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.L., Burkhard, C., Schuler, D., 
Probst-Hensch, N.M., Maiorka, P.C., Baeza, N., Pisani, P., Yonekawa, Y., Yasargil, M.G., Lutolf, U.M. and 
Kleihues, P. (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res, 64, 6892-9. 
16. Salvati, M., Artico, M., Caruso, R., Rocchi, G., Orlando, E.R. and Nucci, F. (1991) A report on radiation-induced 
gliomas. Cancer, 67, 392-7. 
17. Vowels, M.R., Tobias, V. and Mameghan, H. (1991) Second intracranial neoplasms following treatment of 
childhood acute lymphoblastic leukaemia. J Paediatr Child Health, 27, 43-6. 
18. Brustle, O., Ohgaki, H., Schmitt, H.P., Walter, G.F., Ostertag, H. and Kleihues, P. (1992) Primitive 
neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with 
an activated K-ras gene. Cancer, 69, 2385-92. 
19. Cavin, L.W., Dalrymple, G.V., McGuire, E.L., Maners, A.W. and Broadwater, J.R. (1990) CNS tumor induction 
by radiotherapy: a report of four new cases and estimate of dose required. Int J Radiat Oncol Biol Phys, 18, 
399-406. 
20. Neglia, J.P., Meadows, A.T., Robison, L.L., Kim, T.H., Newton, W.A., Ruymann, F.B., Sather, H.N. and 
Hammond, G.D. (1991) Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med, 
325, 1330-6. 
21. Tsang, R.W., Laperriere, N.J., Simpson, W.J., Brierley, J., Panzarella, T. and Smyth, H.S. (1993) Glioma arising 
after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer, 72, 
2227-33. 
22. Kitanaka, C., Shitara, N., Nakagomi, T., Nakamura, H., Genka, S., Nakagawa, K., Akanuma, A., Aoyama, H. and 
Takakura, K. (1989) Postradiation astrocytoma. Report of two cases. J Neurosurg, 70, 469-74. 
23. Hodges, L.C., Smith, J.L., Garrett, A. and Tate, S. (1992) Prevalence of glioblastoma multiforme in subjects 
with prior therapeutic radiation. J Neurosci Nurs, 24, 79-83. 
24. Shapiro, S., Mealey, J., Jr. and Sartorius, C. (1989) Radiation-induced intracranial malignant gliomas. J 
Neurosurg, 71, 77-82. 
25. Kleihues, P., Schauble, B., zur Hausen, A., Esteve, J. and Ohgaki, H. (1997) Tumors associated with p53 
germline mutations: a synopsis of 91 families. Am J Pathol, 150, 1-13. 
26. Paraf, F., Jothy, S. and Van Meir, E.G. (1997) Brain tumor-polyposis syndrome: two genetic diseases? J Clin 
Oncol, 15, 2744-58. 
27. Hochstrasser, H., Boltshauser, E. and Valavanis, A. (1988) Brain tumors in children with von Recklinghausen 
neurofibromatosis. Neurofibromatosis, 1, 233-9. 
28. Visted, T., Enger, P.O., Lund-Johansen, M. and Bjerkvig, R. (2003) Mechanisms of tumor cell invasion and 
angiogenesis in the central nervous system. Front Biosci, 8, e289-304. 
29. Sanai, N., Alvarez-Buylla, A. and Berger, M.S. (2005) Neural stem cells and the origin of gliomas. N Engl J 
Med, 353, 811-22. 
30. Holland, E.C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R.E. and Fuller, G.N. (2000) Combined activation of 
Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet, 25, 55-7. 
31. Oren, M. (2003) Decision making by p53: life, death and cancer. Cell Death Differ, 10, 431-42. 
32. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31. 
33. Miled, C., Pontoglio, M., Garbay, S., Yaniv, M. and Weitzman, J.B. (2005) A genomic map of p53 binding sites 
identifies novel p53 targets involved in an apoptotic network. Cancer Res, 65, 5096-104. 
34. Cho, Y., Gorina, S., Jeffrey, P.D. and Pavletich, N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA 
complex: understanding tumorigenic mutations. Science, 265, 346-55. 
 56
35. Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., 
Montesano, R. and Harris, C.C. (1994) Database of p53 gene somatic mutations in human tumors and cell 
lines. Nucleic Acids Res, 22, 3551-5. 
36. Van Meir, E.G., Roemer, K., Diserens, A.C., Kikuchi, T., Rempel, S.A., Haas, M., Huang, H.J., Friedmann, T., de 
Tribolet, N. and Cavenee, W.K. (1995) Single cell monitoring of growth arrest and morphological changes 
induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci U S A, 92, 1008-12. 
37. Mercer, W.E., Shields, M.T., Amin, M., Sauve, G.J., Appella, E., Romano, J.W. and Ullrich, S.J. (1990) Negative 
growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc 
Natl Acad Sci U S A, 87, 6166-70. 
38. Louis, D.N. (1994) The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol, 53, 11-21. 
39. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A., Jr., Butel, J.S. and Bradley, A. 
(1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 
356, 215-21. 
40. Reilly, K.M., Loisel, D.A., Bronson, R.T., McLaughlin, M.E. and Jacks, T. (2000) Nf1;Trp53 mutant mice develop 
glioblastoma with evidence of strain-specific effects. Nat Genet, 26, 109-13. 
41. Schmidt, E.E., Ichimura, K., Reifenberger, G. and Collins, V.P. (1994) CDKN2 (p16/MTS1) gene deletion or 
CDK4 amplification occurs in the majority of glioblastomas. Cancer Res, 54, 6321-4. 
42. Ueki, K., Ono, Y., Henson, J.W., Efird, J.T., von Deimling, A. and Louis, D.N. (1996) CDKN2/p16 or RB 
alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res, 56, 150-3. 
43. Nevins, J.R. (2001) The Rb/E2F pathway and cancer. Hum Mol Genet, 10, 699-703. 
44. Henson, J.W., Schnitker, B.L., Correa, K.M., von Deimling, A., Fassbender, F., Xu, H.J., Benedict, W.F., 
Yandell, D.W. and Louis, D.N. (1994) The retinoblastoma gene is involved in malignant progression of 
astrocytomas. Ann Neurol, 36, 714-21. 
45. Dimova, D.K. and Dyson, N.J. (2005) The E2F transcriptional network: old acquaintances with new faces. 
Oncogene, 24, 2810-26. 
46. Serrano, M., Hannon, G.J. and Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific 
inhibition of cyclin D/CDK4. Nature, 366, 704-7. 
47. James, C.D., He, J., Carlbom, E., Nordenskjold, M., Cavenee, W.K. and Collins, V.P. (1991) Chromosome 9 
deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer 
Res, 51, 1684-8. 
48. Olopade, O.I., Jenkins, R.B., Ransom, D.T., Malik, K., Pomykala, H., Nobori, T., Cowan, J.M., Rowley, J.D. and 
Diaz, M.O. (1992) Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. 
Cancer Res, 52, 2523-9. 
49. Daido, S., Takao, S., Tamiya, T., Ono, Y., Terada, K., Ito, S., Ouchida, M., Date, I., Ohmoto, T. and Shimizu, K. 
(2004) Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic 
tumors, and discovery of novel loss regions. Oncol Rep, 12, 789-95. 
50. Fults, D. and Pedone, C. (1993) Deletion mapping of the long arm of chromosome 10 in glioblastoma 
multiforme. Genes Chromosomes Cancer, 7, 173-7. 
51. James, C.D., Carlbom, E., Dumanski, J.P., Hansen, M., Nordenskjold, M., Collins, V.P. and Cavenee, W.K. 
(1988) Clonal genomic alterations in glioma malignancy stages. Cancer Res, 48, 5546-51. 
52. von Deimling, A., von Ammon, K., Schoenfeld, D., Wiestler, O.D., Seizinger, B.R. and Louis, D.N. (1993) 
Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol, 3, 19-26. 
53. Li, D.M. and Sun, H. (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle 
arrest in human glioblastoma cells. Proc Natl Acad Sci U S A, 95, 15406-11. 
54. Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., 
Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D.H. and Tavtigian, S.V. (1997) Identification of a 
candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced 
cancers. Nat Genet, 15, 356-62. 
55. Bose, S., Wang, S.I., Terry, M.B., Hibshoosh, H. and Parsons, R. (1998) Allelic loss of chromosome 10q23 is 
associated with tumor progression in breast carcinomas. Oncogene, 17, 123-7. 
56. Kobayashi, H., Hosoda, F., Maseki, N., Sakurai, M., Imashuku, S., Ohki, M. and Kaneko, Y. (1997) Hematologic 
malignancies with the t(10;11) (p13;q21) have the same molecular event and a variety of morphologic or 
immunologic phenotypes. Genes Chromosomes Cancer, 20, 253-9. 
57. Wang, S.I., Puc, J., Li, J., Bruce, J.N., Cairns, P., Sidransky, D. and Parsons, R. (1997) Somatic mutations of 
PTEN in glioblastoma multiforme. Cancer Res, 57, 4183-6. 
58. Teng, D.H., Hu, R., Lin, H., Davis, T., Iliev, D., Frye, C., Swedlund, B., Hansen, K.L., Vinson, V.L., Gumpper, 
K.L., Ellis, L., El-Naggar, A., Frazier, M., Jasser, S., Langford, L.A., Lee, J., Mills, G.B., Pershouse, M.A., 
Pollack, R.E., Tornos, C., Troncoso, P., Yung, W.K., Fujii, G., Berson, A., Steck, P.A. and et al. (1997) 
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res, 57, 5221-5. 
59. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, 
R., Bigner, S.H., Giovanella, B.C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M.H. and Parsons, R. (1997) 
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. 
Science, 275, 1943-7. 
60. von Deimling, A., Fimmers, R., Schmidt, M.C., Bender, B., Fassbender, F., Nagel, J., Jahnke, R., Kaskel, P., 
Duerr, E.M., Koopmann, J., Maintz, D., Steinbeck, S., Wick, W., Platten, M., Muller, D.J., Przkora, R., Waha, A., 
Blumcke, B., Wellenreuther, R., Meyer-Puttlitz, B., Schmidt, O., Mollenhauer, J., Poustka, A., Stangl, A.P., 
Lenartz, D. and von Ammon, K. (2000) Comprehensive allelotype and genetic anaysis of 466 human nervous 
system tumors. J Neuropathol Exp Neurol, 59, 544-58. 
61. Myers, M.P., Pass, I., Batty, I.H., Van der Kaay, J., Stolarov, J.P., Hemmings, B.A., Wigler, M.H., Downes, C.P. 
and Tonks, N.K. (1998) The lipid phosphatase activity of PTEN is critical for its tumor supressor function. 
Proc Natl Acad Sci U S A, 95, 13513-8. 
62. Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J.M., 
Siderovski, D.P. and Mak, T.W. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor 
suppressor PTEN. Cell, 95, 29-39. 
63. Wu, X., Senechal, K., Neshat, M.S., Whang, Y.E. and Sawyers, C.L. (1998) The PTEN/MMAC1 tumor suppressor 
phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad 
Sci U S A, 95, 15587-91. 
 57
64. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M.E. (1997) Akt phosphorylation 
of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91, 231-41. 
65. Furnari, F.B., Lin, H., Huang, H.S. and Cavenee, W.K. (1997) Growth suppression of glioma cells by PTEN 
requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A, 94, 12479-84. 
66. Cheney, I.W., Johnson, D.E., Vaillancourt, M.T., Avanzini, J., Morimoto, A., Demers, G.W., Wills, K.N., 
Shabram, P.W., Bolen, J.B., Tavtigian, S.V. and Bookstein, R. (1998) Suppression of tumorigenicity of 
glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res, 58, 2331-4. 
67. Furnari, F.B., Huang, H.J. and Cavenee, W.K. (1998) The phosphoinositol phosphatase activity of PTEN 
mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res, 58, 5002-8. 
68. Albarosa, R., DiDonato, S. and Finocchiaro, G. (1995) Redefinition of the coding sequence of the MXI1 gene 
and identification of a polymorphic repeat in the 3' non-coding region that allows the detection of loss of 
heterozygosity of chromosome 10q25 in glioblastomas. Hum Genet, 95, 709-11. 
69. Mollenhauer, J., Wiemann, S., Scheurlen, W., Korn, B., Hayashi, Y., Wilgenbus, K.K., von Deimling, A. and 
Poustka, A. (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted 
in malignant brain tumours. Nat Genet, 17, 32-9. 
70. Libermann, T.A., Nusbaum, H.R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M.D., Ullrich, A. 
and Schlessinger, J. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor 
gene in primary human brain tumours of glial origin. Nature, 313, 144-7. 
71. Bigner, S.H., Humphrey, P.A., Wong, A.J., Vogelstein, B., Mark, J., Friedman, H.S. and Bigner, D.D. (1990) 
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer 
Res, 50, 8017-22. 
72. Wong, A.J., Bigner, S.H., Bigner, D.D., Kinzler, K.W., Hamilton, S.R. and Vogelstein, B. (1987) Increased 
expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with 
gene amplification. Proc Natl Acad Sci U S A, 84, 6899-903. 
73. Burrows, R.C., Wancio, D., Levitt, P. and Lillien, L. (1997) Response diversity and the timing of progenitor cell 
maturation are regulated by developmental changes in EGFR expression in the cortex. Neuron, 19, 251-67. 
74. Hamel, W. and Westphal, M. (2000) Growth factors in gliomas revisited. Acta Neurochir (Wien), 142, 113-37; 
discussion 137-8. 
75. Tang, P., Steck, P.A. and Yung, W.K. (1997) The autocrine loop of TGF-alpha/EGFR and brain tumors. J 
Neurooncol, 35, 303-14. 
76. Heimberger, A.B., Suki, D., Yang, D., Shi, W. and Aldape, K. (2005) The natural history of EGFR and EGFRvIII 
in glioblastoma patients. J Transl Med, 3, 38. 
77. Kaur, B., Tan, C., Brat, D.J., Post, D.E. and Van Meir, E.G. (2004) Genetic and hypoxic regulation of 
angiogenesis in gliomas. J Neurooncol, 70, 229-43. 
78. Plate, K.H. and Risau, W. (1995) Angiogenesis in malignant gliomas. Glia, 15, 339-47. 
79. Holland, E.C. (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A, 97, 6242-4. 
80. Kung, A.L., Wang, S., Klco, J.M., Kaelin, W.G. and Livingston, D.M. (2000) Suppression of tumor growth 
through disruption of hypoxia-inducible transcription. Nat Med, 6, 1335-40. 
81. Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia 
may mediate hypoxia-initiated angiogenesis. Nature, 359, 843-5. 
82. Jung, F., Palmer, L.A., Zhou, N. and Johns, R.A. (2000) Hypoxic regulation of inducible nitric oxide synthase 
via hypoxia inducible factor-1 in cardiac myocytes. Circ Res, 86, 319-25. 
83. Semenza, G.L. and Wang, G.L. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis 
binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell 
Biol, 12, 5447-54. 
84. Wesseling, P., Ruiter, D.J. and Burger, P.C. (1997) Angiogenesis in brain tumors; pathobiological and clinical 
aspects. J Neurooncol, 32, 253-65. 
85. Plate, K.H., Breier, G., Weich, H.A., Mennel, H.D. and Risau, W. (1994) Vascular endothelial growth factor and 
glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in 
vivo regulatory mechanisms. Int J Cancer, 59, 520-9. 
86. Stratmann, A., Risau, W. and Plate, K.H. (1998) Cell type-specific expression of angiopoietin-1 and 
angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol, 153, 1459-66. 
87. Ferrara, N. and Henzel, W.J. (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor 
specific for vascular endothelial cells. Biochem Biophys Res Commun, 161, 851-8. 
88. Breier, G., Clauss, M. and Risau, W. (1995) Coordinate expression of vascular endothelial growth factor 
receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn, 
204, 228-39. 
89. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N.P., Risau, W. and Ullrich, A. (1993) High 
affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis 
and angiogenesis. Cell, 72, 835-46. 
90. Breier, G., Albrecht, U., Sterrer, S. and Risau, W. (1992) Expression of vascular endothelial growth factor 
during embryonic angiogenesis and endothelial cell differentiation. Development, 114, 521-32. 
91. Plate, K.H., Breier, G., Weich, H.A. and Risau, W. (1992) Vascular endothelial growth factor is a potential 
tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845-8. 
92. Brat, D.J., Kaur, B. and Van Meir, E.G. (2003) Genetic modulation of hypoxia induced gene expression and 
angiogenesis: relevance to brain tumors. Front Biosci, 8, d100-16. 
93. Zagzag, D., Zhong, H., Scalzitti, J.M., Laughner, E., Simons, J.W. and Semenza, G.L. (2000) Expression of 
hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. 
Cancer, 88, 2606-18. 
94. Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S. and Nose, T. (1996) Concentration of 
vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res, 56, 
2185-90. 
95. Peles, E., Lidar, Z., Simon, A.J., Grossman, R., Nass, D. and Ram, Z. (2004) Angiogenic factors in the 
cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery, 55, 562-7; discussion 567-8. 
96. Goldbrunner, R.H., Bendszus, M., Sasaki, M., Kraemer, T., Plate, K.H., Roosen, K. and Tonn, J.C. (2000) 
Vascular endothelial growth factor-driven glioma growth and vascularization in an orthotopic rat model 
monitored by magnetic resonance imaging. Neurosurgery, 47, 921-9; discussion 929-30. 
 58
97. Rubenstein, J.L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D.F. and Shuman, M.A. (2000) Anti-VEGF 
antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia, 
2, 306-14. 
98. Kanno, S., Oda, N., Abe, M., Terai, Y., Ito, M., Shitara, K., Tabayashi, K., Shibuya, M. and Sato, Y. (2000) Roles 
of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular 
endothelial cells. Oncogene, 19, 2138-46. 
99. Dvorak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M. (1995) Vascular permeability factor/vascular 
endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146, 1029-39. 
100. Strugar, J.G., Criscuolo, G.R., Rothbart, D. and Harrington, W.N. (1995) Vascular endothelial 
growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema 
and tumor-associated cysts. J Neurosurg, 83, 682-9. 
101. Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J. and Keshet, E. (1995) Vascular endothelial growth factor acts as 
a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat 
Med, 1, 1024-8. 
102. Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D. and Semenza, G.L. (1996) Activation 
of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol, 16, 4604-
13. 
103. Damert, A., Machein, M., Breier, G., Fujita, M.Q., Hanahan, D., Risau, W. and Plate, K.H. (1997) Up-regulation of 
vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven 
mechanisms. Cancer Res, 57, 3860-4. 
104. Rak, J., Filmus, J., Finkenzeller, G., Grugel, S., Marme, D. and Kerbel, R.S. (1995) Oncogenes as inducers of 
tumor angiogenesis. Cancer Metastasis Rev, 14, 263-77. 
105. Arbiser, J.L., Moses, M.A., Fernandez, C.A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., 
Parangi, S., Byers, H.R. and Folkman, J. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two 
distinct pathways. Proc Natl Acad Sci U S A, 94, 861-6. 
106. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T. and Kerbel, R.S. (1995) Mutant ras 
oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor 
angiogenesis. Cancer Res, 55, 4575-80. 
107. Mazure, N.M., Chen, E.Y., Laderoute, K.R. and Giaccia, A.J. (1997) Induction of vascular endothelial growth 
factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-
transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood, 90, 3322-31. 
108. Maity, A., Pore, N., Lee, J., Solomon, D. and O'Rourke, D.M. (2000) Epidermal growth factor receptor 
transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via 
a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res, 60, 
5879-86. 
109. Clarke, K., Smith, K., Gullick, W.J. and Harris, A.L. (2001) Mutant epidermal growth factor receptor enhances 
induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase 
dependent pathway. Br J Cancer, 84, 1322-9. 
110. Gollmer, J.C., Ladoux, A., Gioanni, J., Paquis, P., Dubreuil, A., Chatel, M. and Frelin, C. (2000) Expression of 
vascular endothelial growth factor-b in human astrocytoma. Neuro-oncol, 2, 80-6. 
111. Maisonpierre, P.C., Goldfarb, M., Yancopoulos, G.D. and Gao, G. (1993) Distinct rat genes with related profiles 
of expression define a TIE receptor tyrosine kinase family. Oncogene, 8, 1631-7. 
112. Schnurch, H. and Risau, W. (1993) Expression of tie-2, a member of a novel family of receptor tyrosine 
kinases, in the endothelial cell lineage. Development, 119, 957-68. 
113. Hanahan, D. (1997) Signaling vascular morphogenesis and maintenance. Science, 277, 48-50. 
114. Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J., Radziejewski, C., Compton, D., 
McClain, J., Aldrich, T.H., Papadopoulos, N., Daly, T.J., Davis, S., Sato, T.N. and Yancopoulos, G.D. (1997) 
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, 55-60. 
115. Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N. and Yancopoulos, G.D. 
(1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 
87, 1171-80. 
116. Sato, T.N., Qin, Y., Kozak, C.A. and Audus, K.L. (1993) Tie-1 and tie-2 define another class of putative receptor 
tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci U S A, 90, 9355-8. 
117. Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T.N., Yancopoulos, G.D. and McDonald, D.M. (1999) 
Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science, 286, 2511-4. 
118. Thurston, G. (2002) Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. 
J Anat, 200, 575-80. 
119. Lee, S.W., Kim, W.J., Choi, Y.K., Song, H.S., Son, M.J., Gelman, I.H., Kim, Y.J. and Kim, K.W. (2003) SSeCKS 
regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med, 9, 900-6. 
120. Zhang, Z.G., Zhang, L., Tsang, W., Soltanian-Zadeh, H., Morris, D., Zhang, R., Goussev, A., Powers, C., Yeich, 
T. and Chopp, M. (2002) Correlation of VEGF and angiopoietin expression with disruption of blood-brain 
barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab, 22, 379-92. 
121. Zagzag, D., Hooper, A., Friedlander, D.R., Chan, W., Holash, J., Wiegand, S.J., Yancopoulos, G.D. and Grumet, 
M. (1999) In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of 
tumor angiogenesis. Exp Neurol, 159, 391-400. 
122. Tse, V., Xu, L., Yung, Y.C., Santarelli, J.G., Juan, D., Fabel, K., Silverberg, G. and Harsh, G.t. (2003) The 
temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their 
functional correlation with tumor neovascular architecture. Neurol Res, 25, 729-38. 
123. Hatva, E., Kaipainen, A., Mentula, P., Jaaskelainen, J., Paetau, A., Haltia, M. and Alitalo, K. (1995) Expression 
of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol, 
146, 368-78. 
124. Hesselager, G. and Holland, E.C. (2003) Using mice to decipher the molecular genetics of brain tumors. 
Neurosurgery, 53, 685-94; discussion 695. 
125. Laerum, O.D. and Rajewsky, M.F. (1975) Neoplastic transformation of fetal rat brain cells in culture after 
exposure to ethylnitrosourea in vivo. J Natl Cancer Inst, 55, 1177-87. 
126. Koestner, A., Swenberg, J.A. and Wechsler, W. (1971) Transplacental production with ethylnitrosourea of 
neoplasms of the nervous system in Sprague-Dawley rats. Am J Pathol, 63, 37-56. 
 59
127. Kleihues, P., Lantos, P.L. and Magee, P.N. (1976) Chemical carcinogenesis in the nervous system. Int Rev Exp 
Pathol, 15, 153-232. 
128. Westphal, M. and Meissner, H. (1998) Establishing human glioma-derived cell lines. Methods Cell Biol, 57, 
147-65. 
129. Paulus, W., Huettner, C. and Tonn, J.C. (1994) Collagens, integrins and the mesenchymal drift in 
glioblastomas: a comparison of biopsy specimens, spheroid and early monolayer cultures. Int J Cancer, 58, 
841-6. 
130. Holland, E.C. (2001) Brain tumor animal models: importance and progress. Curr Opin Oncol, 13, 143-7. 
131. Engebraaten, O., Hjortland, G.O., Hirschberg, H. and Fodstad, O. (1999) Growth of precultured human glioma 
specimens in nude rat brain. J Neurosurg, 90, 125-32. 
132. Mahesparan, R., Read, T.A., Lund-Johansen, M., Skaftnesmo, K.O., Bjerkvig, R. and Engebraaten, O. (2003) 
Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol 
(Berl), 105, 49-57. 
133. Bjerkvig, R., Tonnesen, A., Laerum, O.D. and Backlund, E.O. (1990) Multicellular tumor spheroids from human 
gliomas maintained in organ culture. J Neurosurg, 72, 463-75. 
134. Nygaard, S.J., Haugland, H.K., Laerum, O.D., Lund-Johansen, M., Bjerkvig, R. and Tysnes, O.B. (1998) 
Dynamic determination of human glioma invasion in vitro. J Neurosurg, 89, 441-7. 
135. Backlund, E.O. and Bjerkvig, R. (1989) Stereotactic biopsies as a model for studying the interaction between 
gliomas and normal brain tissue in vitro. J Neurosurg Sci, 33, 31-3. 
136. Engebraaten, O., Bjerkvig, R., Lund-Johansen, M., Wester, K., Pedersen, P.H., Mork, S., Backlund, E.O. and 
Laerum, O.D. (1990) Interaction between human brain tumour biopsies and fetal rat brain tissue in vitro. Acta 
Neuropathol (Berl), 81, 130-40. 
137. Geoerger, B., Grill, J., Opolon, P., Morizet, J., Aubert, G., Terrier-Lacombe, M.J., Bressac De-Paillerets, B., 
Barrois, M., Feunteun, J., Kirn, D.H. and Vassal, G. (2002) Oncolytic activity of the E1B-55 kDa-deleted 
adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer 
Res, 62, 764-72. 
138. Lamfers, M.L., Grill, J., Dirven, C.M., Van Beusechem, V.W., Geoerger, B., Van Den Berg, J., Alemany, R., 
Fueyo, J., Curiel, D.T., Vassal, G., Pinedo, H.M., Vandertop, W.P. and Gerritsen, W.R. (2002) Potential of the 
conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced 
effect with radiotherapy. Cancer Res, 62, 5736-42. 
139. Enger, P.O., Thorsen, F., Lonning, P.E., Bjerkvig, R. and Hoover, F. (2002) Adeno-associated viral vectors 
penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Hum Gene Ther, 13, 
1115-25. 
140. Huszthy, P.C., Svendsen, A., Wilson, J.M., Kotin, R.M., Lonning, P.E., Bjerkvig, R. and Hoover, F. (2005) 
Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors 
in the rat central nervous system and in human glioblastoma multiforme xenografts. Hum Gene Ther, 16, 381-
92. 
141. Aguzzi, A., Brandner, S., Isenmann, S., Steinbach, J.P. and Sure, U. (1995) Transgenic and gene disruption 
techniques in the study of neurocarcinogenesis. Glia, 15, 348-64. 
142. Macleod, K.F. and Jacks, T. (1999) Insights into cancer from transgenic mouse models. J Pathol, 187, 43-60. 
143. Weissenberger, J., Steinbach, J.P., Malin, G., Spada, S., Rulicke, T. and Aguzzi, A. (1997) Development and 
malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene, 14, 2005-13. 
144. Peterson, D.L., Sheridan, P.J. and Brown, W.E., Jr. (1994) Animal models for brain tumors: historical 
perspectives and future directions. J Neurosurg, 80, 865-76. 
145. Uhrbom, L., Hesselager, G., Nister, M. and Westermark, B. (1998) Induction of brain tumors in mice using a 
recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res, 58, 5275-9. 
146. Uhrbom, L. and Holland, E.C. (2001) Modeling gliomagenesis with somatic cell gene transfer using retroviral 
vectors. J Neurooncol, 53, 297-305. 
147. Burton, E.C. and Prados, M.D. (2000) Malignant gliomas. Curr Treat Options Oncol, 1, 459-68. 
148. Brandes, A.A. (2003) State-of-the-art treatment of high-grade brain tumors. Semin Oncol, 30, 4-9. 
149. Lonardi, S., Tosoni, A. and Brandes, A.A. (2005) Adjuvant chemotherapy in the treatment of high grade 
gliomas. Cancer Treat Rev, 31, 79-89. 
150. Gupta, T. and Sarin, R. (2002) Poor-prognosis high-grade gliomas: evolving an evidence-based standard of 
care. Lancet Oncol, 3, 557-64. 
151. Castro, M.G., Cowen, R., Williamson, I.K., David, A., Jimenez-Dalmaroni, M.J., Yuan, X., Bigliari, A., Williams, 
J.C., Hu, J. and Lowenstein, P.R. (2003) Current and future strategies for the treatment of malignant brain 
tumors. Pharmacol Ther, 98, 71-108. 
152. Shapiro, W.R. (1982) Treatment of neuroectodermal brain tumors. Ann Neurol, 12, 231-7. 
153. Black, P. (1998) Management of malignant glioma: role of surgery in relation to multimodality therapy. J 
Neurovirol, 4, 227-36. 
154. Simpson, J.R., Horton, J., Scott, C., Curran, W.J., Rubin, P., Fischbach, J., Isaacson, S., Rotman, M., Asbell, 
S.O., Nelson, J.S. and et al. (1993) Influence of location and extent of surgical resection on survival of 
patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group 
(RTOG) clinical trials. Int J Radiat Oncol Biol Phys, 26, 239-44. 
155. Rostomily, R.C., Spence, A.M., Duong, D., McCormick, K., Bland, M. and Berger, M.S. (1994) Multimodality 
management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and 
analysis of cytoreductive surgery. Neurosurgery, 35, 378-88; discussion 388. 
156. Metcalfe, S.E. and Grant, R. (2001) Biopsy versus resection for malignant glioma. Cochrane Database Syst 
Rev, CD002034. 
157. Kristiansen, K., Hagen, S., Kollevold, T., Torvik, A., Holme, I., Nesbakken, R., Hatlevoll, R., Lindgren, M., Brun, 
A., Lindgren, S., Notter, G., Andersen, A.P. and Elgen, K. (1981) Combined modality therapy of operated 
astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation 
of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. 
Cancer, 47, 649-52. 
158. Walker, M.D., Alexander, E., Jr., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Jr., Mealey, J., Jr., Norrell, H.A., 
Owens, G., Ransohoff, J., Wilson, C.B., Gehan, E.A. and Strike, T.A. (1978) Evaluation of BCNU and/or 
radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 49, 333-43. 
 60
159. Pawlik, T.M. and Keyomarsi, K. (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat 
Oncol Biol Phys, 59, 928-42. 
160. Larson, D.A. and Wara, W.M. (1998) Radiotherapy of primary malignant brain tumors. Semin Surg Oncol, 14, 
34-42. 
161. Walker, M.D., Strike, T.A. and Sheline, G.E. (1979) An analysis of dose-effect relationship in the radiotherapy 
of malignant gliomas. Int J Radiat Oncol Biol Phys, 5, 1725-31. 
162. Bleehen, N.M. and Stenning, S.P. (1991) A Medical Research Council trial of two radiotherapy doses in the 
treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J 
Cancer, 64, 769-74. 
163. Leksell, L. (1983) Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry, 46, 797-803. 
164. Goodman, M.L. (1990) Gamma knife radiosurgery: current status and review. South Med J, 83, 551-4. 
165. Ganz, J.C., Smievoll, A.I. and Thorsen, F. (1994) Radiosurgical treatment of gliomas of the diencephalon. Acta 
Neurochir Suppl, 62, 62-6. 
166. Kihlstrom, L., Lindquist, C., Lindquist, M. and Karlsson, B. (1994) Stereotactic radiosurgery for tectal low-
grade gliomas. Acta Neurochir Suppl, 62, 55-7. 
167. Roberge, D. and Souhami, L. (2003) Stereotactic radiosurgery in the management of intracranial gliomas. 
Technol Cancer Res Treat, 2, 117-25. 
168. Ulm, A.J., 3rd, Friedman, W.A., Bradshaw, P., Foote, K.D. and Bova, F.J. (2005) Radiosurgery in the treatment 
of malignant gliomas: the University of Florida experience. Neurosurgery, 57, 512-7; discussion 512-7. 
169. Lustig, R.A., Scott, C.B. and Curran, W.J. (2004) Does stereotactic eligibility for the treatment of glioblastoma 
cause selection bias in randomized studies? Am J Clin Oncol, 27, 516-21. 
170. Loeffler, J.S., Alexander, E., 3rd, Wen, P.Y., Shea, W.M., Coleman, C.N., Kooy, H.M., Fine, H.A., Nedzi, L.A., 
Silver, B., Riese, N.E. and et al. (1990) Results of stereotactic brachytherapy used in the initial management of 
patients with glioblastoma. J Natl Cancer Inst, 82, 1918-21. 
171. Gutin, P.H., Prados, M.D., Phillips, T.L., Wara, W.M., Larson, D.A., Leibel, S.A., Sneed, P.K., Levin, V.A., 
Weaver, K.A., Silver, P. and et al. (1991) External irradiation followed by an interstitial high activity iodine-125 
implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol 
Phys, 21, 601-6. 
172. Laperriere, N.J., Leung, P.M., McKenzie, S., Milosevic, M., Wong, S., Glen, J., Pintilie, M. and Bernstein, M. 
(1998) Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. 
Int J Radiat Oncol Biol Phys, 41, 1005-11. 
173. Selker, R.G., Shapiro, W.R., Burger, P., Blackwood, M.S., Arena, V.C., Gilder, J.C., Malkin, M.G., Mealey, J.J., 
Jr., Neal, J.H., Olson, J., Robertson, J.T., Barnett, G.H., Bloomfield, S., Albright, R., Hochberg, F.H., Hiesiger, 
E. and Green, S. (2002) The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of 
surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external 
radiation therapy, and carmustine. Neurosurgery, 51, 343-55; discussion 355-7. 
174. Carlsson, J., Sjoberg, S. and Larsson, B.S. (1992) Present status of boron neutron capture therapy. Acta 
Oncol, 31, 803-13. 
175. Saris, S.C., Solares, G.R., Wazer, D.E., Cano, G., Kerley, S.E., Joyce, M.A., Adelman, L.S., Harling, O.K., 
Madoc-Jones, H. and Zamenhof, R.G. (1992) Boron neutron capture therapy for murine malignant gliomas. 
Cancer Res, 52, 4672-7. 
176. Matalka, K.Z., Barth, R.F., Staubus, A.E., Moeschberger, M.L. and Coderre, J.A. (1994) Neutron capture 
therapy of a rat glioma using boronophenylalanine as a capture agent. Radiat Res, 137, 44-51. 
177. Joensuu, H., Kankaanranta, L., Seppala, T., Auterinen, I., Kallio, M., Kulvik, M., Laakso, J., Vahatalo, J., 
Kortesniemi, M., Kotiluoto, P., Seren, T., Karila, J., Brander, A., Jarviluoma, E., Ryynanen, P., Paetau, A., 
Ruokonen, I., Minn, H., Tenhunen, M., Jaaskelainen, J., Farkkila, M. and Savolainen, S. (2003) Boron neutron 
capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J 
Neurooncol, 62, 123-34. 
178. Coderre, J.A., Elowitz, E.H., Chadha, M., Bergland, R., Capala, J., Joel, D.D., Liu, H.B., Slatkin, D.N. and 
Chanana, A.D. (1997) Boron neutron capture therapy for glioblastoma multiforme using p-
boronophenylalanine and epithermal neutrons: trial design and early clinical results. J Neurooncol, 33, 141-
52. 
179. Capala, J., Stenstam, B.H., Skold, K., af Rosenschold, P.M., Giusti, V., Persson, C., Wallin, E., Brun, A., 
Franzen, L., Carlsson, J., Salford, L., Ceberg, C., Persson, B., Pellettieri, L. and Henriksson, R. (2003) Boron 
neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neurooncol, 62, 135-44. 
180. Hatanaka, H. and Nakagawa, Y. (1994) Clinical results of long-surviving brain tumor patients who underwent 
boron neutron capture therapy. Int J Radiat Oncol Biol Phys, 28, 1061-6. 
181. Curran, W.J., Jr., Scott, C.B., Horton, J., Nelson, J.S., Weinstein, A.S., Fischbach, A.J., Chang, C.H., Rotman, 
M., Asbell, S.O., Krisch, R.E. and et al. (1993) Recursive partitioning analysis of prognostic factors in three 
Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst, 85, 704-10. 
182. Laramore, G.E. and Spence, A.M. (1996) Boron neutron capture therapy (BNCT) for high-grade gliomas of the 
brain: a cautionary note. Int J Radiat Oncol Biol Phys, 36, 241-6. 
183. Barth, R.F., Coderre, J.A., Vicente, M.G. and Blue, T.E. (2005) Boron neutron capture therapy of cancer: 
current status and future prospects. Clin Cancer Res, 11, 3987-4002. 
184. Dahl, O., Den Norske kreftforening and Universitetet i Oslo . Institutt for farmakoterapi (1999) Cytostatika : 
medikamentell kreftbehandling. Institutt for farmakoterapi : Den norske kreftforening, Oslo. 
185. Parney, I.F. and Chang, S.M. (2003) Current chemotherapy for glioblastoma. Cancer J, 9, 149-56. 
186. Fewer, D., Wilson, C.B., Boldrey, E.B., Enot, K.J. and Powell, M.R. (1972) The chemotherapy of brain tumors. 
Clinical experience with carmustine (BCNU) and vincristine. Jama, 222, 549-52. 
187. Clark, J.W. (1997) Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Semin 
Oncol, 24, S18-19-S18-24. 
188. Wendell, K.L., Wilson, L. and Jordan, M.A. (1993) Mitotic block in HeLa cells by vinblastine: ultrastructural 
changes in kinetochore-microtubule attachment and in centrosomes. J Cell Sci, 104 ( Pt 2), 261-74. 
189. Jordan, M.A., Thrower, D. and Wilson, L. (1991) Mechanism of inhibition of cell proliferation by Vinca 
alkaloids. Cancer Res, 51, 2212-22. 
190. Newlands, E.S., Blackledge, G.R., Slack, J.A., Rustin, G.J., Smith, D.B., Stuart, N.S., Quarterman, C.P., 
Hoffman, R., Stevens, M.F., Brampton, M.H. and et al. (1992) Phase I trial of temozolomide (CCRG 81045: M&B 
39831: NSC 362856). Br J Cancer, 65, 287-91. 
 61
191. Yung, W.K., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada, M., Spence, A., Hohl, R.J., 
Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., 
Bruner, J., Yue, N., Osoba, D., Zaknoen, S. and Levin, V.A. (2000) A phase II study of temozolomide vs. 
procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer, 83, 588-93. 
192. Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.Y., Dirix, L.Y., Macdonald, D., Heimans, J.J., Zonnenberg, 
B.A., Bravo-Marques, J.M., Henriksson, R., Stupp, R., Yue, N., Bruner, J., Dugan, M., Rao, S. and Zaknoen, S. 
(2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann 
Oncol, 12, 259-66. 
193. Brandes, A.A., Ermani, M., Basso, U., Paris, M.K., Lumachi, F., Berti, F., Amista, P., Gardiman, M., Iuzzolino, 
P., Turazzi, S. and Monfardini, S. (2002) Temozolomide in patients with glioblastoma at second relapse after 
first line nitrosourea-procarbazine failure: a phase II study. Oncology, 63, 38-41. 
194. Fine, H.A., Dear, K.B., Loeffler, J.S., Black, P.M. and Canellos, G.P. (1993) Meta-analysis of radiation therapy 
with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 71, 2585-97. 
195. Stewart, L.A. (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of 
individual patient data from 12 randomised trials. Lancet, 359, 1011-8. 
196. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., 
Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., 
Cairncross, J.G., Eisenhauer, E. and Mirimanoff, R.O. (2005) Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med, 352, 987-96. 
197. Dix, A.R., Brooks, W.H., Roszman, T.L. and Morford, L.A. (1999) Immune defects observed in patients with 
primary malignant brain tumors. J Neuroimmunol, 100, 216-32. 
198. Ruffini, P.A., Rivoltini, L., Silvani, A., Boiardi, A. and Parmiani, G. (1993) Factors, including transforming 
growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-
activated killer cells. Cancer Immunol Immunother, 36, 409-16. 
199. Fakhrai, H., Dorigo, O., Shawler, D.L., Lin, H., Mercola, D., Black, K.L., Royston, I. and Sobol, R.E. (1996) 
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene 
therapy. Proc Natl Acad Sci U S A, 93, 2909-14. 
200. Elliott, L.H., Brooks, W.H. and Roszman, T.L. (1984) Cytokinetic basis for the impaired activation of 
lymphocytes from patients with primary intracranial tumors. J Immunol, 132, 1208-15. 
201. Morford, L.A., Elliott, L.H., Carlson, S.L., Brooks, W.H. and Roszman, T.L. (1997) T cell receptor-mediated 
signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol, 159, 4415-
25. 
202. Brooks, W.H., Latta, R.B., Mahaley, M.S., Roszman, T.L., Dudka, L. and Skaggs, C. (1981) Immunobiology of 
primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status. J Neurosurg, 54, 
331-7. 
203. Akbasak, A., Oldfield, E.H. and Saris, S.C. (1991) Expression and modulation of major histocompatibility 
antigens on murine primary brain tumor in vitro. J Neurosurg, 75, 922-9. 
204. Saas, P., Walker, P.R., Hahne, M., Quiquerez, A.L., Schnuriger, V., Perrin, G., French, L., Van Meir, E.G., de 
Tribolet, N., Tschopp, J. and Dietrich, P.Y. (1997) Fas ligand expression by astrocytoma in vivo: maintaining 
immune privilege in the brain? J Clin Invest, 99, 1173-8. 
205. Yu, J.S., Lee, P.K., Ehtesham, M., Samoto, K., Black, K.L. and Wheeler, C.J. (2003) Intratumoral T cell subset 
ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol, 64, 55-61. 
206. Ehtesham, M., Samoto, K., Kabos, P., Acosta, F.L., Gutierrez, M.A., Black, K.L. and Yu, J.S. (2002) Treatment 
of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer 
Gene Ther, 9, 925-34. 
207. Liu, Y., Ehtesham, M., Samoto, K., Wheeler, C.J., Thompson, R.C., Villarreal, L.P., Black, K.L. and Yu, J.S. 
(2002) In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in 
glioma. Cancer Gene Ther, 9, 9-15. 
208. Herrlinger, U., Kramm, C.M., Johnston, K.M., Louis, D.N., Finkelstein, D., Reznikoff, G., Dranoff, G., 
Breakefield, X.O. and Yu, J.S. (1997) Vaccination for experimental gliomas using GM-CSF-transduced glioma 
cells. Cancer Gene Ther, 4, 345-52. 
209. Plautz, G.E., Touhalisky, J.E. and Shu, S. (1997) Treatment of murine gliomas by adoptive transfer of ex vivo 
activated tumor-draining lymph node cells. Cell Immunol, 178, 101-7. 
210. Boskovitz, A., Wikstrand, C.J., Kuan, C.T., Zalutsky, M.R., Reardon, D.A. and Bigner, D.D. (2004) Monoclonal 
antibodies for brain tumour treatment. Expert Opin Biol Ther, 4, 1453-71. 
211. Hermanson, M., Funa, K., Hartman, M., Claesson-Welsh, L., Heldin, C.H., Westermark, B. and Nister, M. (1992) 
Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and 
protein suggests the presence of autocrine and paracrine loops. Cancer Res, 52, 3213-9. 
212. Kjellman, C., Olofsson, S.P., Hansson, O., Von Schantz, T., Lindvall, M., Nilsson, I., Salford, L.G., Sjogren, H.O. 
and Widegren, B. (2000) Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at 
different stages of human glioma. Int J Cancer, 89, 251-8. 
213. Wikstrand, C.J., Cokgor, I., Sampson, J.H. and Bigner, D.D. (1999) Monoclonal antibody therapy of human 
gliomas: current status and future approaches. Cancer Metastasis Rev, 18, 451-64. 
214. Reardon, D.A., Akabani, G., Coleman, R.E., Friedman, A.H., Friedman, H.S., Herndon, J.E., 2nd, Cokgor, I., 
McLendon, R.E., Pegram, C.N., Provenzale, J.M., Quinn, J.A., Rich, J.N., Regalado, L.V., Sampson, J.H., 
Shafman, T.D., Wikstrand, C.J., Wong, T.Z., Zhao, X.G., Zalutsky, M.R. and Bigner, D.D. (2002) Phase II trial of 
murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection 
cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol, 20, 1389-97. 
215. Quang, T.S. and Brady, L.W. (2004) Radioimmunotherapy as a novel treatment regimen: 125I-labeled 
monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys, 58, 972-5. 
216. Okada, H., Villa, L., Attanucci, J., Erff, M., Fellows, W.K., Lotze, M.T., Pollack, I.F. and Chambers, W.H. (2001) 
Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by 
peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther, 8, 1157-66. 
217. Glick, R.P., Lichtor, T., Mogharbel, A., Taylor, C.A. and Cohen, E.P. (1997) Intracerebral versus subcutaneous 
immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of 
central nervous system glioma and melanoma. Neurosurgery, 41, 898-906; discussion 906-7. 
 62
218. Kikuchi, T., Joki, T., Saitoh, S., Hata, Y., Abe, T., Kato, N., Kobayashi, A., Miyazaki, T. and Ohno, T. (1999) Anti-
tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma 
cells located in the central nervous system. Int J Cancer, 80, 425-30. 
219. Benedetti, S., Bruzzone, M.G., Pollo, B., DiMeco, F., Magrassi, L., Pirola, B., Cirenei, N., Colombo, M.P. and 
Finocchiaro, G. (1999) Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the 
interleukin 4 gene. Cancer Res, 59, 645-52. 
220. Yu, J.S., Wei, M.X., Chiocca, E.A., Martuza, R.L. and Tepper, R.I. (1993) Treatment of glioma by engineered 
interleukin 4-secreting cells. Cancer Res, 53, 3125-8. 
221. Jean, W.C., Spellman, S.R., Wallenfriedman, M.A., Hall, W.A. and Low, W.C. (1998) Interleukin-12-based 
immunotherapy against rat 9L glioma. Neurosurgery, 42, 850-6; discussion 856-7. 
222. Packer, R.J., Prados, M., Phillips, P., Nicholson, H.S., Boyett, J.M., Goldwein, J., Rorke, L.B., Needle, M.N., 
Sutton, L., Zimmerman, R.A., Fitz, C.R., Vezina, L.G., Etcubanas, E., Wallenberg, J.C., Reaman, G. and Wara, 
W. (1996) Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-
interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study. Cancer, 77, 
2150-6. 
223. Nagai, M. and Arai, T. (1984) Clinical effect of interferon in malignant brain tumours. Neurosurg Rev, 7, 55-64. 
224. Zou, J.P., Yamamoto, N., Fujii, T., Takenaka, H., Kobayashi, M., Herrmann, S.H., Wolf, S.F., Fujiwara, H. and 
Hamaoka, T. (1995) Systemic administration of rIL-12 induces complete tumor regression and protective 
immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor 
T cells. Int Immunol, 7, 1135-45. 
225. Thomas, G.R., Chen, Z., Enamorado, I., Bancroft, C. and Van Waes, C. (2000) IL-12- and IL-2-induced tumor 
regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 
co-stimulatory molecule and interferon-gamma. Int J Cancer, 86, 368-74. 
226. Merchant, R.E., Ellison, M.D. and Young, H.F. (1990) Immunotherapy for malignant glioma using human 
recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical 
investigations. J Neurooncol, 8, 173-88. 
227. Ehtesham, M., Kabos, P., Gutierrez, M.A., Chung, N.H., Griffith, T.S., Black, K.L. and Yu, J.S. (2002) Induction 
of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related 
apoptosis-inducing ligand. Cancer Res, 62, 7170-4. 
228. Ehtesham, M., Kabos, P., Kabosova, A., Neuman, T., Black, K.L. and Yu, J.S. (2002) The use of interleukin 12-
secreting neural stem cells for the treatment of intracranial glioma. Cancer Res, 62, 5657-63. 
229. Ehtesham, M., Stevenson, C.B. and Thompson, R.C. (2005) Stem cell therapies for malignant glioma. 
Neurosurg Focus, 19, E5. 
230. Aboody, K.S., Brown, A., Rainov, N.G., Bower, K.A., Liu, S., Yang, W., Small, J.E., Herrlinger, U., Ourednik, V., 
Black, P.M., Breakefield, X.O. and Snyder, E.Y. (2000) Neural stem cells display extensive tropism for 
pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A, 97, 12846-51. 
231. Young, H., Kaplan, A. and Regelson, W. (1977) Immunotherapy with autologous white cell infusions 
("lymphocytes") in the treatment of recurrrent glioblastoma multiforme: a preliminary report. Cancer, 40, 
1037-44. 
232. Trouillas, P. and Lapras, C. (1970) [Active immunotherapy of cerebral tumor. 20 cases]. Neurochirurgie, 16, 
143-70. 
233. Neuwelt, E.A., Clark, K., Kirkpatrick, J.B. and Toben, H. (1978) Clinical studies of intrathecal autologous 
lymphocyte infusions in patients with malignant glioma: a toxicity study. Ann Neurol, 4, 307-12. 
234. Vaquero, J., Martinez, R., Barbolla, L., de Haro, J., de Oya, S., Coca, S. and Ramiro, J. (1987) Intrathecal 
injection of autologous leucocytes in glioblastoma: circulatory dynamics within the subarachnoid space and 
clinical results. Acta Neurochir (Wien), 89, 37-42. 
235. Hayes, R.L., Koslow, M., Hiesiger, E.M., Hymes, K.B., Hochster, H.S., Moore, E.J., Pierz, D.M., Chen, D.K., 
Budzilovich, G.N. and Ransohoff, J. (1995) Improved long term survival after intracavitary interleukin-2 and 
lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer, 76, 840-52. 
236. Merchant, R.E., Grant, A.J., Merchant, L.H. and Young, H.F. (1988) Adoptive immunotherapy for recurrent 
glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer, 62, 
665-71. 
237. Barba, D., Saris, S.C., Holder, C., Rosenberg, S.A. and Oldfield, E.H. (1989) Intratumoral LAK cell and 
interleukin-2 therapy of human gliomas. J Neurosurg, 70, 175-82. 
238. Plautz, G.E., Miller, D.W., Barnett, G.H., Stevens, G.H., Maffett, S., Kim, J., Cohen, P.A. and Shu, S. (2000) T cell 
adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res, 6, 2209-18. 
239. Dermime, S., Armstrong, A., Hawkins, R.E. and Stern, P.L. (2002) Cancer vaccines and immunotherapy. Br 
Med Bull, 62, 149-62. 
240. Holladay, F.P., Heitz, T. and Wood, G.W. (1992) Antitumor activity against established intracerebral gliomas 
exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg, 77, 757-62. 
241. Ehtesham, M., Black, K.L. and Yu, J.S. (2004) Recent progress in immunotherapy for malignant glioma: 
treatment strategies and results from clinical trials. Cancer Control, 11, 192-207. 
242. Sobol, R.E., Fakhrai, H., Shawler, D., Gjerset, R., Dorigo, O., Carson, C., Khaleghi, T., Koziol, J., Shiftan, T.A. 
and Royston, I. (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther, 2, 164-7. 
243. Celluzzi, C.M. and Falo, L.D., Jr. (1998) Physical interaction between dendritic cells and tumor cells results in 
an immunogen that induces protective and therapeutic tumor rejection. J Immunol, 160, 3081-5. 
244. Albert, M.L., Sauter, B. and Bhardwaj, N. (1998) Dendritic cells acquire antigen from apoptotic cells and 
induce class I-restricted CTLs. Nature, 392, 86-9. 
245. Albert, M.L., Pearce, S.F., Francisco, L.M., Sauter, B., Roy, P., Silverstein, R.L. and Bhardwaj, N. (1998) 
Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens 
to cytotoxic T lymphocytes. J Exp Med, 188, 1359-68. 
246. Ehtesham, M., Kabos, P., Gutierrez, M.A., Samoto, K., Black, K.L. and Yu, J.S. (2003) Intratumoral dendritic 
cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother, 26, 107-
16. 
247. Kikuchi, T., Akasaki, Y., Abe, T. and Ohno, T. (2002) Intratumoral injection of dendritic and irradiated glioma 
cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother, 51, 424-30. 
248. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6. 
 63
249. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during 
tumorigenesis. Cell, 86, 353-64. 
250. Folkman, J. (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg, 175, 409-16. 
251. Kerbel, R.S. (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-
cancer therapeutic agents. Bioessays, 13, 31-6. 
252. Kerbel, R. and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2, 727-39. 
253. Jansen, M., de Witt Hamer, P.C., Witmer, A.N., Troost, D. and van Noorden, C.J. (2004) Current perspectives 
on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rev, 45, 143-63. 
254. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K.H. and Augustin, H.G. (2000) Heterogeneity of 
angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. 
Cancer Res, 60, 1388-93. 
255. Porkka, K., Laakkonen, P., Hoffman, J.A., Bernasconi, M. and Ruoslahti, E. (2002) A fragment of the HMGN2 
protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A, 99, 
7444-9. 
256. Arap, W., Kolonin, M.G., Trepel, M., Lahdenranta, J., Cardo-Vila, M., Giordano, R.J., Mintz, P.J., Ardelt, P.U., 
Yao, V.J., Vidal, C.I., Chen, L., Flamm, A., Valtanen, H., Weavind, L.M., Hicks, M.E., Pollock, R.E., Botz, G.H., 
Bucana, C.D., Koivunen, E., Cahill, D., Troncoso, P., Baggerly, K.A., Pentz, R.D., Do, K.A., Logothetis, C.J. and 
Pasqualini, R. (2002) Steps toward mapping the human vasculature by phage display. Nat Med, 8, 121-7. 
257. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor 
vasculature in a mouse model. Science, 279, 377-80. 
258. Grifman, M., Trepel, M., Speece, P., Gilbert, L.B., Arap, W., Pasqualini, R. and Weitzman, M.D. (2001) 
Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther, 3, 964-
75. 
259. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R. and 
Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-85. 
260. Oh, S.P., Kamagata, Y., Muragaki, Y., Timmons, S., Ooshima, A. and Olsen, B.R. (1994) Isolation and 
sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of 
collagenous proteins. Proc Natl Acad Sci U S A, 91, 4229-33. 
261. Ferreras, M., Felbor, U., Lenhard, T., Olsen, B.R. and Delaisse, J. (2000) Generation and degradation of human 
endostatin proteins by various proteinases. FEBS Lett, 486, 247-51. 
262. Kuroi, K., Tanaka, C. and Toi, M. (2001) Circulating levels of endostatin in cancer patients. Oncol Rep, 8, 405-
9. 
263. Hajitou, A., Grignet, C., Devy, L., Berndt, S., Blacher, S., Deroanne, C.F., Bajou, K., Fong, T., Chiang, Y., 
Foidart, J.M. and Noel, A. (2002) The antitumoral effect of endostatin and angiostatin is associated with a 
down-regulation of vascular endothelial growth factor expression in tumor cells. Faseb J, 16, 1802-4. 
264. Kim, Y.M., Hwang, S., Pyun, B.J., Kim, T.Y., Lee, S.T., Gho, Y.S. and Kwon, Y.G. (2002) Endostatin blocks 
vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem, 277, 
27872-9. 
265. Kim, Y.M., Jang, J.W., Lee, O.H., Yeon, J., Choi, E.Y., Kim, K.W., Lee, S.T. and Kwon, Y.G. (2000) Endostatin 
inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix 
metalloproteinase. Cancer Res, 60, 5410-3. 
266. Hanai, J., Dhanabal, M., Karumanchi, S.A., Albanese, C., Waterman, M., Chan, B., Ramchandran, R., Pestell, R. 
and Sukhatme, V.P. (2002) Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J 
Biol Chem, 277, 16464-9. 
267. Shichiri, M. and Hirata, Y. (2001) Antiangiogenesis signals by endostatin. Faseb J, 15, 1044-53. 
268. Abdollahi, A., Hahnfeldt, P., Maercker, C., Grone, H.J., Debus, J., Ansorge, W., Folkman, J., Hlatky, L. and 
Huber, P.E. (2004) Endostatin's antiangiogenic signaling network. Mol Cell, 13, 649-63. 
269. Lyden, D., Young, A.Z., Zagzag, D., Yan, W., Gerald, W., O'Reilly, R., Bader, B.L., Hynes, R.O., Zhuang, Y., 
Manova, K. and Benezra, R. (1999) Id1 and Id3 are required for neurogenesis, angiogenesis and 
vascularization of tumour xenografts. Nature, 401, 670-7. 
270. Volpert, O.V., Pili, R., Sikder, H.A., Nelius, T., Zaichuk, T., Morris, C., Shiflett, C.B., Devlin, M.K., Conant, K. and 
Alani, R.M. (2002) Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. 
Cancer Cell, 2, 473-83. 
271. Sorensen, D.R. and Read, T.A. (2002) Delivery of endostatin in experimental cancer therapy. Int J Exp Pathol, 
83, 265-74. 
272. Li, G., Sham, J., Yang, J., Su, C., Xue, H., Chua, D., Sun, L., Zhang, Q., Cui, Z., Wu, M. and Qian, Q. (2005) 
Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular 
carcinoma. Int J Cancer, 113, 640-8. 
273. Schmitz, V., Wang, L., Barajas, M., Gomar, C., Prieto, J. and Qian, C. (2004) Treatment of colorectal and 
hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule 
in mice. Gut, 53, 561-7. 
274. Wang, X., Liu, F.K., Li, X., Li, J.S. and Xu, G.X. (2002) Retrovirus-mediated gene transfer of human endostatin 
inhibits growth of human liver carcinoma cells SMMC7721 in nude mice. World J Gastroenterol, 8, 1045-9. 
275. Sorensen, D.R., Read, T.A., Porwol, T., Olsen, B.R., Timpl, R., Sasaki, T., Iversen, P.O., Benestad, H.B., Sim, 
B.K. and Bjerkvig, R. (2002) Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. 
Neuro-oncol, 4, 1-8. 
276. Sim, B.K., MacDonald, N.J. and Gubish, E.R. (2000) Angiostatin and endostatin: endogenous inhibitors of 
tumor growth. Cancer Metastasis Rev, 19, 181-90. 
277. Ding, I., Sun, J.Z., Fenton, B., Liu, W.M., Kimsely, P., Okunieff, P. and Min, W. (2001) Intratumoral 
administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary 
carcinomas. Cancer Res, 61, 526-31. 
278. Szary, J. and Szala, S. (2001) Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin 
inhibits renal carcinoma growth. Int J Cancer, 91, 835-9. 
279. Chen, Q.R., Kumar, D., Stass, S.A. and Mixson, A.J. (1999) Liposomes complexed to plasmids encoding 
angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res, 59, 3308-12. 
280. Sauter, B.V., Martinet, O., Zhang, W.J., Mandeli, J. and Woo, S.L. (2000) Adenovirus-mediated gene transfer of 
endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and 
metastases. Proc Natl Acad Sci U S A, 97, 4802-7. 
 64
281. Pulkkanen, K.J., Laukkanen, J.M., Fuxe, J., Kettunen, M.I., Rehn, M., Kannasto, J.M., Parkkinen, J.J., 
Kauppinen, R.A., Pettersson, R.F. and Yla-Herttuala, S. (2002) The combination of HSV-tk and endostatin gene 
therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther, 9, 908-16. 
282. Dkhissi, F., Lu, H., Soria, C., Opolon, P., Griscelli, F., Liu, H., Khattar, P., Mishal, Z., Perricaudet, M. and Li, H. 
(2003) Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer 
cells. Hum Gene Ther, 14, 997-1008. 
283. Calvo, A., Feldman, A.L., Libutti, S.K. and Green, J.E. (2002) Adenovirus-mediated endostatin delivery results 
in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice. Cancer Res, 62, 3934-
8. 
284. Jin, X., Bookstein, R., Wills, K., Avanzini, J., Tsai, V., LaFace, D., Terracina, G., Shi, B. and Nielsen, L.L. (2001) 
Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther, 8, 982-9. 
285. Mori, K., Ando, A., Gehlbach, P., Nesbitt, D., Takahashi, K., Goldsteen, D., Penn, M., Chen, C.T., Melia, M., 
Phipps, S., Moffat, D., Brazzell, K., Liau, G., Dixon, K.H. and Campochiaro, P.A. (2001) Inhibition of choroidal 
neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J 
Pathol, 159, 313-20. 
286. Wen, X.Y., Bai, Y. and Stewart, A.K. (2001) Adenovirus-mediated human endostatin gene delivery 
demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum Gene Ther, 
12, 347-58. 
287. Hutter, R., Sauter, B.V., Reis, E.D., Roque, M., Vorchheimer, D., Carrick, F.E., Fallon, J.T., Fuster, V. and 
Badimon, J.J. (2003) Decreased reendothelialization and increased neointima formation with endostatin 
overexpression in a mouse model of arterial injury. Circulation, 107, 1658-63. 
288. Scappaticci, F.A., Smith, R., Pathak, A., Schloss, D., Lum, B., Cao, Y., Johnson, F., Engleman, E.G. and Nolan, 
G.P. (2001) Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity 
in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther, 3, 186-96. 
289. Chen, W., Fu, J., Liu, Q., Ruan, C. and Xiao, S. (2003) Retroviral endostatin gene transfer inhibits human colon 
cancer cell growth in vivo. Chin Med J (Engl), 116, 1582-4. 
290. Wang, X., Liu, F., Li, X., Li, J. and Xu, G. (2002) Anti-tumor effect of human endostatin mediated by retroviral 
gene transfer in nude mice. Chin Med J (Engl), 115, 1664-9. 
291. Ye, C., Feng, C., Wang, S., Liu, X., Lin, Y. and Li, M. (2002) Antiangiogenic and antitumor effects of endostatin 
on follicular thyroid carcinoma. Endocrinology, 143, 3522-8. 
292. Indraccolo, S., Gola, E., Rosato, A., Minuzzo, S., Habeler, W., Tisato, V., Roni, V., Esposito, G., Morini, M., 
Albini, A., Noonan, D.M., Ferrantini, M., Amadori, A. and Chieco-Bianchi, L. (2002) Differential effects of 
angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. 
Gene Ther, 9, 867-78. 
293. Eisterer, W., Jiang, X., Bachelot, T., Pawliuk, R., Abramovich, C., Leboulch, P., Hogge, D. and Eaves, C. (2002) 
Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic 
leukemia. Mol Ther, 5, 352-9. 
294. Pawliuk, R., Bachelot, T., Zurkiya, O., Eriksson, A., Cao, Y. and Leboulch, P. (2002) Continuous intravascular 
secretion of endostatin in mice from transduced hematopoietic stem cells. Mol Ther, 5, 345-51. 
295. Yamanaka, R., Zullo, S.A., Ramsey, J., Onodera, M., Tanaka, R., Blaese, M. and Xanthopoulos, K.G. (2001) 
Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered 
endostatin-producing Semliki Forest virus. Cancer Gene Ther, 8, 796-802. 
296. Davidoff, A.M., Leary, M.A., Ng, C.Y., Spurbeck, W.W., Frare, P., Vanhove, M., Nienhuis, A.W. and Vanin, E.F. 
(2001) Autocrine expression of both endostatin and green fluorescent protein provides a synergistic 
antitumor effect in a murine neuroblastoma model. Cancer Gene Ther, 8, 537-45. 
297. Feldman, A.L., Alexander, H.R., Hewitt, S.M., Lorang, D., Thiruvathukal, C.E., Turner, E.M. and Libutti, S.K. 
(2001) Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine 
tumors. J Natl Cancer Inst, 93, 1014-20. 
298. Noro, T., Miyake, K., Suzuki-Miyake, N., Igarashi, T., Uchida, E., Misawa, T., Yamazaki, Y. and Shimada, T. 
(2004) Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and 
metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer Res, 64, 7486-90. 
299. Ponnazhagan, S., Mahendra, G., Kumar, S., Shaw, D.R., Stockard, C.R., Grizzle, W.E. and Meleth, S. (2004) 
Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector 
encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res, 64, 1781-7. 
300. Shi, W., Teschendorf, C., Muzyczka, N. and Siemann, D.W. (2003) Gene therapy delivery of endostatin 
enhances the treatment efficacy of radiation. Radiother Oncol, 66, 1-9. 
301. Kikuchi, E., Menendez, S., Ohori, M., Cordon-Cardo, C., Kasahara, N. and Bochner, B.H. (2004) Inhibition of 
orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res, 10, 1835-
42. 
302. Shichinohe, T., Bochner, B.H., Mizutani, K., Nishida, M., Hegerich-Gilliam, S., Naldini, L. and Kasahara, N. 
(2001) Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther, 8, 879-89. 
303. Read, T.A., Sorensen, D.R., Mahesparan, R., Enger, P.O., Timpl, R., Olsen, B.R., Hjelstuen, M.H., Haraldseth, O. 
and Bjerkvig, R. (2001) Local endostatin treatment of gliomas administered by microencapsulated producer 
cells. Nat Biotechnol, 19, 29-34. 
304. Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N.T., Dunn, I.F., Abe, T., Carroll, R.S. and Black, P.M. (2001) 
Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat 
Biotechnol, 19, 35-9. 
305. Kirn, D., Niculescu-Duvaz, I., Hallden, G. and Springer, C.J. (2002) The emerging fields of suicide gene therapy 
and virotherapy. Trends Mol Med, 8, S68-73. 
306. Pulkkanen, K.J. and Yla-Herttuala, S. (2005) Gene therapy for malignant glioma: current clinical status. Mol 
Ther, 12, 585-98. 
307. Hemminki, A. (2002) From molecular changes to customised therapy. Eur J Cancer, 38, 333-8. 
308. Okada, H. (2004) Biologic therapy for brain cancers--based on cellular and immunobiology. Yonsei Med J, 45 
Suppl, 68-70. 
309. Bjerkvig, R., Read, T.A., Vajkoczy, P., Aebischer, P., Pralong, W., Platt, S., Melvik, J.E., Hagen, A. and Dornish, 
M. (2003) Cell therapy using encapsulated cells producing endostatin. Acta Neurochir Suppl, 88, 137-41. 
 65
310. Soon-Shiong, P., Heintz, R.E., Merideth, N., Yao, Q.X., Yao, Z., Zheng, T., Murphy, M., Moloney, M.K., Schmehl, 
M., Harris, M. and et al. (1994) Insulin independence in a type 1 diabetic patient after encapsulated islet 
transplantation. Lancet, 343, 950-1. 
311. Thorsen, F., Read, T.A., Lund-Johansen, M., Tysnes, B.B. and Bjerkvig, R. (2000) Alginate-encapsulated 
producer cells: a potential new approach for the treatment of malignant brain tumors. Cell Transplant, 9, 773-
83. 
312. Read, T.A., Stensvaag, V., Vindenes, H., Ulvestad, E., Bjerkvig, R. and Thorsen, F. (1999) Cells encapsulated in 
alginate: a potential system for delivery of recombinant proteins to malignant brain tumours. Int J Dev 
Neurosci, 17, 653-63. 
313. Ross, C.J., Ralph, M. and Chang, P.L. (1999) Delivery of recombinant gene products to the central nervous 
system with nonautologous cells in alginate microcapsules. Hum Gene Ther, 10, 49-59. 
314. Read, T.A., Farhadi, M., Bjerkvig, R., Olsen, B.R., Rokstad, A.M., Huszthy, P.C. and Vajkoczy, P. (2001) 
Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by 
alginate-encapsulated cells. Cancer Res, 61, 6830-7. 
315. Aebischer, P., Schluep, M., Deglon, N., Joseph, J.M., Hirt, L., Heyd, B., Goddard, M., Hammang, J.P., Zurn, 
A.D., Kato, A.C., Regli, F. and Baetge, E.E. (1996) Intrathecal delivery of CNTF using encapsulated genetically 
modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med, 2, 696-9. 
316. Read, T.A., Thorsen, F. and Bjerkvig, R. (2002) Localised delivery of therapeutic agents to CNS malignancies: 
old and new approaches. Curr Pharm Biotechnol, 3, 257-73. 
317. Lam, P.Y. and Breakefield, X.O. (2001) Potential of gene therapy for brain tumors. Hum Mol Genet, 10, 777-87. 
318. Izquierdo, M., Martin, V., de Felipe, P., Izquierdo, J.M., Perez-Higueras, A., Cortes, M.L., Paz, J.F., Isla, A. and 
Blazquez, M.G. (1996) Human malignant brain tumor response to herpes simplex thymidine kinase 
(HSVtk)/ganciclovir gene therapy. Gene Ther, 3, 491-5. 
319. Ram, Z., Culver, K.W., Oshiro, E.M., Viola, J.J., DeVroom, H.L., Otto, E., Long, Z., Chiang, Y., McGarrity, G.J., 
Muul, L.M., Katz, D., Blaese, R.M. and Oldfield, E.H. (1997) Therapy of malignant brain tumors by intratumoral 
implantation of retroviral vector-producing cells. Nat Med, 3, 1354-61. 
320. Chiocca, E.A., Aghi, M. and Fulci, G. (2003) Viral therapy for glioblastoma. Cancer J, 9, 167-79. 
321. Rainov, N.G. and Ren, H. (2003) Clinical trials with retrovirus mediated gene therapy--what have we learned? J 
Neurooncol, 65, 227-36. 
322. Hansen, W., Grabenhorst, E., Nimtz, M., Muller, K., Conradt, H.S. and Wirth, M. (2005) Generation of serum-
stabilized retroviruses: reduction of alpha1,3gal-epitope synthesis in a murine NIH3T3-derived packaging cell 
line by expression of chimeric glycosyltransferases. Metab Eng, 7, 221-8. 
323. Izquierdo, M., Cortes, M.L., Martin, V., de Felipe, P., Izquierdo, J.M., Perez-Higueras, A., Paz, J.F., Isla, A. and 
Blazquez, M.G. (1997) Gene therapy in brain tumours: implications of the size of glioblastoma on its 
curability. Acta Neurochir Suppl, 68, 111-7. 
324. Klatzmann, D., Valery, C.A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.L. and 
Philippon, J. (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy 
for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther, 9, 2595-604. 
325. Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A.G. and Barbier, 
N. (1999) A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor 
transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-
Canadian Study Group. Hum Gene Ther, 10, 2325-35. 
326. Rainov, N.G. (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and 
ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously 
untreated glioblastoma multiforme. Hum Gene Ther, 11, 2389-401. 
327. Lyons, R.M., Forry-Schaudies, S., Otto, E., Wey, C., Patil-Koota, V., Kaloss, M., McGarrity, G.J. and Chiang, 
Y.L. (1995) An improved retroviral vector encoding the herpes simplex virus thymidine kinase gene increases 
antitumor efficacy in vivo. Cancer Gene Ther, 2, 273-80. 
328. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. and Oldfield, E.H. (1993) In situ retroviral-mediated gene 
transfer for the treatment of brain tumors in rats. Cancer Res, 53, 83-8. 
329. Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin, D.S., Moolten, F.L. and Abraham, G.N. 
(1993) The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. 
Cancer Res, 53, 5274-83. 
330. Sandmair, A.M., Turunen, M., Tyynela, K., Loimas, S., Vainio, P., Vanninen, R., Vapalahti, M., Bjerkvig, R., 
Janne, J. and Yla-Herttuala, S. (2000) Herpes simplex virus thymidine kinase gene therapy in experimental rat 
BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, 
survival time, and tissue reactions. Cancer Gene Ther, 7, 413-21. 
331. Harsh, G.R., Deisboeck, T.S., Louis, D.N., Hilton, J., Colvin, M., Silver, J.S., Qureshi, N.H., Kracher, J., 
Finkelstein, D., Chiocca, E.A. and Hochberg, F.H. (2000) Thymidine kinase activation of ganciclovir in 
recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg, 92, 804-11. 
332. Long, Z., Lu, P., Grooms, T., Mychkovsky, I., Westley, T., Fitzgerald, T., Sharma-Chibber, S., Shand, N., 
McGarrity, G. and Otto, E. (1999) Molecular evaluation of biopsy and autopsy specimens from patients 
receiving in vivo retroviral gene therapy. Hum Gene Ther, 10, 733-40. 
333. Verma, I.M. and Weitzman, M.D. (2005) Gene therapy: twenty-first century medicine. Annu Rev Biochem, 74, 
711-38. 
334. Flint, J. and Shenk, T. (1997) Viral transactivating proteins. Annu Rev Genet, 31, 177-212. 
335. Jiang, H., Gomez-Manzano, C., Alemany, R., Medrano, D., Alonso, M., Bekele, B.N., Lin, E., Conrad, C.C., 
Yung, W.K. and Fueyo, J. (2005) Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa 
deletions in malignant gliomas. Neoplasia, 7, 48-56. 
336. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P.S., McDonnell, T.J., Mitlianga, P., Shi, Y.X., Levin, V.A., 
Yung, W.K. and Kyritsis, A.P. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-
glioma effect in vivo. Oncogene, 19, 2-12. 
337. Barnett, B.G., Crews, C.J. and Douglas, J.T. (2002) Targeted adenoviral vectors. Biochim Biophys Acta, 1575, 
1-14. 
338. Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G.N., Khan, A., Conrad, C.A., Liu, T.J., Jiang, H., Lemoine, 
M.G., Suzuki, K., Sawaya, R., Curiel, D.T., Yung, W.K. and Lang, F.F. (2003) Preclinical characterization of the 
antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer 
Inst, 95, 652-60. 
 66
339. Post, D.E. and Van Meir, E.G. (2003) A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for 
cancer therapy. Oncogene, 22, 2065-72. 
340. Post, D.E., Devi, N.S., Li, Z., Brat, D.J., Kaur, B., Nicholson, A., Olson, J.J., Zhang, Z. and Van Meir, E.G. (2004) 
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. 
Clin Cancer Res, 10, 8603-12. 
341. Lang, F.F., Bruner, J.M., Fuller, G.N., Aldape, K., Prados, M.D., Chang, S., Berger, M.S., McDermott, M.W., 
Kunwar, S.M., Junck, L.R., Chandler, W., Zwiebel, J.A., Kaplan, R.S. and Yung, W.K. (2003) Phase I trial of 
adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol, 21, 
2508-18. 
342. Sandmair, A.M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., Hurskainen, H., Tyynela, K., 
Turunen, M., Vanninen, R., Lehtolainen, P., Paljarvi, L., Johansson, R., Vapalahti, M. and Yla-Herttuala, S. 
(2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or 
adenoviruses. Hum Gene Ther, 11, 2197-205. 
343. Immonen, A., Vapalahti, M., Tyynela, K., Hurskainen, H., Sandmair, A., Vanninen, R., Langford, G., Murray, N. 
and Yla-Herttuala, S. (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human 
malignant glioma: a randomised, controlled study. Mol Ther, 10, 967-72. 
344. Latchman, D.S. (2001) Gene delivery and gene therapy with herpes simplex virus-based vectors. Gene, 264, 1-
9. 
345. Jacobs, A., Breakefield, X.O. and Fraefel, C. (1999) HSV-1-based vectors for gene therapy of neurological 
diseases and brain tumors: part II. Vector systems and applications. Neoplasia, 1, 402-16. 
346. Wang, X., Zhang, G.R., Yang, T., Zhang, W. and Geller, A.I. (2000) Fifty-one kilobase HSV-1 plasmid vector can 
be packaged using a helper virus-free system and supports expression in the rat brain. Biotechniques, 28, 
102-7. 
347. Sundaresan, P., Hunter, W.D., Martuza, R.L. and Rabkin, S.D. (2000) Attenuated, replication-competent herpes 
simplex virus type 1 mutant G207: safety evaluation in mice. J Virol, 74, 3832-41. 
348. Brown, S.M., MacLean, A.R., Aitken, J.D. and Harland, J. (1994) ICP34.5 influences herpes simplex virus type 
1 maturation and egress from infected cells in vitro. J Gen Virol, 75 ( Pt 12), 3679-86. 
349. Tan, S.L. and Katze, M.G. (2000) HSV.com: maneuvering the internetworks of viral neuropathogenesis and 
evasion of the host defense. Proc Natl Acad Sci U S A, 97, 5684-6. 
350. Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D. and Martuza, R.L. (1995) Attenuated multi-mutated herpes 
simplex virus-1 for the treatment of malignant gliomas. Nat Med, 1, 938-43. 
351. Kramm, C.M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P.A., Rainov, N.G., Sena-Esteves, M., Aghi, M., 
Barnett, F.H., Chiocca, E.A. and Breakefield, X.O. (1997) Therapeutic efficiency and safety of a second-
generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther, 8, 2057-68. 
352. Markert, J.M., Medlock, M.D., Rabkin, S.D., Gillespie, G.Y., Todo, T., Hunter, W.D., Palmer, C.A., Feigenbaum, 
F., Tornatore, C., Tufaro, F. and Martuza, R.L. (2000) Conditionally replicating herpes simplex virus mutant, 
G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther, 7, 867-74. 
353. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., 
Harland, J., McKie, E., Mabbs, R. and Brown, M. (2000) Toxicity evaluation of replication-competent herpes 
simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther, 7, 859-66. 
354. Papanastassiou, V., Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R. and 
Brown, M. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 
following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther, 9, 398-
406. 
355. Harrow, S., Papanastassiou, V., Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, 
S.M. and Rampling, R. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection 
of high-grade glioma: safety data and long-term survival. Gene Ther, 11, 1648-58. 
356. Smith, R.a.K.R. (2002) Adeno-associated virus. ASM Press, Washington, D.C. 
357. Atchison, R.W., Casto, B.C. and Hammon, W.M. (1965) Adenovirus-Associated Defective Virus Particles. 
Science, 149, 754-6. 
358. Parks, W.P., Melnick, J.L., Rongey, R. and Mayor, H.D. (1967) Physical assay and growth cycle studies of a 
defective adeno-satellite virus. J Virol, 1, 171-80. 
359. Mayor, H.D., Drake, S., Stahmann, J. and Mumford, D.M. (1976) Antibodies to adeno-associated satellite virus 
and herpes simplex in sera from cancer patients and normal adults. Am J Obstet Gynecol, 126, 100-4. 
360. Moskalenko, M., Chen, L., van Roey, M., Donahue, B.A., Snyder, R.O., McArthur, J.G. and Patel, S.D. (2000) 
Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene 
therapy and virus structure. J Virol, 74, 1761-6. 
361. Hoggan, M.D. (1970) Adenovirus associated viruses. Prog Med Virol, 12, 211-39. 
362. Rommelaere, J. and Cornelis, J.J. (1991) Antineoplastic activity of parvoviruses. J Virol Methods, 33, 233-51. 
363. Raj, K., Ogston, P. and Beard, P. (2001) Virus-mediated killing of cells that lack p53 activity. Nature, 412, 914-
7. 
364. Kotin, R.M., Siniscalco, M., Samulski, R.J., Zhu, X.D., Hunter, L., Laughlin, C.A., McLaughlin, S., Muzyczka, N., 
Rocchi, M. and Berns, K.I. (1990) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S 
A, 87, 2211-5. 
365. Weitzman, M.D., Kyostio, S.R., Kotin, R.M. and Owens, R.A. (1994) Adeno-associated virus (AAV) Rep proteins 
mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci U S 
A, 91, 5808-12. 
366. Grimm, D. and Kay, M.A. (2003) From virus evolution to vector revolution: use of naturally occurring 
serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther, 3, 281-
304. 
367. Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V. and Srivastava, A. (1999) Human fibroblast growth factor 
receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nature Medicine. Jan., 5, 71-77. 
368. Summerford, C. and Samulski Richard, J. (1998) Membrane-associated heparan sulfate proteoglycan is a 
receptor for adeno-associated virus type 2 virions. Journal of Virology. Feb., 72, 1438-1445. 
369. Summerford, C., Bartlett Jeffrey, S. and Samulski Richard, J. (1999) alphaVbeta5 integrin: A co-receptor for 
adeno-associated virus type 2 infection. Nature Medicine. Jan., 5, 78-82. 
 67
370. Kaludov, N., Brown Kevin, E., Walters Robert, W., Zabner, J. and Chiorini John, A. (2001) Adeno-associated 
virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient 
transduction but differ in sialic acid linkage specificity. Journal of Virology, 75, 6884-6893. 
371. Walters, R.W., Yi, S.M., Keshavjee, S., Brown, K.E., Welsh, M.J., Chiorini, J.A. and Zabner, J. (2001) Binding of 
adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem, 276, 20610-6. 
372. Di Pasquale, G., Davidson, B.L., Stein, C.S., Martins, I., Scudiero, D., Monks, A. and Chiorini, J.A. (2003) 
Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med, 9, 1306-12. 
373. Dong, J.Y., Fan, P.D. and Frizzell, R.A. (1996) Quantitative analysis of the packaging capacity of recombinant 
adeno-associated virus. Hum Gene Ther, 7, 2101-12. 
374. Okada, H., Miyamura, K., Itoh, T., Hagiwara, M., Wakabayashi, T., Mizuno, M., Colosi, P., Kurtzman, G. and 
Yoshida, J. (1996) Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene 
Ther, 3, 957-64. 
375. Mizuno, M., Yoshida, J., Colosi, P. and Kurtzman, G. (1998) Adeno-associated virus vector containing the 
herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human 
gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res, 89, 76-80. 
376. Hadaczek, P., Mirek, H., Berger, M.S. and Bankiewicz, K. (2005) Limited efficacy of gene transfer in herpes 
simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors. J Neurosurg, 102, 328-35. 
377. Vite, C.H., Passini, M.A., Haskins, M.E. and Wolfe, J.H. (2003) Adeno-associated virus vector-mediated 
transduction in the cat brain. Gene Ther, 10, 1874-81. 
378. Passini, M.A., Watson, D.J., Vite, C.H., Landsburg, D.J., Feigenbaum, A.L. and Wolfe, J.H. (2003) 
Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in 
complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions 
in the brains of beta-glucuronidase-deficient mice. J Virol, 77, 7034-40. 
379. Wang, C., Wang, C.M., Clark, K.R. and Sferra, T.J. (2003) Recombinant AAV serotype 1 transduction efficiency 
and tropism in the murine brain. Gene Ther, 10, 1528-34. 
380. Mella, O., Bjerkvig, R., Schem, B.C., Dahl, O. and Laerum, O.D. (1990) A cerebral glioma model for 
experimental therapy and in vivo invasion studies in syngeneic BD IX rats. J Neurooncol, 9, 93-104. 
381. Barth, R.F. (1998) Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-
2 and CNS-1 gliomas. J Neurooncol, 36, 91-102. 
382. Druckrey, H. (1971) Genotypes and phenotypes of ten inbred strains of BD-rats. Arzneimittelforschung, 21, 
1274-8. 
383. Druckrey, H., Ivankovic, S. and Gimmy, J. (1973) [Cancerogenic effects of methyl- and ethyl-nitrosourea (MNU 
and ENU) at single intracerebral and intracarotidal injection in newborn and young BD-rats]. Z Krebsforsch 
Klin Onkol Cancer Res Clin Oncol, 79, 282-97. 
384. Vajkoczy, P., Schilling, L., Ullrich, A., Schmiedek, P. and Menger, M.D. (1998) Characterization of 
angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic 
approach in the athymic nude mouse. J Cereb Blood Flow Metab, 18, 510-20. 
385. Johansson, M., Bergenheim, A.T., Widmark, A. and Henriksson, R. (1999) Effects of radiotherapy and 
estramustine on the microvasculature in malignant glioma. Br J Cancer, 80, 142-8. 
386. Jia, W. and Zhou, Q. (2005) Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. 
Curr Gene Ther, 5, 133-42. 
387. Wang, Y. and Yuan, F. (2006) Delivery of viral vectors to tumor cells: extracellular transport, systemic 
distribution, and strategies for improvement. Ann Biomed Eng, 34, 114-27. 
388. Jooss, K. and Chirmule, N. (2003) Immunity to adenovirus and adeno-associated viral vectors: implications 
for gene therapy. Gene Ther, 10, 955-63. 
389. Wang, L., Calcedo, R., Nichols, T.C., Bellinger, D.A., Dillow, A., Verma, I.M. and Wilson, J.M. (2005) Sustained 
correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene 
therapy. Blood, 105, 3079-86. 
390. Acland, G.M., Aguirre, G.D., Ray, J., Zhang, Q., Aleman, T.S., Cideciyan, A.V., Pearce-Kelling, S.E., Anand, V., 
Zeng, Y., Maguire, A.M., Jacobson, S.G., Hauswirth, W.W. and Bennett, J. (2001) Gene therapy restores vision 
in a canine model of childhood blindness. Nat Genet, 28, 92-5. 
391. Acland, G.M., Aguirre, G.D., Bennett, J., Aleman, T.S., Cideciyan, A.V., Bennicelli, J., Dejneka, N.S., Pearce-
Kelling, S.E., Maguire, A.M., Palczewski, K., Hauswirth, W.W. and Jacobson, S.G. (2005) Long-term restoration 
of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of 
childhood blindness. Mol Ther, 12, 1072-82. 
392. McCown, T.J. (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther, 5, 333-8. 
393. Hansma, A.H., Broxterman, H.J., van der Horst, I., Yuana, Y., Boven, E., Giaccone, G., Pinedo, H.M. and 
Hoekman, K. (2005) Recombinant human endostatin administered as a 28-day continuous intravenous 
infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with 
advanced cancer. Ann Oncol, 16, 1695-701. 
394. Thomas, J.P., Arzoomanian, R.Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., Tutsch, K., Dresen, A., Geiger, 
P., Pluda, J., Fogler, W., Schiller, J.H. and Wilding, G. (2003) Phase I pharmacokinetic and pharmacodynamic 
study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol, 21, 223-31. 
395. Herbst, R.S., Hess, K.R., Tran, H.T., Tseng, J.E., Mullani, N.A., Charnsangavej, C., Madden, T., Davis, D.W., 
McConkey, D.J., O'Reilly, M.S., Ellis, L.M., Pluda, J., Hong, W.K. and Abbruzzese, J.L. (2002) Phase I study of 
recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol, 20, 3792-803. 
396. Eder, J.P., Jr., Supko, J.G., Clark, J.W., Puchalski, T.A., Garcia-Carbonero, R., Ryan, D.P., Shulman, L.N., 
Proper, J., Kirvan, M., Rattner, B., Connors, S., Keogan, M.T., Janicek, M.J., Fogler, W.E., Schnipper, L., 
Kinchla, N., Sidor, C., Phillips, E., Folkman, J. and Kufe, D.W. (2002) Phase I clinical trial of recombinant 
human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol, 20, 3772-84. 
397. McDonald, D.M. and Choyke, P.L. (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med, 9, 713-
25. 
398. Boehm, T., Folkman, J., Browder, T. and O'Reilly, M.S. (1997) Antiangiogenic therapy of experimental cancer 
does not induce acquired drug resistance. Nature, 390, 404-7. 
399. Sasaki, T., Larsson, H., Kreuger, J., Salmivirta, M., Claesson-Welsh, L., Lindahl, U., Hohenester, E. and Timpl, 
R. (1999) Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor 
endostatin. Embo J, 18, 6240-8. 
 68
400. Dhanabal, M., Ramchandran, R., Waterman, M.J., Lu, H., Knebelmann, B., Segal, M. and Sukhatme, V.P. (1999) 
Endostatin induces endothelial cell apoptosis. J Biol Chem, 274, 11721-6. 
401. Ponnazhagan, S., Wang, X.S., Woody, M.J., Luo, F., Kang, L.Y., Nallari, M.L., Munshi, N.C., Zhou, S.Z. and 
Srivastava, A. (1996) Differential expression in human cells from the p6 promoter of human parvovirus B19 
following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human 
megakaryocytic leukaemia cells are non-permissive for AAV infection. J Gen Virol, 77 ( Pt 6), 1111-22. 
402. Sanlioglu, S., Monick, M.M., Luleci, G., Hunninghake, G.W. and Engelhardt, J.F. (2001) Rate limiting steps of 
AAV transduction and implications for human gene therapy. Curr Gene Ther, 1, 137-47. 
403. Ding, W., Zhang, L., Yan, Z. and Engelhardt, J.F. (2005) Intracellular trafficking of adeno-associated viral 
vectors. Gene Ther, 12, 873-80. 
404. Bartlett, J.S., Wilcher, R. and Samulski, R.J. (2000) Infectious entry pathway of adeno-associated virus and 
adeno-associated virus vectors. J Virol, 74, 2777-85. 
405. Bantel-Schaal, U., Hub, B. and Kartenbeck, J. (2002) Endocytosis of adeno-associated virus type 5 leads to 
accumulation of virus particles in the Golgi compartment. J Virol, 76, 2340-9. 
406. Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K.J. and Engelhardt, J.F. (1998) Circular 
intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for 
long-term episomal persistence in muscle tissue. J Virol, 72, 8568-77. 
407. Hansen, J., Qing, K., Kwon, H.J., Mah, C. and Srivastava, A. (2000) Impaired intracellular trafficking of adeno-
associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol, 74, 992-6. 
408. Zhong, L., Li, W., Yang, Z., Qing, K., Tan, M., Hansen, J., Li, Y., Chen, L., Chan, R.J., Bischof, D., Maina, N., 
Weigel-Kelley, K.A., Zhao, W., Larsen, S.H., Yoder, M.C., Shou, W. and Srivastava, A. (2004) Impaired nuclear 
transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary 
murine hematopoietic cells. Hum Gene Ther, 15, 1207-18. 
409. Ohnishi, T., Arita, N., Hiraga, S., Taki, T., Izumoto, S., Fukushima, Y. and Hayakawa, T. (1997) Fibronectin-
mediated cell migration promotes glioma cell invasion through chemokinetic activity. Clin Exp Metastasis, 15, 
538-46. 
410. Knott, J.C., Mahesparan, R., Garcia-Cabrera, I., Bolge Tysnes, B., Edvardsen, K., Ness, G.O., Mork, S., Lund-
Johansen, M. and Bjerkvig, R. (1998) Stimulation of extracellular matrix components in the normal brain by 
invading glioma cells. Int J Cancer, 75, 864-72. 
411. Mattern, R.H., Read, S.B., Pierschbacher, M.D., Sze, C.I., Eliceiri, B.P. and Kruse, C.A. (2005) Glioma cell 
integrin expression and their interactions with integrin antagonists: Research Article. Cancer Ther, 3A, 325-
340. 
412. Belot, N., Rorive, S., Doyen, I., Lefranc, F., Bruyneel, E., Dedecker, R., Micik, S., Brotchi, J., Decaestecker, C., 
Salmon, I., Kiss, R. and Camby, I. (2001) Molecular characterization of cell substratum attachments in human 
glial tumors relates to prognostic features. Glia, 36, 375-90. 
413. Sauthoff, H., Hu, J., Maca, C., Goldman, M., Heitner, S., Yee, H., Pipiya, T., Rom, W.N. and Hay, J.G. (2003) 
Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus 
persists and spreads systemically at late time points. Hum Gene Ther, 14, 425-33. 
414. Grill, J., Van Beusechem, V.W., Van Der Valk, P., Dirven, C.M., Leonhart, A., Pherai, D.S., Haisma, H.J., Pinedo, 
H.M., Curiel, D.T. and Gerritsen, W.R. (2001) Combined targeting of adenoviruses to integrins and epidermal 
growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res, 7, 
641-50. 
415. Wang, W., Zhu, N.L., Chua, J., Swenson, S., Costa, F.K., Schmitmeier, S., Sosnowski, B.A., Shichinohe, T., 
Kasahara, N. and Chen, T.C. (2005) Retargeting of adenoviral vector using basic fibroblast growth factor 
ligand for malignant glioma gene therapy. J Neurosurg, 103, 1058-66. 
416. Gaini, S.M., Riboni, L., Cerri, C., Grimoldi, N., Sganzerla, E.P. and Berra, B. (1988) Ganglioside content and 
composition in human gliomas. Acta Neurochir Suppl (Wien), 43, 126-9. 
417. Sonmez, H., Kokoglu, E., Suer, S. and Ozyurt, E. (1995) Fibronectin and sialic acid levels in human 
meningiomas and gliomas. Cancer Lett, 90, 119-22. 
418. Boucher, Y., Salehi, H., Witwer, B., Harsh, G.R.t. and Jain, R.K. (1997) Interstitial fluid pressure in intracranial 
tumours in patients and in rodents. Br J Cancer, 75, 829-36. 
419. Baxter, L.T. and Jain, R.K. (1989) Transport of fluid and macromolecules in tumors. I. Role of interstitial 
pressure and convection. Microvasc Res, 37, 77-104. 
420. Teschendorf, C., Warrington, K.H., Jr., Shi, W., Siemann, D.W. and Muzyczka, N. (2006) Recombinant adeno-
associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma. Anticancer Res, 
26, 311-7. 
421. Burger, C., Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., Williams, P., Zolotukhin, S., Reier, P.J., Mandel, R.J. 
and Muzyczka, N. (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, 
and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous 
system. Mol Ther, 10, 302-17. 
422. McCarty, D.M., Young, S.M., Jr. and Samulski, R.J. (2004) Integration of adeno-associated virus (AAV) and 
recombinant AAV vectors. Annu Rev Genet, 38, 819-45. 
423. Nakai, H., Montini, E., Fuess, S., Storm, T.A., Grompe, M. and Kay, M.A. (2003) AAV serotype 2 vectors 
preferentially integrate into active genes in mice. Nat Genet, 34, 297-302. 
424. Nakai, H., Yant, S.R., Storm, T.A., Fuess, S., Meuse, L. and Kay, M.A. (2001) Extrachromosomal recombinant 
adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol, 
75, 6969-76. 
425. Owens, R.A. (2002) Second generation adeno-associated virus type 2-based gene therapy systems with the 
potential for preferential integration into AAVS1. Curr Gene Ther, 2, 145-59. 
426. Surosky, R.T., Urabe, M., Godwin, S.G., McQuiston, S.A., Kurtzman, G.J., Ozawa, K. and Natsoulis, G. (1997) 
Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol, 
71, 7951-9. 
427. Tong, X., Engehausen, D.G., Freund, C.T., Agoulnik, I., Oehler, M.K., Kim, T.E., Hasenburg, A., Guo, Z., 
Contant, C.F., Woo, S.L. and Kieback, D.G. (1999) Comparison of long-term survival of cytomegalovirus 
promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing 
human ovarian cancer. Hybridoma, 18, 93-7. 
428. Foecking, M.K. and Hofstetter, H. (1986) Powerful and versatile enhancer-promoter unit for mammalian 
expression vectors. Gene, 45, 101-5. 
 69
429. Prosch, S., Stein, J., Staak, K., Liebenthal, C., Volk, H.D. and Kruger, D.H. (1996) Inactivation of the very 
strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler, 377, 195-
201. 
430. Teschendorf, C., Warrington, K.H., Jr., Siemann, D.W. and Muzyczka, N. (2002) Comparison of the EF-1 alpha 
and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. 
Anticancer Res, 22, 3325-30. 
431. Klein, R.L., Meyer, E.M., Peel, A.L., Zolotukhin, S., Meyers, C., Muzyczka, N. and King, M.A. (1998) Neuron-
specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated 
virus vectors. Exp Neurol, 150, 183-94. 
432. Xu, R., Janson, C.G., Mastakov, M., Lawlor, P., Young, D., Mouravlev, A., Fitzsimons, H., Choi, K.L., Ma, H., 
Dragunow, M., Leone, P., Chen, Q., Dicker, B. and During, M.J. (2001) Quantitative comparison of expression 
with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther, 8, 1323-32. 
433. Klein, R.L., Hamby, M.E., Gong, Y., Hirko, A.C., Wang, S., Hughes, J.A., King, M.A. and Meyer, E.M. (2002) 
Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the 
rat brain. Exp Neurol, 176, 66-74. 
434. Okada, T., Uchibori, R., Iwata-Okada, M., Takahashi, M., Nomoto, T., Nonaka-Sarukawa, M., Ito, T., Liu, Y., 
Mizukami, H., Kume, A., Kobayashi, E. and Ozawa, K. (2006) A histone deacetylase inhibitor enhances 
recombinant adeno-associated virus-mediated gene expression in tumor cells. Mol Ther, 13, 738-46. 
435. Kunkel, P., Ulbricht, U., Bohlen, P., Brockmann, M.A., Fillbrandt, R., Stavrou, D., Westphal, M. and Lamszus, 
K. (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal 
antibody against vascular endothelial growth factor receptor-2. Cancer Res, 61, 6624-8. 
436. Chiocca, E.A. (2002) Oncolytic viruses. Nat Rev Cancer, 2, 938-50. 
 
 
 
 
 Appendix
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table I. Classification of the tumors of neuroepithelial tissues= 
 
Designation of the tumor group Constituent neoplastic cells WHO grades of tumor types* Characteristics of the tumor 
Astrocytic tumors astrocytes I:     pilocytic astrocytoma 
II:    astrocytoma 
III:   anaplastic astrocytoma 
IV:   glioblastoma multiforme 
more diffuse infiltration and 
increasing cellularity with increasing 
grade, micro-vascular proliferation 
and necrosis in gr. IV  
Oligodendroglial tumors oligodendrocytes, occasionally mixed 
with astrocytes 
 II:     oligodendroglioma, mixed  
          oligoastrocytoma 
III:  anaplastic oligodendroglioma 
highly vascular, diffusely infiltrating 
lesions,  pleomorphism is 
characteristic for the anaplastic type  
Ependymal and choroid plexus 
tumors 
 
ependymal cells and cells of the 
choroid plexus respectively 
 I:        ependymoma 
II-III:   anaplastic ependymoma 
circumscribed lesions, rarely 
infiltrating, perivascular rosettes are 
characteristic  
Pineal cell tumors mature pineal parenchymal cells 
(pineocytoma) and pineal precursor 
cells (pineoblastoma) 
 II:     pineocytoma  
III:    pineoblastoma (rare)  
moderately cellular with delicate 
connective tissue stroma (gr. II); 
increased cellularity,  mitoses and 
necrosis in gr. III  
Neuronal tumors mature ganglion cells, occasionally 
with glial or neural elements 
 I:      gangliocytoma  
II:     ganglioglioma 
III:    anaplastic ganglioglioma 
low cellularity and highly 
differentiated cells exhibiting well-
delineated growth; in gr. III, the glial 
components show features of 
anaplasia  
Poorly differentiated and embryonal 
tumors 
undifferentiated cells IV: medulloblastoma, neuroblastoma, 
ependymoblastoma 
rapid growth, often well-delineated, 
high cellularity 
 
= a modified version of the classification presented in Neuroradiology (Zulch, 1980)   * not all tumor types of each group are included  
 
 
 
 
 
 
 
 
     Table II. Genes often mutated during the progression of secondary glioblastomas 
 
 
Gene product Function of the gene product Stage of 
malignancy* 
References 
TP 53  (mutated or lost) -arrest of cell in G1 phase of the cell cycle 
-initiation of DNA repair 
-induction of apoptosis 
-promotion of cellular differentiation 
 
 gr. I-IV 
Sidransky et al., 1992 
Louis, 1994 
Watanabe et al., 1996 
Fulci et al., 1998  
von Deimling et al., 2000 
PDGF-A (overexpression) 
 
mitogen  for  a variety of fibroblast-like cells gr. I-IV Hermanson et al., 1992 
Westermark et al., 1995 
PDGFR-α (overexpression) receptor  for PDGF  gr. I-IV Hermanson et al., 1996 
Galanis et al., 1998 
Smits et al., 1998 
RB1 (mutated or lost) 
 
tumor suppressor gene gr. II-IV Henson et al., 1994 
CDKN2A (mutated or lost) tumor suppressor gene gr. II-IV Arap et al., 1997 
Von Deimling et al., 2000 
EGFR    (amplified) mitogen for a variety of cells gr. IV von Deimling et al., 1992 
Galanis et al., 1998 
Frederick et al., 2000 
      
     PDGF-A: Platelet Derived Growth Factor-A, PDGFR-α: Platelet Derived Growth Factor Receptor-α, RB 1: Retinoblastoma 1 
     CDKN2A: Cyclin-Dependent Kinase Inhibitor 2A, EGFR: Epidermal Growth Factor Receptor 
     
 * The stages of astrocytoma malignancy where mutation in the gene coding for this protein is usually found 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table III. Growth factors involved in the angiogenesis of gliomas 
 
 
Growth factor 
 
Mechanisms of angiogenic effect References 
VEGF Mitogen to endothelial cells, induces plasminogen 
activator and plasminogen activator inhibitor. 
Plate at al., 1992 
Plate et al., 1994 
Plate et al., 1997 
aFGF and bFGF Mitogen and chemotactic to endothelial cells. 
 
Stefanik et al., 1991 
PDGF Stimulates the proliferation, cord formation and 
morphogenesis of endothelial cells. 
Hermanson et al., 1988 
 EGF Stimulates endothelial cell motility and 
proliferation. Stimulates the VEGF production in  
glioma cells 
Goldman et al., 1993 
Zagzag et al., 1995 
TGF-α Mitogen to endothelial cells, has a 40 % sequence 
identity with EGF. Competes with EGF for 
binding on endothelial cells. 
Tang et al., 1997 
TGF-β Angiogenic in vivo, but inhibits the growth of 
endothelial cells in vitro. 
Jennings et al., 1997 
Jensen, 1998 
Angiopoietin-1 Remodeling of vasculature. Possibly involved in 
regulation of endothelial-matrix interactions 
Stratmann et al., 1998 
Scatter factor (SF) Mitogen to endothelial cells. Activates latent 
matrix metalloproteases 
Moriyama et al., 1999 
Lamszus et al., 1999 
 
aFGF: acidic fibroblast growth factor, bFGF: basic fibroblast growth factor, VEGF: Vascular endothelial growth factor, PDGF: Platelet derived growth factor, 
EGF: Epidermal growth factor, TGF-α: Transforming growth factor α, TGF-β: Transforming growth factor β 
 
 
 
 
 
 
 
 
 
 
 
 
Table IV. A selection of anti-angiogenic compounds tested in in vivo brain tumor models 
 
Angiogenesis inhibitor  (source) 
 
Mechanism Results References 
Polyclonal bFGF antibody Binds bFGF, inhibits bFGF mediated 
angiogenesis 
Significant reduction of tumor mass and 
vascularity 
Stan et al., 1995 
Angiostatin (endogenous) Specific inhibitor of EC proliferation Significant inhibition of tumor growth, 
reduction of vascularity, apoptosis 
Kirsch et al., 1998 
Endostatin (endogenous) Inhibition of EC proliferation, leads 
to apoptosis 
Reduction in intratumoral blood flow and 
tumor size, apoptosis 
Read et al., 2001 
Sørensen et al., 2002 
Suramin  (synthetic) Inhibits the actions of several growth 
factors (bFGF, PDGF) 
No growth retardation in cerebrally 
implanted glioma;  growth inhibition of 
subcutanously implanted glioma 
Takano et al., 1994 
Olson et al., 1994 
Bernsen et al., 1999 
Soluble truncated VEGF receptor  
(synthetic) 
Binds VEGF, inhibits VEGF induced 
angiogenesis 
Significant increase of survival  Goldman et al., 1998 
TNP-470  (synthetic) Inhibits of EC proliferation by 
interfering with DNA synthesis 
Reduced tumor growth and vessel density Taki et al., 1994 
Bernsen, 1998 
VEGF165-DT385  (synthetic) Inhibition of EC proliferation Significant inhibition of tumor growth Olson et al., 1997 
Monoclonal antibody A.4.6.1. 
specific for VEGF (synthetic) 
Inhibits EC growth, abrogates the 
effect of secreted VEGF on EC 
80 % decrease in tumor weight after 4 
weeks 
Kim et al.,  1993 
 
EC: Endothelial cells, TIMPs: Tissue inhibitors of metalloproteinases, bFGF: basic Fibroblast growth factor, VEGF: Vascular endothelial growth factor, 
VEGF165-DT385: VEGF bound to truncated Diphteria toxin, TNP-470: (3R,4S,5S,6R)-5- methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-butenyl)-oxiranyl]-1- 
oxaspiro[2,5]oct-6-yl(chloroacetyl) carbamate 
 
